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Abstract 
Background and Aims: Diabetes mellitus (DM) is associated with a high risk of developing 
complications and severe co-morbidities. Over the past few years, diabetes (Type 1 and 2) 
and its associated costs have risen, particularly those related to treatment of complications.  
Our aims are to identify and compare the diabetes burden of disease, costs (direct and 
indirect) and diabetes outcomes, focusing on complications across France, Germany, Italy, 
Spain, and the UK (EU5).  We will then have an understanding of the state of diabetes 
management in EU5 from which to make informed policy options. 
Materials and methods: A survey was designed and sent to health economists in the EU5 
countries.  In turn, key diabetes clinicians, decision makers and health officials were 
interviewed in order to answer the survey.  In addition, secondary data was collected from 
PubMed, diabetes association publications and health government publications and websites, 
including national statistics. 
Results: Diabetes record keeping in all EU5 countries is poor for prevalence, direct diabetes 
costs, cost of complications, indirect costs and diabetes outcomes.  No diabetes registers exist 
in any of the EU5 countries. Diabetes prevalence ranges between 4.8% (Italy) to 8.9% 
(Germany), and has increased over time.  Although none of the EU5 countries record diabetes 
costs directly, including complications, estimates for 2010 suggest that the total direct annual 
cost ranges from €5.45bn (Spain) to €43.2bn (Germany); across EU5 the total direct cost 
burden of people with diabetes was €90 billion; this figure includes the cost of complications 
or medical conditions some of which may not necessarily be caused by diabetes, but can be 
exacerbated by it. Incremental costs are reported in Germany only and stand at €19.7 billion 
in 2010. Per patient direct medical costs are more comparable across countries, with some 
variation (€1,708 (Spain) to €5,899 (Germany) in 2010), suggesting a key driver behind total 
diabetes costs is prevalence. Inpatient costs are consistently higher than outpatient costs in all 
countries, due to increased medical care required with diabetes-related complications.  
Outpatient costs on the other hand, as well as diabetes medications, can be less than half of 
inpatient costs due to the relatively low costs of maintaining good glycaemic control via 
medication and regular monitoring. Expenditure on insulin and oral anti-diabetic medicines 
ranges between 6.2% and 10.5% of total direct cost. A significant majority of inpatient direct 
costs account for treatment of diabetes related complications, affecting approximately 18.3 
million diabetic patients each year across the five study countries. Indirect costs, relate to 
reduced productivity, absenteeism, early retirement, social benefits and carer costs; these 
costs are significant and, having quantified part of these costs for the first time in Europe 
(relating to absenteeism, early retirement and social benefits), it appears that they stand at 
€98.4 billion and can exceed direct costs by at least a factor of 2- or even 3- to-1 depending 
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on the country. Significant variations exist between countries in the availability of outcomes 
data and the quality of the relevant indicators.  In some cases, improvements in quality of care 
for diabetic patients are shown over time (Italy, UK), whereas in others discrepancies exist 
between the quality of care in metropolitan versus rural areas (France, Spain).   
Conclusions:  Rising diabetes prevalence (both Type 1 & 2) and associated costs, including 
management of diabetes complications, are a growing concern.  The absence of precise 
diabetes prevalence and cost data is challenging, given its prominent role in population health 
including its role in cardiovascular health.  Furthermore, the relative lack of outcomes data 
(especially France, Germany, Spain) limits the ability to accurately gauge the health of the 
diabetes population or make any appropriate impacts on quality of care.  As a result, the true 
impact of diabetes and its associated complications is likely to be underestimated or 
altogether unmeasured in all EU5 countries.   
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Executive summary 
What this study does 
This study aims to provide a comprehensive, up-to-date representation of Type 1 & 2 diabetes 
in 5 EU countries (Germany, UK, France, Italy, Spain) and address the associated costs, both 
direct and indirect, in as comprehensive a manner as possible. The study also quantifies 
prevalence data from the local perspective and uses a stratification of both qualitative and 
quantitative analysis to provide policy options – the first study of this kind since CODE2. 
Background 
There is increasing concern amongst government officials and public health agencies about 
diabetes care in Europe.  Both diabetes prevalence and spending appear to be increasing. 
Comprehensive studies on diabetes costs are limited, particularly ones that include 
complications, diabetes Type 1 & 2, all ages as well as direct and indirect costs.  This study 
attempts to rectify this by examining all aspects of diabetes management, from the macro 
government view to the micro patient view, and includes costs and outcomes whenever 
possible. 
A primary search for relevant diabetes information was performed via a survey sent to a 
representative in each EU5 country (France, Germany, Italy, Spain, the UK
i
) encompassing 
national and regional programmes, patient and professional groups, incidence and prevalence, 
diabetes guidelines and practice, monitoring for complications, diabetes spending and costs, 
diabetes outcomes and complications.  This was substantiated and supplemented by a 
secondary search for all reports coming from academic, government and other interested 
parties (patient groups). 
Diabetes Burden and National Strategies 
Diabetes prevalence has been increasing steadily over the past two decades, along with an 
aging European population, increasing, high obesity prevalence and changing ethnic make-
up.  This study estimates that Germany has the highest diabetes prevalence at 8.9%, followed 
by Spain (8.1%), France (6.4%), the UK (6.1%) and Italy (4.8%); based on medium-size 
studies and extrapolated to the national level, due to the absence of national or regional 
diabetes registries in the study countries, and poor prevalence data collection in all EU5 
countries.   
Only three countries have national diabetes programmes (NDPs) (Italy, Spain, UK), while 
France‘s has not been operational since 2005. Germany has Diabetes Disease Management 
Programmes (D-DMP), however, not all patients with diabetes are registered.  None of these 
                                                     
i
 This study includes England, Wales and Scotland, but excludes Northern Ireland due to data 
insufficiencies on prevalence, outcomes and costs. 
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strategies have hard targets to achieve ideal diabetes management, instead they discuss multi-
disciplinary care, patient-centred care, patient education and paediatric management among 
others.  Only France and Germany have diabetes screening programmes for high-risk patients, 
although participation is variable.  The UK began screening high-risk patients for vascular 
diseases, including diabetes, in 2009, but implementation is slow.  Most patients with Type 2 
are seen by their GP, while insulin-dependent Type 2 patients and Type 1 patients are seen by 
a diabetologist or a paediatrician respectively.  Access to other services, such as chiropody, 
diabetes nurse specialists and dieticians, is limited or not covered (France) and partially 
dependent on the primary point of diabetes care (outpatient clinic versus community GP 
care).  All countries have care guidelines, the UK‘s being the most prolific, but none have 
guidelines written for patients.  Patient education appears to be highly regionalised within 
countries with differing content and focus; only the UK has national diabetes education 
training protocols (DAFNE and DESMOND) but these are not universally used.  Thus, 
despite having national plans in place, policy and monitoring to ensure their success is either 
limited or applies only to some patients. 
Economic Burden of Diabetes 
Diabetes spending in all EU5 countries is difficult to determine precisely, as with prevalence 
data collection, diabetes cost collection is neglected.  None of the governments collect 
diabetes spending accurately. In part this is due to the complexity of diabetes in conjunction 
with its complications, which makes cost coding more difficult and inaccurate.   
The study takes into consideration the direct medical cost for treating diabetes as well as other 
medical cost, for instance, in terms of treating complications related to diabetes and other 
medical conditions, which may not be associated with or caused by diabetes, but their extent 
can be exacerbated by it. All five study countries include these medical cost components. 
Based  on the above, and being mindful of the close association between diabetes and other –
often related- co-morbidities, the study estimates that in 2010, the direct cost burden of people 
with diabetes was highest in Germany, in part due to the greater diabetes population, at €43.2 
billion, followed by the UK (€20.2 [£13.8] billion), France (€12.9 billion), Italy (€7.9 billion) 
and Spain (€5.4 billion).  Inpatient costs are consistently higher than outpatient costs in all 
countries, due to increased medical care required with diabetes-related complications.  
Outpatient costs on the other hand, as well as diabetes medications, can be less than half of 
inpatient costs due to the relatively low costs of maintaining good glycaemic control via 
medication and regular monitoring. The presence of complications, particularly multiple 
complications, can multiply diabetes costs several times. Diabetes drug costs are the smallest 
component of drug, in- and out-patient costs combined, ranging from 6.2% (France, Italy) to 
10.5% (Spain). Conversely, non-diabetes medications are 3 to 4 times the diabetes 
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medications in terms of total costs, with cardiovascular medicines consuming the largest 
portion in cost and prescribing. 
Annual per patient direct costs are primarily derived from small regional studies, and in some 
countries the data is differentiated between diabetes types.  The total per patient costs are 
highest in Germany (€5,899) (€2,684 if only incremental costs are taken into account), 
followed by France (€5,432), the UK (€4,744-€5,470 [£3,233-£3,717]), Italy (€2,756) and 
Spain (€1,708-€3,015 depending on the study and approach).  Type 1 patients can be more 
expensive to treat than Type 2 annually however, they represent a minority of all diabetes 
patients.  The inpatient costs are in some instances more than double the outpatient costs, 
particularly when patients experience complications involving renal failure or diabetic foot 
(the former requiring dialysis and transplant, and the latter amputation at last stages) (France 
inpatient €2,022 and outpatient €1,950, the latter including injection devices, self-blood 
glucose monitoring equipment, insulin pumps and other medical devices, Germany in- €1,985 
out-patient €1,672; Italy in- €1,569 out-patient €373; Spain in- €829 out-patient €247; UK in- 
€2,681 [£1,807]-€3,786 [£2,552] out-patient €439 [£304] - €530 [£367]). Many diabetic 
patients experience multiple complications, compounding the complexity of treatment and 
thus costs. 
Cardiovascular disease, including angina (16%), myocardial infarctions (1-8%), stroke (1.7-
7%), ischemic heart disease and heart failure (6.3-11%) are the major complications resulting 
from diabetes. Treatment costs range from €2,100 (fatal MI, UK) - €9,767 (MI, Germany) for 
myocardial infarctions and €4,314 (UK) - €11,786 (Germany) for stroke.  Renal damage is 
another costly complication, with up to 3% of patients annually experiencing end stage renal 
disease costing €41,052 (Spain) - €81,449 (France) annually for haemodialysis and €33,437 
(UK) - €76,852 (Germany) for renal transplants.  Diabetic foot is relatively easy and 
inexpensive to prevent with frequent checks and foot care.Peripheral arterial occlusive disease 
is the initial stage of foot disease, affecting up to 10% of diabetic patients resulting in ulcers 
and wounds. 
 
If blood glucose control remains poor and foot checks are not performed daily 
this may result in gangrene, amputation of toes or all or part of a foot (0.2-0.3% of all cases). 
Depending on the severity of the amputation, this can –up to 32,000 (France) per patient, not 
including any mobility rehabilitation or prostheses. 
Very little information on the indirect costs of diabetes is available. However, the potential 
impact of diabetes is manifold and entails significant indirect costs, chiefly relating to the 
economy (i.e. external to the health care services), such as reduced productivity and sickness 
absence, the wider social sector, such as early retirement, drawing social benefits – 
particularly due to job-loss as a result of insulin use in some professions (e.g. professional 
driving). In addition, there is an impact on the family, through informal caring and carer costs 
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as well as dealing with the effects of premature mortality. This study identified costs due to 
absenteeism, early retirement and expenditure on social benefits, amounting to a total of 
€98.4 billion across the study countries in 2010 (€37.9 billion in Germany, €17.6 billion in 
Spain, €17.3 billion in the UK, €12.9 billion in France and €12.6 billion in Italy). In the cases 
of Germany, the UK and France, these indirect costs are on a par with direct costs, whereas in 
the cases of Italy and Spain, they are shown to exceed direct costs by a factor of 2-to-1 and 3-
to-1 respectively. This is an under-estimate since the costs of reduced productivity, premature 
mortality or informal carer costs could not be accounted for.   
Overall, the direct and indirect cost burden of people with diabetes across the 5 study 
countries amounts to €188 billion in 2010. The direct costs include medical costs of treating 
complications and other conditions not necessarily related to diabetes. The indirect costs are 
likely to be under-estimates, since it was only possible to account for a part of the economic 
impact indirectly caused by diabetes. 
Current Diabetes Outcomes and Related Complications 
Only France, Italy and the UK regularly collect and publish monitoring data. France do so 
intermittently (2001, 2007) and Italy and the UK annually.  In Germany these are internal to 
the sickfunds.  
Such data measures how many patients have one or more of the following evaluated: 
glycosylated haemoglobin (HbA1C), blood pressure, BMI, cholesterol (total or LDL), urinary 
albumin, serum creatinine, retinal screening, foot checks and smoking status.  
Examination of outcomes data finds that tight glycaemic control can be variable (HbA1C 
≤6.5%: France 24-32%; Italy 24-44%; England 25%) and slightly more with good glycaemic 
control (HbA1C ≤7.5%: France 24-52%; England 28-66.5%; Scotland 22-64%).  Results for 
blood pressure are similarly variable, in both excellent levels(≤130 mmHg: France 15-22%; 
Italy 15-36%; England 50-63%) and good levels (≤140 mmHg: France 46%, England 61-69; 
Scotland 75-79%).   
Although the measurement of these process and outcome indicators is encouraging, there are 
some missing or misleading elements.  It is commonly recommended that many of these 
indicators (HbA1C, blood pressure, urinary albumin, serum albumin, foot checks) are tested 
more than once annually, thus the annual period does not correspond with the monitoring 
guidelines.  Publications focus on how many patients achieve good control, but neglect how 
many are in serious danger of complications.  A combination of indicators, again important in 
identifying higher risk sub-groups, is also ignored.  It appears that both process and outcome 
indicators are worse in Type 1 patients, suggesting these patients might be receiving poorer 
care than Type 2 patients, or that clinicians caring for Type 1 patients place less importance 
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on reporting indicator data.  All but the UK appear to ignore data collection and reporting in 
children, a serious omission, particularly considering only 4% of all children in the UK had 
all monitoring variables measured (or reported) in 2008/09.  Finally, the choice of outcome 
indicators neglects renal function, and frequently fails to differentiate between Type 1 & 2 
diabetes. 
Implications for National Diabetes Planning 
Overall, this study suggests diabetes management in the EU5 countries is not ideal.  There 
appears to be significant room for improvement starting with improved data collection of 
prevalence (and incidence, mortality), the cost burden to the health system and society 
(including diabetes-related complications and how diabetes exacerbates complications and 
other potentially unrelated co-morbidities), monitoring adherence and outcomes.  Creating 
national diabetes registries would be an ideal platform to help steer diabetes care from patient 
and economic perspectives, particularly if national diabetes strategies emerged from these 
organisations independent from the national health services.  Additionally, it would provide a 
better understanding of complications associated with diabetes and their impact on variables 
such as resource use, length of stay and, ultimately, total cost reimbursed from health 
insurance to providers. In many settings hospitalisations for certain conditions are not 
considered to be diabetes-related, even if they are caused by diabetes. It is also known that 
diabetes has a significant impact on hospitalisation cost because it increases the length of 
stay.  
A greater understanding of indirect costs is also needed, not least because this is a cost borne 
by all segments of society, including patients, carers where applicable, employers, and the 
broader social protection network (pensions, social security & benefits payments), funded 
largely by the taxpayer. 
Further, it appears that greater effort must be placed on obesity prevention to help halt 
diabetes incidence, in addition to targeted screening of high-risk individuals, the majority of 
whom are diagnosed with diabetes-related complications already in place.  As with other 
chronic disease care, creation of hard targets to encourage monitoring in line with guideline 
recommendations might be needed if softer planning does not create an ideal platform for 
complication prevention.   
Greater differentiation of care and data collection between Type 1 and 2 patients should be 
supported, as the life pathway is not the same, particularly with childhood diagnosis.  
Education programmes should be targeted to specific groups, such as time since diagnosis, 
age ranges, diabetes type and complications present, in order for diabetes education to be 
effective.    
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Greater effort should be placed on ideal care pathways, with guaranteed access to 
endocrinologists for insulin users, as well as access to other diabetes professionals (diabetes 
nurse specialists, dieticians, chiropodists, ophthalmologists) to prevent or halt diabetes 
related-complications.  On the same note as multi-disciplinary care, is patient-centred care.  
Diabetes is a chronic illness demanding high levels of self care by patients – patients must be 
involved in their care plans from the beginning (including childhood if possible) to create a 
communicated vested interest in their diagnosis. 
On the whole, greater emphasis must be placed on diabetes in the health and social care 
system and in the broader national context.  The fact that none of these countries collects 
accurate prevalence data or has precise accounting for diabetes (or related complications) 
suggests potential neglect of a significant and populous disease, which, for the most part, is 
preventable.  Not only must more effort be made from the bottom up in terms of patient level 
care, but significantly greater effort must be made from the top down to create an atmosphere 
and environment of prevention of diabetes and diabetes complications, in addition to ideal 
management. 
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1. Background and Objectives 
 Background 1.1
Diabetes
ii
 presents a multi-faceted challenge to health systems in Europe and beyond. 
Globally, diabetes prevalence is increasing and is responsible for 5% of all deaths annually 
(World Health Organisation 2011). The 2010 diabetes prevalence is 285 million people and 
expected to increase to 438 million people by 2030 (Diabetes Help 2010). Given current 
projections, without urgent action, mortality due to diabetes is expected to increase by 50% in 
the next 10 years (World Health Organisation 2011). 
Diabetes alone is a disease requiring high levels of independent self-care with regards to diet, 
activity and medication.  The impact of diabetes and related complications on costs can be 
classified into two categories (International Diabetes Federation (IDF) 2009). The first is 
diabetes itself, with 12 people per minute globally diagnosed with diabetes and 6 per minute 
dying of its complications.  The treatment of diabetes itself is costly; on the other hand, as 
much as 80% of Type 2 diabetes is avoidable through lifestyle changes and obesity 
prevention.   
Although costly and time consuming to treat, the real impact of diabetes is through its 
complications, the second impact of diabetes. People with Type 2 diabetes are twice as likely 
to have a heart attack or stroke than non-diabetics. Cardiovascular disease is the major cause 
of death in diabetes with 50% of all diabetes fatalities and also a premature cause of mortality 
with 5-10 years of shortened life expectancy. Globally >2.5 million people are affected by 
diabetic retinopathy, the leading cause of vision loss in adults in developed countries.  
Diabetes (all types) is the most frequent cause of kidney failure and amputations.  These are 
all extremely costly, more costly in fact than treatment and monitoring of diabetes itself. 
Reducing diabetes burden requires action on prevention via lifestyle interventions, early 
diagnosis via targeted screening for Type 2 diabetes, high quality monitoring and treatment to 
delay the onset of complications, as well early identification and treatment of complications. 
Targeted screening of patients with a family history of diabetes or overweight can be useful in 
preventing more costly and complicated diabetes (Waugh et al. 2007). Furthermore, effective 
monitoring and treatment of diabetes patients can delay or prevent the incidence of extremely 
costly complications. 
                                                     
ii
 Type 1 diabetes is usually juvenile onset, although it may occur in mid-adulthood, and always 
requires daily blood glucose monitoring and injection of long- and short-acting insulin (insulin 
dependent diabetes IDDM).  Type 2 is usually adult onset, although can be seen in obese children, and 
requires weight loss, oral anti-diabetic medicine (non-insulin dependent diabetes NIDDM) and may 
over time develop into requiring insulin injections.   
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 Objectives 1.2
This study analyses diabetes prevention and management, including spending and policy in 
each area in 5 EU countries (France, Germany, Italy, Spain, the UK) (known as EU5).  
The specific objectives, including comparisons between EU5, are fivefold: first, to outline 
longitudinal diabetes prevalence in each EU5 country; second, to outline any diabetes 
prevention and treatment policies (from initial diagnosis to complications as a result of 
diabetes) in each EU5 country.  Intricacies in care will be outlined, including indices 
monitored and treatment pathways, as well as source of care provision. Third, to examine the 
cost of diabetes management in each EU5 country, providing perspectives in health systems, 
and including both direct and indirect costs. Fourth, to examine diabetes outcomes in each 
EU5 country, comparing these to monitoring and treatment guidelines outlined per country. A 
final objective is to provide a number of options on diabetes policies and practices at national 
and wider (European) levels. 
The study is structured as follows: Section 2 outlines the methodology used. Section 3 
considers the diabetes burden of disease and outlines national diabetes policies in the study 
countries.  Section 4 reviews diabetes guidelines, diagnosis and treatment processes.  Section 
5 provides a detailed breakdown –to the extent possible- of the direct and indirect cost of 
diabetes and diabetes-related complications and other co-morbidities. Section 6 examines the 
available evidence on diabetes outcomes.  Section 7 discusses the challenges in diabetes care 
in the study countries that have emerged from the discussion, while section 8 outlines a series 
of policy options for stakeholders at national and EU level, developed from the findings. 
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2. Methodology 
In order to address the objectives outlined earlier, data from both primary and secondary 
sources was collected. Secondary sources included: (i) Medline peer review literature 
focusing on ―cost of diabetes" and ―outcomes of diabetes care‖; (ii) grey literature 
(government, EU and international organisations); and (iii) reports from stakeholder groups, 
diabetes organisations and other NGOs (January 2000 to March 2011). 
Primary data was collected through a survey, developed to collect country-level data via 
interviews with key diabetes stakeholders, and diabetes databases, nationally and regionally.  
This survey was developed in July 2010, piloted in August and September 2010 and, after 
having incorporated the feedback, it was subsequently administered electronically to health 
policy analysts in each study country to complete.  The survey requested information on 
longitudinal prevalence, incidence, spending, as well as current screening, diagnosis, 
treatment, monitoring, outcomes and complications management. Additional input was 
acquired through direct contacts with leading clinicians, a range of decision-makers at 
national and/or regional level, as well as representatives from national NGOs. Issues relating 
to the organisation and delivery of health care related to diabetes were also included in the 
survey tool.  
A list of experts interviewed and the country correspondents who participated is shown in 
Appendix 1.  The section that follows outlines the data sources used in the study as well as 
the issues and limitations encountered in the research process with regards to prevalence, 
direct cost calculations, cost of complications, indirect costs and outcomes data. 
2.1 Data sources and caveats 
2.2.1 Precision of Prevalence 
Despite reports of rising diabetes prevalence in Europe, there are a number of difficulties in 
determining precise diabetes prevalence.  First, none of the EU5 have active national 
(country-wide) diabetes registries, which means there is no central data collection.  Second, 
undiagnosed diabetes is estimated to be significant, as supported by diagnosis for another 
purpose (Simmons et al. 2010). Both factors are significant in determining the exact diabetes 
prevalence, in addition to Type 1 (insulin dependent, IDDM) versus Type 2 (IDDM or non-
insulin dependent, NIDDM) differentiation. 
Prevalence estimates from the International Diabetes Federation (IDF) are available. 
However, in view of potential underestimation and older base years (Sicree et al. 2011), 
alternative estimations of prevalence have been used in this study based on national or 
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regional data (as shown in Box 2.1 and outlined in Figure 3.2) drawn from the peer review 
literature.
iii
 
In France, previous estimates in pharmacologically treated diabetes include 3.6% (public 
healthcare, 2005) (Kusnik-Joinville et al. 2008), 3.95% (with annual 5.7% increases, 2007) 
(Fagot-Campagna et al. 2009) and 4.4% (Type 1 & 2, 2010) (Ricci et al. 2010). The estimate 
of 4.57% as part of the national INSTANT study was selected as it reflects all Type 2 patients 
treated with lifestyle modification, oral anti-diabetics and/or insulin (2006 data) (Bringer et al. 
2009). This is comparable to the national ENTRED adult data (2009 prevalence 4.4% (Fagot-
Campagna et al. 2010; Ricci et al. 2010)), although the latter does not include non-
pharmacologically treated patients (Fagot-Campagna et al. 2010). Unfortunately, the 
INSTANT study does not include either childhood or adult cases of Type 1 diabetes, thus the 
national ENTRED Type 1 patients (2001 data) (Lecomte et al. 2008) were added to the 2006 
INSTANT Type 2 patients (all >18 years) to find a prevalence of 6.39%.  
In Germany, a population-based study assessed the prevalence of treated diabetes patients 
using a retrospective analysis of routine health insurance data, and estimated a prevalence of 
6.45% (1999) (Stock et al. 2005). This is roughly in line with another estimate of 6.5% (2000 
data) (Köster et al. 2011). A more recent evaluation of 18.75% of the AOK statutory health 
insurance provider estimates diabetes prevalence of 8.9% as part of the CoDiM study (Köster 
et al. 2011). Despite the limitations of extrapolation of health insurance data nationally, this 
estimate was chosen as the German benchmark; this figure is also in line with other recent 
studies in Germany (Robert Koch Institute 2011). 
In Italy, a 2006 study (Ruiz-Ramos et al. 2006) estimated prevalence for Type 1, Type 2 and 
gestational diabetes ranging from 0.08-0.2%, 4.8-18.7% and 4.5-16.1%, respectively.  The 
lower end of these figures are similar to the prevalence estimate of 4.8% from ISTAT (2009) 
(ISTAT 2009), which was chosen as the Italian benchmark in part due to its recent collection. 
In Spain, a 2004 (Oliva et al. 2004) study applied prevalence rates of 5-6% to cost 
estimations, determined based on a number of epidemiological studies and is considered a 
conservative estimate given the documented high percentage of undiagnosed cases in the 
country.  CIBERDEM, an association of 30 Spanish diabetes research organizations, 
estimates national Type 2 diabetes prevalence (>18 years) as 8.1%, (2008), (Centro de 
                                                     
iii
 IDF calculates prevalence via comprehensive literature review of prevalence studies and registry 
reports (where available), hospital statistics and government estimates (1980-2006).  Prevalence rates 
are estimated based on total number of expected cased divided by the total country population from UN 
data (20-79 years). A log regression controls for missing data in certain age groups.  It is likely that 
these estimates rest on conservative predictions based on an econometric model using in all EU5 
countries early 2000 data. 
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Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas 
(CIBERDEM) 2008) which is used at the Spanish benchmark in this study. 
Government sources of diabetes prevalence in the UK have been difficult to determine 
historically, as it was not included in health statistics or national accounting until 2006.  The 
English prevalence estimates from the 2006 Health Survey for England (2008) (Ali et al. 
2008) were 5.6% for men and 4.2% for women.  Other academic sources include 3.4% (2005) 
(Morgan et al. 2010), 12.1% (men only 65+ years, 2005) (Thomas et al. 2009),(González et 
al. 2009) 4.3% (2005), and 3.3% (2004) (Millett et al. 2007).  The 2010 Quality and Outcome 
Framework (QOF) estimate total prevalence at 4.26%, however, participation in reporting is 
still not ideal with only 75% of GP practices participating (although improved tremendously 
from its initiation in 2006) (Diabetes UK 2010b). The benchmark figure of 6.1% from the 
APHO Diabetes Prevalence Model was chosen over these alternatives as it was based on 
prevalence modeling accounting for age, sex, ethnic, deprivation and obesity, including 
England, Wales and Scotland, although Northern Ireland is not included (Holman et al. 2011). 
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Box 2.1: Diabetes prevalence benchmarks 
 
France 
INSTANT study (2009)  (Bringer et al. 2009).  Cross sectional representative 
national sample of 10,038 participants (>18 years), interviewed to determine 
diabetes prevalence and subsequent treatment and complications (Sept-Nov 
2006).  The population under 18 was accounted for regionally and integrated 
into the national estimate for Type 2 diabetes of 4.57%.  The inclusion of 
Type 1 patients comes from the national ENTRED study of Type 1 & 2 
patients (2009 data) to derive an estimated prevalence of 6.39% (Fagot-
Campagna et al. 2010; Ricci et al. 2010).
 
Germany 
CoDiM study (2011) (Köster et al. 2011).  The estimate of 8.9% of total Type 
1 & 2 diabetes was derived from an 18.8% sample of ―AOK-Die 
Gesunheitskasse‖ members (German statutory health insurance) (n=357,200) 
(2007 data). 
Italy 
Italy: (ISTAT 2009).  The estimate of 4.8% relates to, both, Type 1 & 2.  This 
is based on telephone interviews conducted in 2009 with a randomly selected 
sample of the population (approximately 54,000 individuals in 850 cities), in 
which they are questioned on their chronic pathology and whether a diagnosis 
of diabetes had been made by their GP. 
Spain 
(Centro de Investigación Biomédica en Red de Diabetes y Enfermedades 
Metabólicas Asociadas (CIBERDEM) 2008).  Prevalence estimate of 8.1% 
reflects Type 2 diabetes in the 18+ years population using 2008 data. An 
additional 3.9% have undiagnosed Type 2 diabetes (18+ years) (excluded 
from our benchmark prevalence). 
United 
Kingdom 
Type 1 from (NHS Information Centre 2010) (<16 years) and Type 1 and 2 
from the APHO Diabetes Prevalence Model (2010) (>16 years), Prevalence 
over 16 years comes from the most recent data from the APHO Diabetes 
Prevalence Model (2010) (Holman et al. 2011), including Type 1 & 2, and 
estimates are in England of 7.4% (range 5.3-10.8%; 3,099,853), in Scotland of 
6.7% (4.3-10.4%; 286,312) and in Wales of 9.0% (6.9-11.9%; 218,956). The 
addition of Type 1 paediatric patients (<16 years) were taken from the 
National Paediatric Diabetes Audit 2008/09, however, less than half of all 
paediatric practices participated in this audit in England (only 44%), and 
Scotland was not included.  The number of registrations was 15,627, and the 
authors have doubled this number to roughly account for the missing practices 
and Scotland.  The total estimated number of people living with diabetes in 
the UK is thus estimated at 3,636,375 (does not include Northern Ireland), 
which gives an estimated prevalence for the UK (excluding Northern Ireland) 
of 6.1% (calculated based on the diabetic populations in England, Scotland 
and Wales divided by the OECD 2009 population for the UK less the NI 
population (estimated as 1,788,896 by the Northern Ireland Statistical 
Research Agency) (Northern Ireland Statistical Research Agency 2010)). 
Details of diabetes prevalence data used in this study
 α
 
α
 Data from the UK excludes Northern Ireland. 
 France Germany Italy Spain UK 
Type 1
 ✓>18y ✓ ✓>18y ㄨ ✓ 
Type 2 ✓>18y ✓ ✓>18y ✓>18y ✓ 
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2.2.2 Direct costs  
A small number of studies exist in different countries enabling calculations of direct costs of 
diabetes.
iv
 In this study, we use a series of studies relying on population data in each of the 
study countries in order to estimate the total direct cost of diabetes, in addition to relying on 
primary data to provide a bottom up approach where possible. Study details, including sample 
size, year and what is included in costs are outlined in Box 2.2. Because the reference year for 
each of these studies is different, depending on the country examined, and in order to provide 
a uniform presentation we adjusted all pecuniary figures to 2010, by using the average GDP 
deflator for each year, relevant to each country. 
 
 
Box 2.2: Diabetes direct cost benchmarks 
 
France 
ENTRED Study: Direct 2007 medical costs from reimbursed health 
expenditures of 6,710 adults with a diagnosis of diabetes (>18 years) with Type 
1 (n=263) and 2 (insulin n=689, non-insulin n=2,777) covered by National 
Health Insurance Fund (2000-2007).  Additional limited data on diabetic 
patients receiving dialysis (n=25) (Ricci et al. 2009). Both diabetes- and non-
diabetes-related costs are included. 
A study of 6 million patients covered under the Affection de Longue Durée 
(ALD8) in 2004 for reimbursed treatments (not exclusively examining 
diabetes) (Vallier et al. 2006). 
Germany 
CoDiM Study: Direct costs for reimbursed diabetes health expenditures based 
on a sample of 18.8% AOK health insurance members, insuring one-third of 
Germany (random sample, matched case-control, n=357,200) (Köster et al. 
2011; Köster et al. 2006).  Included Type 1 and Type 2 diabetics (not 
differentiated in the study coding), and complications. 
Both diabetes- and non-diabetes-related costs are included. 
Italy 
Calculated for 2008 and 2010 using two studies by) (Marchesini et al. 2010 ) 
and) (Osservatorio Arno Diabete 2011); additional material from the same 
source has been used to check for consistency, notably, (Osservatorio Arno 
Diabete 2007) and (Marchesini et al. 2011). The figures are based on a cohort 
of pharmacologically treated Type 1 & 2 patients and include costs of 
complications.  Per patient figures that are provided have been extrapolated to 
the national population by using the OECD population estimates and the 
ISTAT 4.8% national prevalence estimate. 
Both diabetes- and non-diabetes-related costs are included. 
                                                     
iv
 IDF also provides direct cost estimates. The 2007 IDF direct diabetes costs as alternate source 
accounted for national and per capita health expenditure, diabetes prevalence and a ratio of diabetic to 
non-diabetic medical care expenses, however, have a few methodological issues.  Only 20 - 79 years 
diabetics are included, less weight given to national cost data and more weight to prevalence estimates 
and total health expenditure.  They make assumptions of the calculated diabetes cost ratio (R: the ratio 
of medical expenditures for diabetics to age- and sex-matched non-diabetics) using limited country-
specific information. 
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Spain 
Extrapolated from 3 main studies.  Oliva et al (2004) national study of Type 1 
& 2 adult patients (>18y, 2002), varying the degree of prevalence (5-6%) to 
find national and per patient direct cost estimates (Oliva et al. 2004). Additional 
studies include CODE-2 data (1998/99 data) (Mata et al. 2002) and a regional 
Canary Islands study (0-99y) (where prevalence is higher than Spain (8.7%)  
(1998 data), both Type 2 only (López-Bastida et al. 2002). 
Both diabetes- and non-diabetes-related costs are included. 
United 
Kingdom 
The UK numbers were obtained by taking 2 studies, one focusing on outpatient 
data (Currie et al. 2010) and the other on inpatient data (Morgan et al. 2010) 
similar data times, and combining the two to create an annual per patient cost 
and applying to the latest APHO Prevalence Modelling data to arrive at total 
expenditure figures; extrapolation to 2010 was achieved by using the GDP 
deflator. 
Both diabetes- and non-diabetes-related costs are included. 
 Details of direct cost data used in this study 
 
France Germany Italy Spain UK 
Type 1
 ✓ ✓ ✓ ✓ ✓ 
Type 2 ✓ ✓ ✓ ✓ ✓ 
Age range >18 years 
Insuree 
population 
Not detailed 
>18 years  
Whole 
population  
Whole 
population 
Comments 
Pharmaco-
treated 
patients 
only 
 
Pharma- 
treated patients 
 
  
Approach 
Total 
medical 
cost burden 
of people 
with 
diabetes 
Total 
medical 
cost burden 
of people 
with 
diabetes 
Total medical 
cost burden of 
people with 
diabetes 
Total 
medical cost 
burden of 
people with 
diabetes 
Total 
medical cost 
burden of 
people with 
diabetes 
 
 
2.2.3 Cost of complications  
There are a number of difficulties in reporting the cost of complications relating to diabetes 
care.  First, complication costs are often subsumed within diabetes in- and out-patient care, 
making disentangling this figure difficult.  Second, the collection of diabetes cost data is far 
from optimal and can lead to potential inaccuracies. Third, diabetes patients treated for 
complications may be coded as patients under the diagnosis for which they are admitted or 
treated, depending on what the primary reason for their care is, rather than diabetes itself.  
Procedural costs for diabetes-related complications are available in some countries, however, 
further extrapolation to derive complication costs is marred by lack of diabetes complication 
data (particularly for multiple co-morbidities) and their related treatments data. 
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In France, the PMSI (Diagnosis Related Group system) hospital data often does not include 
diabetes coding, thus identification of hospital costs associated with a specific condition is 
easier than identifying complications related to diabetes, nor does it identify ALD status 
(Kusnik-Joinville et al. 2008). Inpatient costs for diabetic patients may be considered a valid 
proxy for the cost of complications, as a significant proportion of these costs relate to 
complications. However, the data is patchy at best. The UK faces similar problems to France, 
in that health accounting coding does not take into account the complexity of diabetes 
treatment.  Although some identification of diabetes patients is possible in hospital, the 
coding is limited in taking into account patients with diabetes in hospital for diabetes-related 
complications, such as cardiovascular or renal disease, or for reasons outside diabetes care. 
This may often result in the inclusion of costs, which are not associated with diabetes or the 
treatment of complications associated with diabetes. Although this is a methodological 
caveat, it can only be acknowledged at this point. The fact that in certain cases the use of 
incremental costs is promoted as a means of accounting for what is attributable to diabetes, 
most frequently by using a control group with the same age characteristics as the target group 
goes some way into addressing the problem, but does not do so completely because (a) the 
epidemiological profile of the control is never identical (bar diabetes) to that of the target 
group and (b) certain cost elements may not be captured by the target group due to reporting 
inconsistencies as raised above. 
Because of the issues surrounding information on complications, the LSE survey to a select 
group of recipients encompassing academic experts, public health practitioners, clinical 
experts and decision-makers, was used as a means of collecting the latest available 
complications data on a bottom-up basis where readily available. However, there is a relative 
paucity of information, as is shown in Appendix 2 as well as Appendices 7A-7D.  
 
2.2.4 Indirect costs  
Indirect costs of diabetes relate, primarily, to absenteeism due to illness, early retirement due 
to diabetes, losses in productivity (cost of ―presenteeism‖) and dependence on social benefits. 
Additional elements of indirect cost relate to premature mortality and carer costs borne by 
family members. 
Certain aspects that can help in calculating indirect costs – particularly the probabilities for 
absenteeism, early retirement and social benefit reliance - have been studied in greater depth 
in a recent Danish registry population (Sorensen 2009). In order to approximate indirect costs 
in each of the study countries we used the relevant probabilities for absenteeism, early 
retirement and social benefit receipts from existing studies, as shown on Table 2.1. 
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In order to address the gap in the literature, cost data have been collected from each country‘s 
statistical services separately and relate to average annual earnings (in order to calculate the 
approximate cost of absenteeism), average annual pension (in order to calculate the 
approximate cost of early retirement due to diabetes) and average annual social benefit (in 
order to calculate the approximate cost of social benefit). Productivity losses due to 
presenteeism have not been able to be identified in any way; the same applies to caregiver 
costs and the costs of premature mortality. As a result, the estimates on indirect cost provided 
in this report are likely to be under-estimates. 
 
Table 2.1: Absenteeism due to diabetes and its complications (days/year), early 
retirement and social benefits (% of diabetes patients). 
Absenteeism (days per year) 41.499 days 
Complications (days per year) 7.725 days 
No complications (days per year) 33.774 days 
Absenteeism (% of economically active diabetics) 46.5% 
Early retirement (% of diabetic population) 17.36% 
Social benefit (% of diabetic population) 2.38% 
Sources: Based on estimates from (Sorensen 2009) and (López-Bastida et al. 2002). 
2.2.5 Process and outcome indicators 
 Using diabetes as an example, process indicators (Mainz 2003)
v
 relate to the frequency of 
blood glucose monitoring in Type 1 patients as well as how many patients are measured 
annually for cholesterol, blood pressure, eye examinations etc. These measures focus on areas 
where a link with particular outcomes has been established in the scientific literature, and 
graded by the diabetes community in terms of strength (e.g. greater strength is attached to 
annual retinal screening for all patients with diabetes than universal home blood glucose 
monitoring).  In contrast, outcome indicators
vi
 examine the results of these examinations as a 
reflection on the quality of the care delivery process (e.g. quarterly HbA1C results across all 
paediatric Type 1 patients).    
Evidence on outcomes is relatively limited and the methods used to monitor and evaluate 
these vary by country.  Both process and outcomes indicators will be examined where 
available: information is available in Italy and the UK (England and Scotland separately) on 
an annual basis and in France less frequently, however, less information is readily available 
for Germany and Spain.   
                                                     
v
 Process indicators evaluate the measurement of monitoring episodes per guideline recommendations.   
vi
 Outcome indicators evaluate the effect of care processes on the health and wellbeing of patients; 
intermediate outcome indicators capture the changes in biological status that subsequently affect health 
outcomes. 
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In France, the indicators have been collected as part of the 2001-2007 and 2007-2010 
ENTRED study focusing on seven indicators, (notably HbA1C (≤6.5%, ≤7%, >10%), blood 
pressure (<130/80 mmHg, <140/90 mmHg, ≥160/95 mmHg), BMI, HDL (<0.40 g/L, ≥0.40 
g/L), LDL (<1g/L, <1.30 g/L, ≥1.30 g/L), triglycerides (<1.50 g/L, ≥1,50 g/L) and urinary 
proteins) (Ndong et al. 2010)
vii
. 
In Italy, outcome indicators are collated by the Italian Association of Diabetologists (AMD) 
annals (2004 to present) (The AMD Annals working group 2009); these examine diabetes 
related process and outcomes indicators to assess the performance of diabetes centres.  The 
2009 AMD edition undertakes longitudinal analysis of these indicators (2004-2007). Five 
outcome indicators examined over the period 2004-2007
viii
 are: percentage of patients with 
HbA1C ≤7% or ≥9%; percentage of patients with LDL cholesterol <100 mg/dl or ≥130 mg/dl; 
percentage of patients with blood pressure ≤130/85 mmHg or ≥140/90 mmHg; BMI; and 
percentage of smokers.  In addition to the AMD Annals, other data regarding the quality of 
care for diabetes are available from the Research Institute of the Italian Society of General 
Medicine (SIMG). In particular, a series of indicators specifically for Type 2 diabetes have 
been developed based on a sample of 650 Italian GPs (The AMD Annals working group 
2009)
ix
. 
In Germany, outcomes data have been collected since 2003 as part of the national disease 
management programmes (DMPs) for Type 2 patients (Schäfer et al. 2010a; Schäfer et al. 
2010b) focusing primarily on patient characteristics to ascertain key enrollment criteria for 
DMPs, and on outcome evaluations having a keen interest in comparing DMP patients with 
patients in routine care in order to provide more scientific care and legitimate DMPs; in this 
process, DMPs are fiercely debated. Key outcome indicators in this context included systolic 
blood pressure, HbA1C, complication rates, activity rates, and participation in education 
programmes (Schäfer et al. 2010a; Schäfer et al. 2010b). 
In England, both process and outcomes indicators are collected by QOF (NHS Information  
Centre 2010)
x
 and are reported annually in National Diabetes Audits, while in Scotland, 
indicators are collected as part of annual Scottish Diabetes Surveys. Of the 134 indicators that 
                                                     
vii
 The 2009 data is reported here, which includes data from 8,926 patients, of which for 4,277 diabetes 
type is known (Type 1 n=275, Type 2 n=3,894) (Fagot-Campagna et al. 2010). 
viii
 A set of final outcome measures were also collected at the same time, however, they have not yet 
been published. 
ix
 SIMG has taken more process indicators into account than the AMD Annals, such as the monitoring 
of other parameters such as BMI (Body Mass Index), retinal fundus, pulse, among others.  
x
 QOFs were introduced in 2004 as the basis for assessing the quality of care of GP surgeries, forming 
the basis of financial incentives.  A GP practice registers diabetic patients, as well as recording visit 
outcomes, which provides a database of treated diabetic patients published annually, including diabetes 
prevalence among registered patients.  The 2009/10 QOF assessed 134 indicators in four categories: 
clinical care, organisation, patient experience and additional services.  
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were part of the QOFs in 2009/10, 17 were used specifically for diabetes management
xi
.  
Furthermore, both England and Scotland collate nine process and outcome measures annually 
into the English National Diabetes Audit and Scottish Diabetes Survey (HbA1C, BMI, blood 
pressure, urinary albumin, serum creatinine, cholesterol, retinal screening, foot examination 
and smoking) in addition to reporting complications. 
                                                     
xi
 It should be noted that the majority of the QOF indicators for diabetes are process and not outcomes 
indicators, yet they do provide an indication of available UK information.  Furthermore, this data does 
not establish a link between patients with diabetes and related complications, or distinguish between 
the different types of diabetes. 
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3. Diabetes Burden and Policies in Europe  
3.1 Incidence 
OECD estimates suggest that Type 1 diabetes incidence is highest in the UK with 24.5 cases 
per 100,000 population, followed by Germany (18), Spain (13), France (12.2), and Italy (8.4) 
(Figure 3.1). The EURODIAB study registers in 20 European countries (not including France 
or Italy) all report annual increases of 3.9% between 1989 and 2003, with a doubling of 
prevalent cases expected by 2010 (Patterson et al. 2009). These results are supported by other 
regional studies in Europe (Bruno et al. 2009; Imkampe et al. 2011; Thümer et al. 2010). 
Type 2 diabetes incidence is increasing in both children and adults, among others due to 
rising obesity in the former and rising obesity in an aging population in the latter (Passa 
2002). Added dimensions are the effect of socioeconomic status, with higher incidence of 
Type 2 diabetes in lower socioeconomic strata in Europe (Espelt et al. 2011), as well as a 
greater association with low birth weight and low childhood weight (Whincup et al. 2008). 
Figure 3.1: Diabetes Type 1 incidence (0-14 years)
 
 
Source: (Organisation for Economic Cooperation and Development (OECD) 2009).  
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3.2 Diabetes prevalence 
Based on IDF data, diabetes prevalence across EU5 is significant and is highest in Germany 
(12%) and lowest in the UK (4.9%) (International Diabetes Federation (IDF) 2009). From 
2007 to 2010 all 5 countries have seen their diabetes prevalence rise (Table 3.1).  Part of the 
increase in the UK is attributed to significant improvements in diabetes reporting during this 
time, which reflects documented under-reporting of diabetes pre-2007 (2006 was the first 
year of encouraged, but not mandatory, diabetes reporting) (Diabetes UK 2010c). 
Germany has the highest number of deaths attributable to diabetes, although this figure has 
declined dramatically between 2007 and 2010; smaller reductions in diabetes-related 
mortality are indicated in Italy and Spain. 
Table 3.1: Diabetes prevalence and attributable mortality (20-79 years) 
 
 France Germany Italy Spain UK 
 2007

 2010 2007 2010 2007 2010 2007 2010 2007 2010 
National Type 2 
prevalence
β
 
8.4% 9.4% 11.8% 12.0% 8.7% 8.8% 7.5% 8.7% 4.0% 4.9% 
Cumulative 
Type 2 
prevalence
δ
 
5.9% 6.7% 7.9% 8.9% 5.8% 5.9% 5.7% 6.6% 2.0% 3.6% 
Annual Type 2 
attributable 
mortality 
30,168 30,427 71,356 54,579 34,667 27,393 22,587 20,550 8,517
ξ 
18,707 
Notes: 

 Estimates for 2007 and 2010 were calculated based on older data (e.g. 1980-2006 for the 2006 
report). 
β 
National prevalence estimated using UN population distribution estimates.  Age- and sex-specific 
prevalence rates (PR) (via logistic regression) were applied to population distributions for 2007 and 
2010 per country, using the formula:  PR (20-79 years) = Total number of expected cases (20-79) 
/Total country population (20-79). 
δ 
Cumulative Prevalence (CP) assumes each country has the same age profile, removing age differences 
between countries to create a figure appropriate for comparison. The CP should not be used for 
assessing the diabetes population within a country due to circularity (inaccurate to extrapolate outwards 
to a population, as already calculated on actual national prevalence in the population).
 
ξ 
Reflects annual mortality for men only as no data for women (2007).   
Source: (International Diabetes Federation (IDF) 2006, 2009) 
 
Against the evidence presented in Table 3.1, the more recent national benchmark data from 
our study shows significant variation, both upward and downward (Figure 3.2).   Based on 
that, Spain and the UK report higher prevalence (8.1% and 6.1% respectively). Spain, 
however, only includes Type 2 adult cases, thus the 8.1% prevalence is likely to be an 
underestimate. France and Germany are very similar between the two.   
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Figure 3.2: Comparison of benchmark national diabetes prevalence versus IDF 
prevalence 
 
Notes: Prevalence (LSE): Germany (2007) (Köster et al. 2011), Italy (2009, >18 years) (ISTAT 2009), 
the UK (no N. Ireland; 2009)(Holman et al. 2011; NHS Information Centre 2010) are Type 1 and 2, 0-
99 years. France (2008) (Bringer et al. 2009; Lecomte et al. 2008) is Type 1 & 2, >18 years.  Spain 
(2008) (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas 
Asociadas (CIBERDEM) 2008) is Type 2, >18 years. 
Prevalence: (IDF) Cumulative prevalence for diabetes (2010 estimates, based on late 1990 and early 
2000 country data) (International Diabetes Federation (IDF) 2009). 
Source: Authors‘ compilation from a variety of sources. 
 
Based on national prevalence and population figures, the total number of people living with 
diabetes in the study countries, shows Germany with the highest total diabetic population (>7 
million) and Italy with the lowest (just under 3 million) (Figure 3.3). Regardless of the source, 
all data point to rising diabetes prevalence rates.  The rationale is manifold. First, obesity and 
Type 2 diabetes are strongly correlated and obesity has increased over the past two decades 
(Figure 3.4) (OECD Statistics (2010)). This well-documented rise in obesity (concurrently 
with cardiovascular disease and diabetes) is largely linked to sedentary lifestyles and poor 
diet. 
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Figure 3.3: National diabetes prevalence, extrapolation from benchmark 
 
Notes: Prevalence (total): OECD population estimates (2010) (Organisation for Economic Cooperation 
and Development (OECD) 2010) and the benchmark prevalence estimates below, except UK (Figure 
3.2, Box 2.1) [Country population * Country prevalence] 
Prevalence (%): Germany (2007) (Köster et al 2011), Italy (2009, >18 years) (ISTAT 2009), the UK 
(no N. Ireland; 2009) (Holman et al. 2011; NHS Information Centre 2010)
 
are Type 1 & 2, 0-99 years. 
France (2008) (Bringer et al. 2009; Lecomte et al. 2008) is Type 1 & 2, >18 years.  Spain (2008) 
(Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas 
(CIBERDEM) 2008) is Type 2, >18 years. 
Source: Authors‘ compilation from various sources. 
Figure 3.4: Diabetes stratification by BMI category in Scotland (2003, 2009) (Scottish 
Diabetes Survey Monitoring Group 2004, 2010) 
 
Notes: Reflects 6 out of 14 NHS Boards, showing BMI distribution of 60,466 diabetes patients  
Source: (Scottish Diabetes Survey Monitoring Group 2004, 2010). 
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Second, population aging has an additional association with diabetes. The projected inversion 
of the European population pyramid (Figure 3.5) is associated with a 30% increase in the 
lifetime risk of diabetes development (Hauner 2006). 
Figure 3.5: Population estimates by age, EU5 average (2000 - 2050)  
 
Note: Calculated as average individual country breakdowns of percent total population per age bracket. 
Source: (Organisation for Economic Cooperation and Development (OECD) 2007). 
Third, diabetes awareness has increased among health professionals and the public, leading to 
more people seeking diabetes testing alongside GPs screening their high-risk patients and 
being more aware of risk factors for Type 2 diabetes. Still, diabetes remains under-diagnosed 
as documented in all government and academic country prevalence sources.  
Fourth, the ethnic make-up of all EU5 countries has changed and continues to change.  
Certain ethnic groups are at higher risk in developing diabetes, primarily African-Caribbean, 
African and Asian (Indian) (Agyemang et al. 2011; Hippisley-Cox et al. 2009)
 
all with 
increasing population presence in EU5.  Whether this association is due to socioeconomic 
status or due to genetic relationships is an interesting discussion currently occurring in the 
literature, but outside the scope of this study. 
Finally, all countries have started to improve their diabetes data collection, some more so than 
others (the UK in particular).  This means that part of the rise in prevalence is due to the 
increased reporting of diabetes patients present all along in the general population, suggesting 
previous prevalence estimates were too low. Appendix 3shows diabetes-related data sources 
in EU5 and Appendix 4 summarises data sources on diabetes health outcomes. 
3.3 National Diabetes Programmes 
Government health departments provide diabetes care policy frameworks. France, Spain and 
the UK have national diabetes planning; Italy is in the planning stages, while Germany has 
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Diabetes Disease Management Programmes (D-DMP) via social health insurance. While not 
exhaustive, this section explores the diabetes policy and programming in the EU5 (Table 3.2).  
3.3.1 France 
In addition to being a serious cause of morbidity, diabetes is also related to almost 30,500 
deaths in France every year (equivalent to 3 citizens per hour) (International Diabetes 
Federation (IDF) 2009).  In terms of diabetes-related complications, more than 13% of 
patients with Type 2 diabetes suffer from coronary heart disease and 4% from stroke (Le 
Floch et al. 2000); 6% suffer from nephropathy and 29% from neuropathy,
 
while 
approximately 33.5% suffer from retinopathy (Delcourt et al. 1998). It is estimated that at 
least 20% of people with diabetes are unaware of their condition and remain untreated 
(International Diabetes Federation European Region et al. 2008). 
The French national diabetes programme (NDP) ―Programme d’Actions de Prevention et 
Prise en Charge du Diabète de Type 2 (2002/05)‖ was implemented by the Ministry of 
Health, focusing on prevention, screening, quality and care organisation, epidemiology (via 
ENTRED) and therapeutic education (Ministère en charge de la santé 2010). However, the 
French NDP is no longer operational since end-2005. Despite having no active NDP 
anymore, diabetes is covered under the National Health Strategy, and public health law has 
made diabetes a priority by setting two objectives: first, to ensure that monitoring practice 
conforms with clinical practice guidelines 80% of the time by 2008, and, second, to reduce 
the frequency and severity of diabetes complications, particularly cardiovascular 
complications. All diabetic patients (type 1 and 2) are included under ALD (long-term disease 
system), i.e. receive 100% reimbursement. This is lost if patients do not follow correctly the 
annual planned exam i.e. eye tests, HbA1C (twice annually), electrocardiogram. Furthermore, 
the national health insurance fund (CNAM) has carried out the SOPHIA programme since 
2008 with an extension in 2011, an adapted disease management programme where patients 
under ALD are followed by phone calls, newsletters and the internet. Currently, in the pilot 
phase, 56,775 patients are involved in the Sophia programme. 
Recent evaluation of a lifestyle campaign (―manger mieux, bouger plus‖ – eat better, move 
more) found that a few targets were not met, specifically a reduction of obesity/overweight by 
20%.  The programme will be continued but modified to address weaknesses in governance 
(important evaluation indicators were not defined) and in the prioritization of objectives 
(greater focus on obesity prevention and treatment) (Jourdain Menninger et al. 2010). In a 
broader context, the French National Nutrition and Health Programme (PNNS) was 
implemented in 2001 and has since been extended to 2010 with the goal of improving the 
health of the French population and reducing risk factors for chronic disease through a focus 
on nutrition. The PNNS is a government sponsored public/private collaboration involving 
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government, research and education institutions, the food industry, healthcare organizations, 
and consumers. The PNNS programme set nine priority objectives focusing on nutrition and 
physical activity (French National Nutrition and Health Program (France-Public-Private)  
2010). 
3.3.2 Germany 
Evidence suggests that approximately 55,000 German citizens die from diabetes each year 
(equal to 6 people per hour) (International Diabetes Federation (IDF) 2009). In terms of 
diabetes-related complications, more than 10% of patients with Type 2 diabetes suffer from 
coronary heart disease and 6.7% from stroke (Liebl et al. 2002); 16% suffer from retinopathy 
(Hesse et al. 2001), 8% suffer from nephropathy and 15% suffer from micro-albuminuria, 
which may lead to nephropathy (Bennett et al. 2001).   
In Germany, because of decentralized/regional governments‘ responsibilities in policies there 
is no legitimacy for ―national plans‖ on specific diseases, be it cancer, cardiovascular disease 
or diabetes. De facto, no national diabetes prevention programme exists, but there is a more 
generalised primary prevention approach as exemplified by the national action plan ―In-
Form‖ since 2008, which focuses on healthy lifestyle in general as primary prevention and is 
supported by the MoH (Bundesministerium für Gesundheit), or the the ―Gesundheitsziele‖ 
programme from federal and regional ministries, focussing on healthy lifestyle in childhood, 
reducing tobacco consumption and detecting T2 diabetes early (Gesellschaft für 
Versicherungswissenschaft und -gestaltrun e.V). In addition, a number of D-DMP facilitating 
diabetes care have been in operation since 2002/04 by all health insurance funds, of which 40-
50% of Type 1 & 2 patients are members (and voluntary check-up for individuals aged 
upwards of 40 years). Both programmes (DMP and check-ups) were defined by law and 
implemented via guidelines issued by the Federal Joint Committee. The evaluation of D-DMP 
versus non-DMP patients found D-DMP patients felt they had better care, despite the lack of 
difference in clinical outcomes between groups.  Conclusions about D-DMP programme are 
difficult, as there is significant selection bias and voluntary self-monitoring of care (Birnbaum 
et al. 2010). 
3.3.3 Italy 
It is estimated that every year, approximately 27,000 Italian citizens (approximately 3 people 
per hour) die from diabetes (International Diabetes Federation (IDF) 2009). Type 2 diabetes 
accounts for 90% of diabetes in Italy (Mladovsky et al. 2009). In terms of diabetes-related 
complications, 10% of patients with Type 2 diabetes suffer from coronary heart disease (DAI 
Study Group 2004); 32% suffer from neuropathy (Fedele et al. 1997) and about 34% of 
diabetics suffer from retinopathy (Giuffre et al. 2004). 
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In Italy, people with diabetes are subject to Law 115/1987 on provisions for the treatment of 
diabetes mellitus, and a Memorandum of Understanding between State and Regions on 
diabetes dated 1991, which partly implements the law. They set the legislative framework for 
the care management of people living with diabetes, as well as state their rights, including 
discrimination at work and school. Italy was the first country in the world to adopt such a law, 
which identifies the standards of care and rights of people with diabetes, and contributed to 
raising awareness on the care of patients with long-term diseases. The Regions are in charge 
of implementing these provisions.  
The National Healthcare Plans (NHP) – 2003-2005, 2006-2008, 2009-2010, and 2011-2013 - 
and National Prevention Plans (NPP) - including the latest one, 2010-2012 - mention, inter 
alia, diabetes, and call for horizontal models to better respond to the need of chronic patients 
and patients with diabetes. In particular, the 2011-2013 NHP is to be considered a National 
Diabetes Programme, because it includes diabetes among the diseases of public health 
interest, acknowledges the need to take action to tackle this disease, and allocates financial 
resources to its prevention and care. The latest NHP also insists on the need to implement 
‗clinical governance‘ for the treatment of diabetes with a multidisciplinary and integrated 
patient-centred approach, which fosters cooperation among the parties involved in care 
management and information sharing. It also calls to identify areas of improvement, create a 
platform to enhance dialogue between various healthcare-related players, initiate cooperation 
activities, and actively involve patients with diabetes in volunteer organisations. 
Diabetes is also specifically addressed in the National Prevention Plan (NPP) 2010-2012. The 
diabetes-related goals include improving early diagnosis in the population at risk, defining 
protocols for integrated management of diabetes, defining appropriate health paths, assessing 
the care network with reference to acute event and chronic illness, and encouraging the 
implementation of IT systems and databases to facilitate the management and assessment of 
the programmes.  
3.3.4 Spain 
It is estimated that every year, diabetes is the underlying cause of approximately 20,550 
deaths in Spain (equal to more than 2 people per hour) (International Diabetes Federation 
(IDF) 2009). Regional variations in diabetes prevalence are evident in Spain, where diabetic 
patients in the south of Spain are three times more likely to die from the disease than those in 
the north of the country (International Diabetes Federation European Region et al. 2008). In 
Spain, Type 2 diabetes accounts for 80-90% of diabetes (Mladovsky et al. 2009). In terms of 
diabetes-related complications, 12% of patients with Type 2 diabetes suffer from coronary 
heart disease, 10% suffer from stroke (Arteagoitia et al. 2003), 24% from neuropathy 
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(Cabezas-Cerrato 1998), 29% from retinopathy (Esmatjes et al. 1996), 23% from nephropathy 
(Arteagoitia et al. 2003) and 1.4% undergo a lower limb amputation. It is estimated that 
poorly controlled diabetes is related to 8-15% of all deaths in the Spanish population 
(International Diabetes Federation (IDF) 2006). 
In Spain, the national "Estrategia Nacional de Diabetes del Sistema Nacional de Salud" 
(Strategy on Diabetes Mellitus of the National Health System) programme has been used to 
coordinate regional health plans and develops guidelines for prevention, care and treatment of 
complications, since 2007.  As part of the Plan de Calidad del Sistema Nacional de Salud 
(Plan for Quality of the National Healthcare System) from March 2006, the NDP aims to set 
consistent operational standards and objectives to be achieved by the healthcare systems in 
place at regional level in order to ensure consistent, quality prevention, diagnosis and care of 
diabetes across the country.  
3.3.5 United Kingdom 
Type 1 diabetes prevalence in children in the UK ranks in the top 10 globally. Diabetes is 
associated with around 19,500 deaths in the UK each year (equal to 52 people per day) 
(International Diabetes Federation (IDF) 2009). In terms of diabetes-related complications, 
25.2% of patients with Type 2 diabetes suffer from coronary heart disease and 9.6% suffer 
from stroke (Morgan et al. 2000); 28.5% suffer from peripheral neuropathy (Young et al. 
1993). In the UK, 73 lower limb amputation are undertaken each week on diabetic patients, 
while, annually, 1,280 people become blind due to diabetes-related complications (Diabetes 
UK; UK Parliament 2010). Diabetes is related to 11.6% of all deaths in the UK population 
(Department of Health 2010). It is estimated that as many as 1million UK citizens who have 
diabetes are unaware of their condition (UK Parliament 2010). 
England implemented the National Service Framework for Diabetes (NSF-D) in 2003, with 
seven main objectives including prevention and early diagnosis, decision-making via patient 
empowerment, quality of care during adulthood and childhood, treating diabetic emergencies 
and inpatient care, pregnancy care, and complications management.  The NSF-D is supported 
by QOF, encouraging, among other things, diabetes data collection, alongside the annual 
National Diabetes Audit, which reports key indicators.  The Diabetes UK patient group also 
conducts regular surveys on quality of care and monitors access and availability of treatments.  
Part of diabetes goals and policies fall under the NSF-D while others sit outside the 
Framework, such as the Expert Patient Programme and self-management courses. Wales has 
introduced a NSF since 2003 (All Wales Consensus Group; NHS Wales 2003), while 
Scotland adopted its NSF in 2010 (The Scottish Government), and has also produced 
guidelines by the Scottish Intercollegiate Guidelines Network (Scottish Intercollegiate 
Guidelines Network 2010).  
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Other NHS points of reference for diabetes care are NHS Diabetes, which aims to improve 
diabetes services and encourage evidence based practice, and the Yorkshire and Humber 
Public Health Observatory which has developed a number of modeling tools as well as a 
national prevalence model (part of the basis for our UK prevalence benchmark). 
3.3.6 Overall 
Despite the recognition in the early 1990s of the impact of increasing obesity rates on national 
health projections for cardiovascular disease and diabetes (Type 2), all EU5 countries have 
only recently implemented national diabetes policies (absent in Germany and Italy).  It 
appears the policies implemented, in the case of France and the UK, are clearly projected in 
terms of objectives, although there are a number of caveats.  First, monitoring and evaluation 
appears to be soft, as objectives in place do not have hard targets (for example theoretically 
creating a target stating 90% of diabetics will have HbA1C measured at least bi-annually).  
Second, there does not appear to be a strong data collection service underpinning any 
objectives, further confounded by poor national capacity to identify people suffering from 
diabetes, particularly those with undiagnosed diabetes.  
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Table 3.2: Compilation of all national diabetes policies, and their goals and evaluations. 
  France Germany Italy Spain United Kingdom 
National 
Diabetes 
Policy 
 SOPHIA 
 ALD 
 Prevention: Regionally 
 Treatment: Disease 
Management 
Programmes 
 Prevention: National 
Diabetes Prevention Plan 
(2010/12) + other lifestyle 
programmes (Guadagnare 
Salute) 
 Treatment: None, but NDP 
under development  
 National and Regional 
programmes (IGEA, 
chronic disease 
management (Maggini 
2009)) 
 Estrategia Nacional de 
Diabetes del Sistema 
Nacional de Salud 
 National Service 
Framework for 
Diabetes, QOF, NICE, 
Diabetes UK and 
National Diabetes Audit  
Goals 
 Prevention, screening, 
quality and organisation 
of care, epidemiology, 
therapeutic education 
N/A 
 Primary and secondary 
prevention. Integrated 
management of care (IGEA 
project) 
 Coordinate regional 
health plans and 
investigation on 
diabetes in Spain 
 Prevention, diagnosis, 
quality, adolescent 
transitions, education, 
screening 
Monitored 
 Evaluation only - 
indicated that 
programme has met its 
objectives and should be 
continued 
Not formally 
 No national or regional 
monitoring, however, the 
AMD undertakes annual 
comprehensive monitoring. 
No 
 
 
 Annual reporting via 
National Diabetes Audit 
and Scottish Diabetes 
Survey, National 
Diabetes Inpatient 
Audit, YPHO diabetes 
profiles, QOF reports 
National 
Obesity 
Policy 
 Programme national 
nutrition et santé (2010) 
No No 
 Estrategia para la 
Nutrición, Actividad 
Física y Prevención de 
la Obesidad 
 Change4Life, National 
Obesity Observatory, 
―Healthy Lives, Healthy 
People‖ 
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3.4 Conclusions 
It appears that data on diabetes patients in the study countries is highly variable and diffuse. 
Compared to cancer, which has a similar burden of disease in all EU countries and either a national 
or regional cancer registries, estimation of burden of diabetes is currently neither accurate nor 
precise. This has a number of implications.  
First, the lack of accurate prevalence data is disappointing for stakeholders in academia and health 
policy and health care financing & resource allocation, resulting in difficulties for governments in 
terms of managing diabetes care and accurately undertaking future planning, both from a policy and 
financial perspective.  
Second, although some countries collect detailed data on small samples of patients (i.e. France 
ENTRED), other countries do not collect any data nationally (Germany) or do so only periodically 
(France, Spain).  There appears to be a lack of representation of outlying patients (i.e. brittle 
diabetes, paediatrics, elderly and minorities), vital yet little understood subsets of the diabetes 
population in all EU5 countries.   
Third, potentially neglecting Type 1 patients or including them within the Type 2 adult dataset 
makes it difficult to target services for patients who suffer for proportionally longer periods, often 
with higher risks of complications than Type 2 patients.   
Fourth, the data collected may not be relevant to all patients – particularly the adult versus paediatric 
populations – with more important information in younger age groups being neglected.xii   
Fifth, a number of important variables appear to be ignored or overlooked in surveys, including 
involvement by auxiliary health professionals (diabetes specialty nurses, dietitians, chiropody), use 
of psychiatric services, participation in diabetes education programmes, use of other specialist 
services (nephrology, cardiology, urology, surgery), documentation of complications, and 
identification of patients with pre-diabetes (impaired glucose tolerance) or brittle diabetes
xiii
. 
Finally, the diffusion of responsibility between diabetologists, endocrinologists and primary care 
professionals means that the creation and maintenance of such a registry would prove challenging, 
however, without improvements in the validity and availability of diabetes data, improvements in 
care will be difficult at best. 
On the other hand, our survey suggests that patient and physician advocacy and support groups 
appear to be well developed and supported in all countries.  As this may be one of the first and most 
                                                     
xii
 For instance the UK National Diabetes Audits have far greater data completion rates for adults than 
children, suggesting an underpinning rationale for paediatric clinics not to participate. 
xiii
 Brittle diabetes occurs in a minority of Type 1 and 2 patients with uncontrolled hyper- and hypo-glycaemia, 
and associated with greater rates of complications and earlier mortality. 
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consistent points of contact for patients, their ongoing activity and involvement is encouraging and 
valued.   
 
Box 3.1: Burden of disease - Key takeaways 
 
 Diabetes prevalence, using national figures described, is variable across the EU5: France 6.39% 
(Type 1/2 >18y), Germany 8.9% (Type 1/2, 0-99y), Italy 4.8% (Type 1/2, 0-99y), Spain 8.1% 
(Type 2, >18y), and the UK 6.1% (Type 1/2, 0-99y).   
 The total number of patients with diabetes in the EU5 is over 20 million, and this is likely to be 
an underestimation due to poor data collection as none of the study countries have national 
diabetes registries limiting data collection and availability. 
 Rising diabetes prevalence is driven by increasing obesity, aging populations, earlier 
identification of patients with diabetes, change in ethnic distribution, and improvements in data 
collection (UK). 
 Italy, Spain and the UK have national diabetes programmes (NDPs), although some are not 
monitored and none appear to have hard targets.  Neither Germany, nor France have NDPs. 
 Monitoring nationally of diabetes outcomes occurs periodically in France and Spain, annually 
in Italy and the UK and occurs through DMPs in Germany. 
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4. Diabetes Guidelines, Diagnosis and Treatment 
This section explores aspects of diabetes treatment, including the existence and content of 
guidelines, screening and diagnosis as well as routine monitoring for diabetes control.  Diabetes 
specific complications will be highlighted. 
4.1 Diabetes Guidelines 
All countries have diabetes treatment guidelines, key aspects of which are outlined in Table 4.1.  In 
France, the Haute Authorité de Santé (HAS) and the Agence Française de Sécurité Sanitaire des 
Produits de Santé (AFSSAPS) develop guidelines covering Type 1 & 2 diabetes treatment and 
monitoring under ALD8
xiv
, pediatric Type 1 diabetes treatment, and pharmaceutical treatment of 
Type 2 diabetes (jointly issued in 2006).  In Germany, the Deutsche Diabetes Gesellschaft (DDG) 
and physicians‘ chamber (Bundesärztekammer - BAK) have developed evidence-based guidelines 
for the diagnosis and treatment of diabetes (Types 1, 2 and gestational).  In Italy, national treatment 
guidelines are produced by the Associazione Medici Diabetologici (AMD), in conjunction with the 
Societa Italiana di Diabetologia (SID) (Associazione Medici Diabetologi (AMD) - Società Italiana di 
Diabetologia 2010). These cover screening, prevention and treatment of Type 1, 2 and gestational 
diabetes. In Spain, the Ministry of Health and National Health Service have published national 
diabetes guidelines (via Guiasalud), focused on the treatment of Type 2 patients – prevention, 
treatment, education and screening for complications (Consumo 2008), while regional authorities 
(e.g. Valencia) have also launched clinical guidelines for management of diabetes. Finally, in 
England, the National Institute for Health and Clinical Excellence (NICE) produces a multitude of 
guidelines for diabetes, including screening, diagnosis, specific treatment (Type 1, 2, gestational), 
medical technology (insulin pumps), medications (e.g. liraglutide), and management of 
complications.  As of March 2011, 48 guidelines and recommendations have been made for diabetes 
management, although no separate division exists within NICE for diabetes as for cancer 
management. 
  
                                                     
xiv
 The affections de longue durée system grants 100% SHI coverage for 30 chronic illnesses requiring 
prolonged treatment including Type 1 and 2 diabetes (ALD8).  The universal coverage applies only to diabetes 
treatment, while non-diabetes costs are covered under the general SHI reimbursement.  Certain payments are 
excluded: excess consultant charges, patient surcharges and transport costs (in certain cases).  
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Table 4.1: Aspects of treatment addressed by national diabetes guidelines 
  France Germany Italy Spain UK 
G
u
id
el
in
e
 Type 1 ✓ ✓ ✓ ㄨ ✓ 
Type 2 ✓ ✓ ✓ ✓ ✓ 
Gestational ㄨ ✓ ✓ ㄨ ✓ 
Pre-diabetes ㄨ ㄨ ㄨ ✓ ✓ 
T
re
a
tm
en
t 
p
a
th
w
a
y
 Type 1 ㄨ ㄨ ✓ ㄨ ✓ 
Type 2 ㄨ ㄨ ✓ ✓ ✓ 
Gestational ㄨ ㄨ ✓ ㄨ ㄨ 
Pre-diabetes ㄨ ㄨ ㄨ ✓ ㄨ 
L
if
es
ty
le
  
Type 2: DES 1
st
, then 
medication 
✓ ㄨ ✓ ✓ ✓ 
Discussion of co-morbidities  ✓ ✓ ✓ ✓ ✓ 
Discussion of DES with 
patients 
✓ ㄨ ✓ ✓ ✓ 
M
o
n
it
o
ri
n
g
 
g
u
id
el
in
e
s 
General ✓ ✓ ✓ ✓ ✓ 
Type 1 ✓ ㄨ ㄨ ㄨ ✓ 
Type 2 ✓ ㄨ ㄨ ✓ ✓ 
Gestational ㄨ ㄨ ㄨ ㄨ ✓ 
Pre-diabetes ㄨ ㄨ ㄨ ㄨ ✓ 
P
re
v
en
t Prevention to reduce incidence ✓ ✓ ✓ ✓ ✓ 
Community Awareness ㄨ ✓ ✓ ㄨ ✓ 
Max waiting times for 
treatment 
ㄨ ㄨ ㄨ ㄨ ㄨ 
R
o
u
ti
n
e 
m
o
n
it
o
ri
n
g
: 
Haemoglobin A1C q3m ✓ q3m q6m q3-6m 
Fasting blood glucose ㄨ ㄨ ㄨ  ✓GC 
Urinary Proteins ✓ ✓ ✓ q1yr q1y 
Body Mass Index ㄨ ✓ ✓ q6m q11y 
HDL cholesterol ✓ ✓ ✓ q1yr q1yr 
LDL cholesterol ✓ ✓ ✓ q1yr q1yr 
Triglycerides ✓ ✓ ✓ q1yr q1yr 
Waist to Hip Ratio ㄨ ㄨ ㄨ q6m ㄨ 
Blood pressure ㄨ ㄨ ✓ q1y q1y 
Foot examination ㄨ ㄨ ✓ q1y q1yr 
Serum creatinine ㄨ ㄨ ✓ q1y q1y 
Retinal examination ㄨ ㄨ ✓ q1yr q1y 
ECG ㄨ ㄨ ㄨ q1y
CVD
 q1y
CVD
 
R
ef
er
ra
ls
 
Dietician ✓ ㄨ ✓  ✓ 
Exercise specialist ㄨ ㄨ ㄨ  ✓ 
Renal Physician ✓ ㄨ ✓ ✓ ✓ 
Opthalmologist ✓ ㄨ ✓ ✓ ✓ 
Cardiologist ✓ ㄨ ✓ ✓ ✓ 
P
a
ti
en
t 
ca
re
 
a
n
d
 
m
a
n
a
g
em
en
t 
Diabetes emergency care ✓ Poor ✓ ✓ ✓ 
In-patient care ✓ Poor ✓ ㄨ ✓ 
Diabetes and pregnancy ㄨ ✓S ✓ ㄨ ✓ 
Long-term complications ㄨ ✓ ✓ ✓ ✓ 
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Psychological issues ㄨ ✓ ✓ ✓DES ✓ 
Choice of diabetic clinics ㄨ ✓ ✓ ㄨ ✓ 
Improving quality of care ㄨ ✓ ✓ ㄨ ✓ 
Improving access to diabetes 
care 
ㄨ ✓ ✓ ㄨ ✓ 
Promote multi-disciplinary 
teams 
ㄨ ✓ ✓ ✓ ✓ 
Promoting patient-centred care ㄨ ✓ ✓ ㄨ ✓ 
Training for diabetes personnel ㄨ ✓ ✓ ㄨ ✓ 
Notes: q = every (e.g. q3m means every 3 months; q1y means every year); CVD only in CVD; DES diet, 
exercise, smoking; GC dependent on glucose control and medication (home blood glucose monitoring more 
likely in patients with either poor control or patients taking insulin); S: only in specialised centres. 
 
4.2 Diagnosis 
4.2.1 Patient testing and screening 
There are some variations in the target patient groups and basis risk factors for routine diabetes 
testing (Table 4.2).  Only France and Germany appear to have concerted efforts to routinely screen 
high-risk patients for diabetes, although these constitute recommendations to physicians and it is not 
known whether they are followed on a routine basis. In Germany a general health check-up is 
voluntarily available to all statutorily insured people every 2
nd
 year for all insures aged 35 and over 
and this is also endorsed by law. Blood and urine glucose as well as other parameters are measured 
at no extra cost to the insuree, but uptake remains low. This screening is also targeted to detect T2D 
early (Bundesministerium für Gesundheit). Screening for gestational diabetes is also offered free of 
charge to all pregnant women by the German sickness funds. Testing for Type 2 diabetes in Italy, 
Spain and the UK is at GP discretion, although screening for gestation diabetes in high-risk 
(overweight, obese) mothers is routinely performed.   
All countries recommend testing for diabetes in patients who present the classical symptoms of 
polydipsia, polyuria and weight loss, or have a family history of the disease.  Additional testing 
criteria for high-risk patients in France are personal or family history of CVD, birth to a baby 
weighing more than 9 pounds, or previous gestational diabetes diagnosis.  Testing criteria in 
Germany are similar to France, with the addition of patients tested previously for Impaired Glucose 
Tolerance (IGT) and those with acanthosis nigricans (a skin condition highly associated with 
diabetes). Italian criteria are identical to Germany, with the addition of testing obese patients.   
Spain undertakes diabetes testing in patients with the following risk factors (although up to GP 
discretion to do so) obesity, high blood pressure, high cholesterol levels, CVD history, acanthosis 
nigricans, polycystic ovary syndrome, birth to a baby more than 9 pounds or gestational diabetes 
diagnosis.   
In the UK, testing of patients for diabetes beyond the routine presentation is dependent on GP 
discretion.  Some GPs may test all their overweight or obese patients, however, no firm guidance 
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exists on this matter (although it may in upcoming May 2012 Pre-Diabetes guidelines(National 
Institute for Health and Clinical Excellence (NICE) In progress, expected May 2012)).  The same 
GP dependency exists for patients with CVD, hypertension and hyper-cholersterolaemia for 
additional diabetes testing associated with these conditions.  In 2009, the NHS implemented the 
Health Check programme, which invites adults aged between 40-74 years without heart disease, 
stroke, diabetes or kidney disease to be screened for the forenamed diseases by their GP, pharmacist 
or nurse.  This programme is still in the early stages, and as yet no information is available on uptake 
or outcomes.  
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Table 4.2: Patient groups tested and screened for diabetes by family physician 
  
France Germany Italy Spain UK 
Patients routinely tested for diabetes 
Classic: polyuria, 
polydispia, weight loss 
✓ ✓ ✓ ✓ ✓ 
Obese patients  ㄨ ㄨ ✓ ✓ 
✓GP, 
NICE
 
Family history: parent, 
sibling 
✓ ✓ ✓ ✓ ✓ GP 
High blood pressure ㄨ ✓ ㄨ ✓ ✓GP 
History of CVD ✓ ✓ ㄨ ✓ ✓GP 
High cholesterol levels ㄨ ✓ ㄨ ✓ ✓GP 
Previous test for IGGT ㄨ ✓ ✓ ✓ ✓ 
Acanthosis nigricans ㄨ ✓ ✓ ✓ ✓ 
Birth of a baby ≥9 lbs or 
gestational diabetes 
✓ ✓ ✓ ✓ ✓ 
Polycystic ovary syndrome  ㄨ ㄨ ㄨ ✓ ✓ 
Retest of patients testing 
normal 
✓ q3y 
(depending 
on age, sex, 
RF) 
ㄨ 
HR tested 
with OGTT 
✓ q1-5y GLD 
Pre-diabetes: next test ✓ 1 year  ㄨ ✓ 6m  ✓ 6-24 m  GLD 
Diabetes screening initiatives 
Type 2 screening 
program 
✓ ✓ ㄨ ㄨ ㄨ 
Patient groups screened HR 
HR and all  
age >35 
GP  GP  GP  
Conditions for screening 
>45y + >1RF; 
OR >45y + 
unstable 
Age >35 - - - 
Screening frequency  q2yr - - - 
Screening rate 71.2% 0-20% - - - 
Notes: GLD: guidelines under development, expected May 2012; GP: Dependent on GP decision; NICE: 
NICE includes diabetes in its 2010 obesity guidelines however makes no recommendations on routine diabetes 
testing: HR: High risk patients; RF: risk factor 
Source: The authors. 
 
4.2.2 Physician involvement 
There is some variation in physician responsibilities in terms of diagnosis and treatment across EU5.  
In general, GPs are responsible for diagnosis of Type 1, Type 2 and pre-diabetic patients, 
particularly in the UK, Italy and Spain, although diabetologists/endocrinologists may be involved, 
paticularly if the patient is first diagnosed with diabetes in emergency care.    Treatment is usually 
differentiated between physicians, with endocrinologists/diabetologist focused on Type 1 or insulin-
dependant Type 2 treatment, while GPs concentrate on the treatment of non-insulin dependent Type 
2 diabetics and patients with pre-diabetes.  There is little consistency in the physicans consulting on 
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Type 2 insulin dependent cases, with some seen by diabetologists/endocrinologists and others seen 
by their GP who may have additional diabetes training. 
Individual care plans are developed for patients in Germany, Italy and the UK.  In Germany, this 
tends to occur primarily for patients seen by a multi-disciplinary care team, academic teaching 
hospitals and occasionally by GP-led care.  In Italy, individual care plans are defined for (and by) 
patients seen by a multi-disciplinary care team and those treated in academic teaching hospitals.  The 
UK encourages all patients with diabetes to receive a patient centred care plan in its National 
Diabetes Framework, however, actual delivery is difficult to measure or monitor. A Diabetes UK 
survey of its members found 60% discussed their diabetes goals with their physician, but only 30% 
received their diabetes test results prior to the appointment in order to plan their discussion (Diabetes 
UK 2010c).  Individual care plans are not defined in France and Spain.  Each physician that a patient 
sees decides on a course of action, within the boundaries of the national diabetes treatment 
guidelines. 
4.2.3 Treatment processes, timelines and patient education 
In all EU5 countries only unstable patients are admitted to hospital upon diagnosis, regardless of 
diabetes type (1 or 2). Outpatient multi-disciplinary diabetes teams exist in all EU5, while in the UK 
there are specialist GP diabetes clinics with GPs who have additional diabetes certification and offer 
multi-disciplinary care (dietetics, chiropody).  In France, patients are treated by a multi-disciplinary 
team only if they are hospitalised or consult outpatient physicians, otherwise Type 1 patients are 
generally seen by endocrinologists or diabetologists and Type 2 patients by their GPs.  In Italy and 
the UK, only Type 1 & 2 insulin-dependent Type 2 patients are seen by multi-disciplinary teams in 
hospital outpatient clinics, while non-insulin dependent Type 2 patients are seen by community GPs.  
In Spain, only Type 1 patients are monitored by multi-disciplinary diabetes teams and Type 2 
patients are seen by community GPs. 
Formal patient education programmes for new patients have been instituted nationally in Germany, 
Italy, Spain and the UK (content and intended audience varies regionally).  In France, Sophia is 
currently in the pilot phase (Box 4.1), and 70% of general education is provided by diabetologists 
(Jaffiol 2009).  In Germany, education is provided to all Type 1 & 2 patients in private practice and 
hospitals, as well as by some GPs, with 50-70% receiving patient education.  In Italy, education 
programmes are offered only for diabetic patients being treated by a multi-disciplinary team, 
delivered in diabetic centres focusing on dietary advice and physical activity. 
In Spain, education programmes are provided only in academic teaching hospitals.  The composition 
of programmes varies by centre, although all usually include the following: general diabetes 
information, diet and exercise, glucose monitoring, hypoglycaemia identification and treatment, 
insulin delivery (when applicable), complications and their prevention.  Education programmes are 
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given to the majority (95%) of Type 1 diabetics at diagnosis. Education for Type 2 diabetics is 
offered to a considerable number of patients by GPs and family nurses and, less often, by 
multidisciplinary teams. 
In the UK, all hospital outpatient clinics and specialist GP clinics offer diabetes education as 
recommended by the National Diabetes Framework.  The difficulty, however, lies in its content and 
its provision, funding and take-up.  In some regions programmes are only available for Type 1 
patients, while others offer education only to Type 2 patients. There are national guidelines and 
programmes for content, namely DAFNE for Type 1 and DESMOND for Type 2 diabetes however, 
regional education programmes do not need to adhere to their content.  A recent survey of diabetes 
patients did reveal a need for continuous diabetes education, including refresher courses (Diabetes 
UK 2010c). It appears that there is no concerted focus, or guaranteed provision of programmes to all 
patients with different diabetes types in any of the EU5. 
4.2.4 Patient monitoring 
Routine visits 
Type 1 patients are seen by an endocrinologist or diabetologist on a quarterly basis (in all countries 
but less frequently in Spain), while Type 2 patients irrespective of medication requirements are seen 
either a GP or endocrinologist with similar frequency. Patients with gestational diabetes seem to be 
treated by a specialist (diabetologist, endocrinologist or gynaecologist depending on the country) 
most regularly in Germany (once to twice per week) and least frequently in Spain (1-2 times per 
trimester). Patients with impaired glucose tolerance are monitored more variably across countries. In 
Spain, these patients are seen up to four times a year by a GP, whereas in France they are seen once 
or twice a year.   
Box 4.1: Patient education & monitoring pilot programme in France (Sophia) 
 
 
Sophia is a voluntary pilot programme offered gratis to Type 1 & 2 patients over 18 years covered 
by the Affections de Longue Durée (ALD8) programme (80% of diabetics are part of this universal 
coverage regime for chronic diseases) to encourage regular contact with patients (ideally every 6 
weeks). Services include information and educational tools, telephone advice provided by medical 
staff (primarily nurses), and Internet services. The tools include a quarterly magazine, patient 
reminders provided through post-it notes, calendars and posters and a magnet with the Sophia 
contact details.  The pilot programme, covering 10 departments (administrative divisions), is 
available to approximately 136,000 patients (nearly 6% of the total diabetic population). 
Sophia stems from 2007 social security financing law providing the development of programmes to 
accompany patients with chronic conditions.  The goal is to improve the quality of life of diabetic 
patients and to reduce costs of complications.  A medical and economic evaluation of the programme 
is currently underway.   
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Home blood glucose monitoring, continuous glucose monitoring & insulin pumps 
Home blood glucose monitoring (HBGM) via glucometers is not routine practice in all EU5 and/or 
for all diabetes types.  In France, all Type 1 patients and one third of Type 2 patients, treated with 
insulin or oral anti-diabetic medication, undertake HBGM.  In Spain and Italy, all Type 1 patients 
and those Type 2 patients treated with oral anti-diabetic drugs are advised to undertake HBGM, 
however, uptake is unclear. In Germany, only patients on insulin therapy and/or unstable diabetes 
may have HBMG covered by statutory health insurance.  In the UK, only patients treated with 
insulin (Type 1 or 2) are advised to HBGM. Patients with gestational diabetes are advised to self-
monitor in Germany, Italy and Spain.  Patients with pre-diabetes are not advised to undertake self-
monitoring in any of the countries studied.  
Continuous glucose monitoring (CGM) is available to unstable patients in Germany, Italy, Spain and 
the UK (by individual application), however, ―very few‖ patients in Germany, 5-10% of patients in 
Italy and fewer than 1% of patients in Spain and the UK receive CGM.  In France CGM is available, 
however it is not currently covered by SHI. 
Insulin pumps are available and wholly reimbursed for unstable and Type 1 patients in France, Italy 
(7-8% uptake) and the UK.  In Germany, approximately 50% of unstable patients and 20-30% of 
Type 1 patients use insulin pumps. Spain provides insulin pumps to all unstable patients, however, 
only a fraction (about 1-2%) use it. Differences also exist in UK uptake, ranging from less than 1% 
to almost 8% of paediatric patients. Significant differences in costs of insulin pumps also exist 
across countries.
xv
 
  
                                                     
xv
 The average cost of an insulin pump is highest in France (€19,633) and lowest in Italy (€2,000-3,000).  
Costs in the other EU5 are: €6,000-6,500 in Spain (at an estimated annual per patient cost of €3,000), €3,680 
in Germany, and in the UK £4,580 (pump and placement cost) for the first year and £1,145 annually thereafter. 
42 
 
Table 4.3: Diabetes treatment practices across EU5 (2010)
 
 France Germany Italy Spain UK 
Diagnosis to treatment 
Type 1: Time 
diagnosis to 
treatment  
0-3 days Quick Immediate < 15 days - 
Type 2: Time 
diagnosis to 
treatment 
Depends on 
GP 
Unknown Immediate < 15 days - 
Target time 
diagnosis to 
treatment 
Type 2: 3m  
diet pre-drugs, 
unless unstable  
ㄨ N/A ㄨ ㄨ 
Education 
programme 
for new 
patients 
Sophia pilot 
programme 
expanded 
All diabetic 
patients 
Only patients 
treated by 
multi-
disciplinary 
diabetes 
team 
Only in 
academic 
teaching 
hospitals 
✓Reg 
Frequency of stable patients visits to health professionals 
Type 1 q3-4m 
E/D
 q3m
D
 q2-4m 
q3-6m 
E/D
 
q3-4m 
GP
 
q3m
D/E
 
Type 2 
(insulin) 
q3-4m
E/D
 q3m
GP/D
 q2-4m 
q0-4m 
E/D
 
q2-4m 
GP
 
q3m
D/E/GPs
 
Type 2 (oral 
anti-diabetic) 
q3-4m 
GP
 q3m
GP
 q4-6m q2-6m 
GP
 q3-4 m 
GP
 
Gestational 
diabetes 
0.5-1m 
E
 q1-2w 
D
  
q1-
2/trimester 
Gyn/E
 
q2-4wks 
D/E/O
 
Pre-diabetes q6-12m 
GP
 Not regular Not regular ✓ q6-12m 
Notes: Reg: depends on region GP: primary care family physician; E: endocrinologist; D: diabetologist; O: 
obstetrics; Gyn: Gynaecologist 
Source: LSE survey in diabetes and diabetes costs in 5 EU countries. 
 
4.3 Diabetes care delivery 
All study countries report a variety of issues in delivering diabetes care (Table 4.4). In France, the 
primary problems relate to regional differences in access to care, insufficient human resources, 
insufficient funding for lifestyle change initiatives and inadequate physician diabetes training. 
Although experts in France consider the level of care to meet international standards, a recent 
evaluation of ENTRED data concluded a number of improvements could be made in the prevention 
and treatment of complications (e.g. when to intensify treatment to include insulin), as well as 
monitoring for micro- and macro-vascular complications.  Additional recommendations included 
reinforced access to paramedical care and greater coordination of treatment (Robert et al. 2009). 
Care delivery issues in Germany relate primarily to insufficient training and care resources, both 
human and facility, limitations in access due to geographical inequities, particularly for the latest 
treatment options, inadequate funding for lifestyle change initiatives and lack of screening 
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programmes. These may be the result of insufficient political support for diabetes care.  While a 
good framework for diabetes care delivery exists, substantial improvements could be made both in 
terms of diabetic practice and standards.
xvi
 Furthermore, practical problems resulting from limited 
financial resources, excessive regulation, poorly trained health professionals and a lack of integrated 
care (between GPs, specialists and hospitals) need to be addressed. 
In Italy, substantial regional variations exist in demand and access to care.  In the south and central 
regions, the number of diabetes centres is proportional to the number of patients. In the north, the 
diabetic population is larger, resulting in an imbalance in demand versus existing resources.  As a 
result, a system of coordinated care and integrated diabetes management is developing in the north 
with diabetic care teams operating within hospitals as well as shared care between GPs and 
diabetologists – however, this is still a minority situation and an ongoing experiment.  By contrast in 
the south, while an integrated management plan is a national goal, diabetes care still tends to be 
ambulatory and undertaken by a diabetologists only rather than. care teams.  Additional problems 
include insufficient human resources (particularly diabetologists) and facility resources (north - 
diabetic centres, south - equipment), plus long waiting times (particularly in the north due to greater 
total prevalence). Specific areas of improvement relate to the integrated management of diabetes, 
coordination of duties among professionals, increased training for professionals and greater use of 
outcomes to monitor progress (a recent AMD undertaking). 
Spanish diabetes care is also organized regionally with geographical variations in resources and 
management, resulting in limited screening, long waiting times for diagnosis and treatment, 
problems in accessing care and inadequate patient surveillance following diagnosis (particularly 
rural regions). In some regions, there are shortages in endocrinologists, specialised nurses and 
trained GPs. As public health care does not provide funding for dietetic care and other lifestyle 
change initiatives, greater demand for these services is shouldered by GPs and general nurses.  In 
some instances, physicians do not receive adequate training, particularly for preventative care. While 
experts interviewed for this study agreed that overall diabetes care meets international standards, 
improvements in the following are sought: increased resources for prevention and lifestyle 
initiatives, and improved co-ordination between primary and specialised care. 
There are a number of issues in the UK in delivering optimal diabetes care.  Despite a stable number 
of diabetologists and increased GPs with additional diabetes care training, Diabetes Specialist 
Nurses (DSN) and dietitians specializing in diabetes care (Diabetes UK 2010a; Diabetes UK et al. 
2009), there appears to be large variations in care between regions and individual practices 
(Department of Health 2010; Diabetes UK 2010c; NHS Information Centre 2011).
 
Under the QOF, 
all GP practices and PCTs must submit data including biomarkers, retinal and foot screening, and 
                                                     
xvi
 For example, diabetes guidelines based on diabetes type and treatment would be welcome in improving the 
standards and quality of diabetes care. 
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complication notation.  The 2010 National Diabetes Audit found only 44% of paediatric practices 
participated, only 75% of GP practices contributed, while all PCTs for adult care participated.  Not 
only was the submission rate highly variable (i.e. paediatrics highest in Wales, lowest in England; 
adult lowest in Wales and highest in England), but content of their outcomes was also highly 
inconsistent (discussed in Section 6).  Access to diagnosis and treatment for complications relating 
to diabetes is also regionally dependent, as is access to new treatments such as insulin pump 
therapies. There is also concern from a workforce perspective, that there is decreasing protection and 
job security of DSN (Diabetes UK et al. 2009) while the number of new vacancies for diabetologists 
in the UK has shown a steady decline since 2004 (Diabetes UK 2010a). This is unfortunate on both 
counts, as DSNs play a major role in patient care and decision making, and diabeteologists provide 
specialist care in a disease that is increasing steadily, including insulin dependent cases. 
Overall, there is little consistency in who delivers diabetes care across EU5, plus all countries 
indicate regional inequalities in access to diabetes care.  General trends include insufficient human 
resources, lack of screening programmes, insufficient funding for lifestyle initiatives and waiting 
times for some patient groups. 
 
4.4 Conclusion 
All EU5 countries have diabetes treatment guidelines, developed either by national agencies or 
diabetes associations, although Spain does not for Type 1, and France and Spain do not for 
gestational diabetes.  The UK appears to be the most prolific in its diabetes guidance development, 
with over 40 recommendations produced to date. 
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Table 4.4: Problems in delivering diabetes care 
α 
Leading diabetic practice ㄨ ㄨ ✓ ㄨ ㄨ 
Meeting international standards ✓ ㄨ ㄨ ㄨ ✓ 
Room for improvement ㄨ ✓ ㄨ ㄨ ✓ 
International practice does not apply ㄨ ㄨ ㄨ ㄨ ㄨ 
Notes: AH: after hours care; C: complications (depending on specialty); E: patient education; R: annual 
retinal screening (+ minimal annual monitoring for micro- and macro-vascular damage); Reg: depends on the 
region;  
α 
The information in this table reflects the opinions of survey respondents from the individual study countries. 
1
 There may be out-of-pocket costs associated with having the condition, rather than – strictly speaking – 
treating the condition. The latter are included, whereas the former are not. 
Source: The authors from the LSE survey. 
 
Routine diabetes screening programmes for high-risk patients exist in France and Germany, both 
countries with social health insurance, but participation is variable.  In the remaining countries 
diabetes testing is at the discretion of the GP and usually based on high-risk situations such as, 
  France Germany Italy Spain UK  
Main delivery of care problems 
Regional differences in access to care ✓ ㄨ ✓ ✓ ✓ 
Insufficient human resources ✓ ✓ ✓ ✓ ✓AH, E 
Insufficient facility resources ㄨ ✓ ㄨ ㄨ ㄨ 
Poor distribution of resources ㄨ ㄨ ㄨ ✓ ✓ 
Inadequate diagnostic facilities ㄨ ㄨ ✓South ㄨ ㄨ 
Inadequate treatment facilities  ㄨ ㄨ ㄨ ㄨ ㄨ 
Absence of screening programs ㄨ ㄨ ✓Gestational ✓ ㄨR 
Poor funding complications treatment  ㄨ ㄨ ㄨ ㄨ ㄨ 
Poor funding lifestyle changes 
initiatives 
✓ ✓ ㄨ ✓ ㄨ/✓Reg 
Long waiting times for diagnosis ㄨ ㄨ ㄨ ✓ ㄨ/✓C 
Long waiting times for treatment ㄨ ㄨ ✓North ✓ ✓C 
Poor access due to geographical 
inequities 
ㄨ ✓ ✓ ㄨ ㄨ 
Poor quality treatment ㄨ ㄨ ㄨ ㄨ ㄨ/✓Reg 
Poor or no practice guidelines ㄨ ㄨ ㄨ ㄨ ㄨ 
Poor physician diabetes resources ㄨ ㄨ ㄨ ㄨ ㄨ 
Inadequate physician diabetes training ✓ ✓ ㄨ ✓ ㄨ 
Poor political interest in diabetic care ㄨ ✓ ㄨ ㄨ ㄨ/✓Reg 
Poor press coverage of diabetic care ㄨ ㄨ ㄨ ㄨ ✓ 
Inadequate patients monitoring ㄨ ㄨ ㄨ ✓ ㄨ/✓Reg 
Inadequate services for complications  ㄨ ㄨ ㄨ ㄨ ㄨ/✓Reg 
High out-of-pocket cost to patient
1 ㄨ ㄨ ㄨ ㄨ ㄨ 
Delays and/or poor access to the latest 
treatments/medicines 
ㄨ ✓ ㄨ ㄨ ㄨ/✓Reg 
Poor participation in diabetes research ㄨ ㄨ ㄨ ㄨ ㄨ 
International comparison 
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diabetes family history, obesity, and abnormal lipid profiles.  Diagnosis still occurs via testing for 
another medical purpose; however, emergency care diagnosis is becoming more rare. 
In all study countries, care of diabetic patients is largely shared between GPs, DSNs, 
endocrinologists and diabetologists.  The majority of cases are diagnosed or identified by GPs and 
then referred onto more specialist care depends on diabetes type with insulin dependent cases are 
usually seen by endocrinologists or diabetologists.  Individual care plans are developed for patients 
in Germany, Italy and the UK, where patient focused care is becoming encouraged.  In France care 
pathways are the responsibility of the treating physician. 
Formal patient education programmes for new and existing patients have been instituted nationally 
in Germany, Italy, Spain and the UK.  France is piloting a new education programme.  All countries, 
however, profess a need to further their tailored education for diabetes patients, realising that ‗one 
size fits all‘ is not the case, with diversity in cultures, age, diabetes type and time since diagnosis. 
 
Box 4.2: Diabetes guidelines, diagnosis and treatment - Key takeaways 
 
 Despite all EU5 producing diabetes guidelines, there is little uniformity in the types of 
organisations producing the guidelines across the EU5.  This may have implications for the 
quality of the guidelines, effectiveness of their implementation as well as their potential impact 
on individual and population diabetes outcomes. 
 Only France and Germany appear to have concerted efforts to routinely screen patients at risk 
for diabetes, the remaining countries appear to rely on GP discretion on testing high-risk 
patients. However, uptake appears to be poor. 
 It appears that only insulin dependent Type 1 or 2 patients receive specialised endocrinology or 
diabetologist care in (perhaps) multi-disciplinary hospital outpatient care, the remaining 
patients cared for in the community by their GP.  This may affect the ability to access auxiliary 
services (diabetes nurse specialists, dieticians, chiropody), as well as exposure to patient 
education programmes. 
 The process and quality of care delivery differs between countries – the primary problems 
being regional inequalities in access to diabetes care, insufficient human resources, lack of 
screening programmes, and insufficient funding for lifestyle change initiatives. 
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5. Cost burden of diabetes and its complications 
As diabetes prevalence is increasing across the EU5, so is total health expenditure, including 
diabetes spending. Available estimates (e.g. IDF) suggest that the cost attributable to diabetes can be 
substantial, as shown in Appendix 5. Based on the methods outlined in section 2, this section 
summarises and discusses the total costs of people with diabetes for the study countries, including 
direct (inpatient, outpatient, pharmaceutical), indirect, as well as the limited sources of costs of 
complications resulting from diabetes.  
5.1 Total health expenditure in EU5 
Health care expenditures are increasing rapidly: from 2000 to 2008, total health expenditure 
increased by 49% in France, 22% in Germany, 48% in Italy, 111% in Spain and 45% in the UK 
(Table 5.1). The greatest health spending growth per capita was in Spain (85%), followed by Italy 
(43%), France (41%), UK (39%) and Germany (22%) (2000-2008) (Figure 5.1). 
Table 5.1: Total health expenditure in EU5, 2000-2008 (€, million) 
 France  Germany  Italy Spain  UK 
2000 €  145,182 €  212,435 €   96,040 €  45,446 €112,793 
2004 €  182,707 €  233,543 €   120,421 €  68,868 €142,491 
2006 €  199,228 €  244,917 €  133,585 €  82,064 €163,883 
2008 €  216,063 €  258,620 €  142,167 €  95,130 €163,593 
Source: (World Health Organisation 2009). Current population estimates are used to arrive at total figures per 
country. Average exchange rates are used to convert to Euros. 
 
Figure 5.1: Total health expenditure per capita in EU5, 2000-2008 (in €)α 
 
Notes: 
α
 Country National Health Accounts data (WHO) (World Health Organisation 2009) divided by total 
population (OECD) estimates (Organisation for Economic Cooperation and Development (OECD) 2010). 
Average exchange rates are used to convert to Euros. 
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5.2 Direct cost burden of diabetes 
5.2.1 Costs in In- and Out-patient Care Settings 
Both in- and out-patient costs are major components of direct diabetes costs.  Difficulties arise in 
their computations: differentiation between Type 1 & 2, whether diabetes medications are included 
or reported separately, and whether the cost of complications is included.  National-level data is 
unavailable for most or all EU5 countries, thus the majority of data is obtained from regional studies, 
as shown on Table 5.2 reporting total direct costs and Table 5.3, reporting per patient costs. 
France 
In France, total direct costs reached €12.9 billion in 2010. The components of direct costs were: 
hospital costs 37.2% (€4.9bn), outpatient costs (excluding drugs), 36% (€4.6bn) and drugs 26.8% 
(€3.5bn).xvii  
Germany 
In Germany, the total direct cost burden arising from the treatment of people with diabetes has been 
estimated to be €43.2 billion in 2010. Inpatient and outpatient direct costs for Type 1 & 2 are very 
close in proportion (33.7% versus 28.2%), while 19.5% (€8.2bn) is expended on pharmaceuticals 
(both diabetes- and non-diabetes-related pharmaceuticals). The incremental cost of diabetes on 
health care costs increased from €12.9 billion in 2000 to €19.1 billion in 2007 (Köster et al. 2011) 
and €19.7 billion in 2010. A comparison of diabetes DMP members versus non-members found non-
significant, higher annual hospital costs in non-members (€1,277 versus €1,158/patient; 2006 costs) 
(Linder et al. 2011). 
Italy 
Total direct costs in Italy amounted to €7.94 billion in 2010. The largest component of total direct 
costs in Italy is the cost of hospitalisation at 56.9% (€4.5bn), followed by 29.5% for drugs (€2.34bn) 
(Osservatorio Arno Diabete 2011).  
Spain 
In Spain, the total direct cost of diabetes reached €5.45 billion in 2010 and the largest component 
thereof was the cost of pharmaceuticals at 46% (€2.55bn), followed by inpatient care at 36% 
(€1.95bn) and by outpatient care (excluding pharmaceuticals) at 18% (€0.95bn) (Oliva et al. 2004).  
The most recent study of Spanish national diabetes direct costs calculate per patient costs at €1,708 
annually (Type 1 & 2); 2002 costs extrapolated to 2010), whereas the average cost of a person 
without diabetes annually are €995 (Oliva et al. 2004) (in both cases 2002 costs extrapolated to 
2010). An older regional study of the Canary Island estimate lower total diabetes costs per patient at 
€758 annually (1998 costs) (López-Bastida et al. 2002). 
                                                     
xvii
 2010 extrapolations based on the 2009 ENTRED study reporting 2007 data. 
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United Kingdom 
From national government sources, the UK only has total diabetes expenditure estimates. The 
Department of Health in England report direct diabetes costs as 5% of total health spending (2002-
2006) based on estimates from a Type 2 cost study (Wanless 2002; Williams et al. 2002; Yorkshire 
and Humber Public Health Observatory et al. 2006), and thereafter increased this estimation to 10% 
(c. £9 billion), however, no costs were directly measured (Department of Health (2006) 2006; 
Diabetes UK March 2010).  A few studies have attempted to quantify the cost of diabetes in the past 
(Bagust et al. 2002; Currie et al. 2004; Currie et al. 2005). Of these, (Bagust et al. 2002) found total 
annual costs £11.49bn for Type 2 diabetes patients (2000 costs inflated to 2010).
 
 
In the context of this study, two recent sources (one focusing on outpatient data over the 1997-2007 
period (Currie et al. 2010) and the other on inpatient data in 2004 (Morgan et al. 2010)) are used to 
calculate the total direct cost of diabetes in the UK on a per patient basis and extrapolate to 2010, 
based on a national prevalence of 6.1%.
 
Based on these, the total direct cost in the UK has been 
calculated to be £13.8 billion (€20.2 billion using the base year rate of exchange). 
5.2.2 Costs by Diabetes Type 
There is little national information regarding diabetes costs by type (Table 5.3).   
France 
French ENTRED 2007 data estimates for total costs were €6,927 for Type 1 patients and €4,890 for 
Type 2 patients. Expenditure for Type 2 patients treated with insulin (€10,413) was nearly 3 times 
higher than that of patients treated with oral anti-diabetic agents (€3,625). Annual outpatient costs 
per patient at €4,329 for Type 1 patients, €3,180 for all Type 2 - €6,546 for Type 2 with insulin and 
€2,409 with Type 2 without insulin.  Annual inpatient costs per patient are €2,597 for Type 1, 
€1,710 per Type 2 - €3,866 for Type 2 with insulin, and €1,216 for Type 2 without insulin (Ricci et 
al 2009). 
Germany 
The German CoDiM study did not differentiate between Type 1 & 2 patients, however, patients 
treated with insulin mono-therapy (predominately Type 1 patients) had 3.4 times higher costs and 
patients with insulin plus oral hypo-glycaemic drugs had 3.1 times higher costs than matched non-
diabetic controls (Köster et al. 2006).   
Italy 
Italian data also suggests Type 1 patients are twice as costly as Type 2 patients (Marchesini et al. 
2010 ).  
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Spain 
The Spanish data did not differentiate between Type 1 and 2 patients.  
United Kingdom 
As already discussed, no formal national government data exists on diabetes expenditure by diabetes 
type in the UK, partly due to the poor reporting of Type 1 versus 2 cases and also due to a lack of 
data systems to do so.  In 2007, The Economist estimated per patient costs to be $4,794, as part of an 
international study (The Economist Intellegence Unit 2007). The academic literature points at the 
influence of diabetes type on costs.  A simple combination of the in- (Morgan et al. 2010) and out-
patient (Currie et al. 2010) costs by type (inflated to 2010 costs), estimates Type 1 annual costs per 
patient as €4,744 (£3,233) and Type 2 €5,470 (£3,717); the cost of pharmaceuticals is included in 
these calculations.  It is estimated the percentage of patients with Type 1 diabetes is 8% for adults 
(15% for children) in the UK, and its application to national prevalence suggests spending €2.64bn 
(£1.8bn) for Type 1 and €17.28bn (£11.94bn) for Type 2, annually. 
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Table 5.2: Total direct diabetes cost burden: Medicines, In- and Outpatient care (estimates in € million)1 
 
France 
Germany  (total cost 
burden)
2 
Germany (incre-
mental cost burden)  
Italy
3 
Spain UK 
Base year 
(2007) 
2010 
Base year 
(2007) 
2010 
Base year 
(2007) 
2010 2008
 β
 2010
 β
 
Base year 
(2002) 
2010 2010 
Total drug  €3,350ξ €3,466 €8,190α €8,438 
€4,053 €4,175 
€3,078 €2,344 €1,389 €2,549 
€904 (£626)T1 
€3,644 (£2,522)T2ψ 
Diabetes Drugs €770 ξ €797 - - 
€2,060 €2,122 €592 €492 €311 €570 €497 (£344)
T1
 
€1,029(£712)T2ψ 
Non-diabetes 
Drugs 
€2,580ξ €2,669 - - 
€1,993 €2,053 €2,486 €1,852 €1,078 €1,978 €406(£281)
T1
 
€2,615(£1,810)T2ψ 
Inpatient  €4,700ξ €4,862 €14,154α €14,582 
€6,003 €6,184 
€3,636 €4,519 €1,060 €1,949 
€1,494(£1,007)T1 
€11,926(£8,038)T2ψ 
Outpatient 
(w/out drugs) 
€3,450 ξ €4,604 €11,860α €12,219 
€4,735 €4,878 
€921 €1,074 €515 €949 
€245(£170)T1 
€1,674(£1158)T2 ψ 
Other  €1,000 ξ - €7,770α €8,005 
€4,310 €4,440 
- - - - €336(£230)
Ϫ
 
Total
 ζ
 €12,500 ξ €12,932 €41,974 €43,244 
€19,100 €19,677 
€7,635 €7,937 €2,674δ €5,447 
€20,223 ψ 
(£13,812)
 
Notes:  1 With the exception of Germany, where costs are presented both as total direct burden as well as incremental costs, in the other study countries it is not possible to disentangle the non-
diabetes-related costs. While a significant proportion of the latter can be attributed to diabetes (e.g. complications), others do not. Totals may be different from the addition of individual 
components due to rounding. 
France: ξ Based on ENTRED 2007 data (Type 1 & 2), published in 2009 (Ricci et al. 2010). Inpatient includes private and state hospitals. ―Outpatient‖ include GP, specialist, physiotherapy, 
nursing, pharmacy, dentistry and laboratory. Other costs include injection devices, self-blood glucose monitoring equipment, insulin pumps (€7m), oxygen-therapy and other medical devices. 
The total figure can be even higher than the one reported on this table if the prevalence of 6.39% is applied.  
Germany: α CoDiM 2007 data (Type 2), published in 2011. Outpatient costs include physician and nursing care, transportation, other remedies, other outpatient services, care at home and long-
term care (nursing insurance).  Breakdown between diabetes and non-diabetes drugs was not available. Data was inflated to 2010 (Köster et al. 2011). 
2 Individual cost items arising from extrapolation of per patient costs to population level based on prevalence information used in the study. 
Italy: 3 Italian cost data relies on 2 studies published in 2010  (Marchesini et al. 2010 ) and 2011 (Osservatorio Arno Diabete 2011) and referring to 2008 and 2010 respectively.  
β Extrapolation of proportional direct cost composition applied to estimate of total direct cost for 2008 and 2011 from per capita figures as reflected in Table 5.3. 
Spain: δ Spanish national data (2002) including Type 1 & 2 patients (Oliva et al. 2004). The 2010 figures are extrapolations based on the 2002 data. 
UK: ψ Bottom up approach based on in-patient 2005 cost data from (Morgan et al. 2010), and out-patient 2007 cost data from (Currie et al. 2010); .The UK figure is susceptible to exchange rate 
fluctuations; the direct cost figure of £13.8 billion has based on 2005 and 2007 data, which have been converted to Euros using the prevailing exchange rates (2005: £0.674/€; 2007: £0.692/€), 
and extrapolated to 2010, then multiplied by UK prevalence (3.6 million) with a 15:85 Type 1:2 ratio (includes children, excludes N. Ireland) in order to arrive at the €20.2 billion figure.  
ϪAnnual social services cost (2007, £230m), converted to 2007 Euros (£0.692/€) and added to the other direct cost extrapolations. 
Other: ζ Cumulative sum of column.  Estimate reflects extrapolated figures across years and studies.  Differs from total direct cost estimate in Table 5.3.    
μ Costs extrapolated to 2010 using annual GDP deflator for each country (International Montary Fund (IMF); Trading economics Main website; World Bank). 
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Table 5.3: Per patient direct diabetes cost burden: Medicines, In- and Outpatient care (estimates in €) 1 
 
France 
Germany (total 
cost burden) 
Germany 
(incremental cost) 
Italy
2 
Spain UK 
Base 
year 
(2007) 
2010 
Base 
year 
(2007) 
2010 
Base 
year 
(2007) 
2010 2008 2010 
Base year 
(2002) 
2010 
Base year  
(2005, 2007) 
2010 
Total Drugs €1,409ξ €1,458  €1,115α €1,149 €553 
 
€569  €1,076  €814 
€649 €632 
€1,532 (£1,060)T1 
€1,089 (£754)T2 
€1,622 (£1,122)T1 
€1,153 (£798)T2 
Inpatient Costs  €1,955ξ €2,022  €1,927α €1,985 
 
€819 
 
€843  €1,271 €1,569 
€557 €829 
€2,419 (£1,630)T1 
€3,417 (£2,303)T2 
€2,681 (£1,807)T1 
€3,786 (£2,552)T2 
Outpatient Costs 
(w/o drugs) €1,483ξ €1,533 €1,623α €1,672 
 
€646 
 
€665  €322 €373 
€128-193 €247 
€415 (£287)T1 
€500 (£346)T2 
€439 (£304)T1 
€530 (£367)T2 
Physician €409δ,ξ €423  €752α €775 €339 €349 - - €128-193 -  - 
Nursing €440ξ €455 €871α €897 €307 €316 - - - -  - 
Other  €403 ξ €417 €1,061α €1,093 
 
€588 
 
€605 - 
- -   - 
Total  €5,251ξ €5,432  €5,726  €5,899 
 
 
€2,605 
 
 
€2,684  €2,669 €2,756 
€1,334-
€1,4763 
€1,708 
(€3,015)n 
€4,367 (£2,977)T1  
€5,007 (£3,403)T2 
€4,744 (£3,233)T1 
€5,470 (£3,717)T2 
Notes: 
1
 With the exception of Germany, where costs are presented both as total direct burden as well as incremental costs, in the other study countries it is not possible to 
disentangle the non-diabetes-related costs. While a significant proportion of the latter can be attributed to diabetes (e.g. complications), others do not. Totals may be different 
from the addition of individual components due to rounding. 
France: ENTRED 2007 cost data (Type 1 & 2) (Ricci et al. 2009). Inpatient includes private and state hospitals.  Outpatient costs include GP, specialist, physiotherapy, 
nursing, pharmacy, dentistry and laboratory. Other costs include injection devices, self-blood glucose monitoring equipment, insulin pumps (€7m) and other medical devices. 
Germany: 
α 
CoDiM 2007 data. ―Other services‖ encompass medical devices, remedies, professional home nursing, transportation (Köster et al. 2011). 
Italy: 
2
 Italian cost data relies on 2 studies published in 2010 (Marchesini et al. 2011) and 2011 (Osservatorio Arno Diabete 2011) and referring to 2008 and 2010 
respectively. 
Spain: Total drugs include diabetes and non-diabetes (complications) drugs.  Outpatient costs include primary and endocrinology outpatient visits.  All include Type 1 & 2 
nationally, assuming 5% prevalence (1.675m patients) (Oliva et al. 2004) 
n
 The figure in brackets relates to an extrapolation of the CODE-2 figure (1998) (Mata et al. 2002) and is inserted here for expositional purposes, although the two figures are 
not directly comparable. 
3
 Range figures relate to different prevalence scenarios in (Oliva et al. 2004). 
UK: 
Ϛ 
Inpatient 2005 costs from (Morgan et al. 2010) and outpatient 2007 costs from (Currie et al. 2010).  Inflated to 2010 costs and converted to Euros.  
Other: 
μ 
Costs extrapolated to 2010 using annual GDP deflator for each country (International Montary Fund (IMF); Trading economics Main website; World Bank). 
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5.2.3 Direct Costs: Diabetes Medications 
Diabetes medications are primarily consumed in outpatient settings, although emergency care 
medications will be administered in inpatient settings. Medication expenditures reported here are for 
all purposes including, but not specific to, complications. 
France 
In France of the €12.9 total direct diabetes cost burden in 2010, spending on medicines for patients 
with diabetes reached €3.47 billion (Ricci et al. 2009)xviii; of this, diabetes medication (oral €445m, 
insulin €352m) constitutes only 6.2% of the total diabetes direct costs. The largest component of non-
diabetes medication was cardiovascular medication (€1.29bn), including cholesterol lowering 
(€320m) and anti-platelet (€207m), followed by psychotropic drugs (€165m), antacids (€155m), 
antibiotics (€62m), immune-suppressants (€54m), anti-anaemic drugs (€54m) and other drugs (Ricci 
et al. 2009). 
Germany 
In Germany, the CODiM study found that total drug costs do not exceed 20% of total diabetes 
expenditure (€8.4 billion of the total 43.2 billion spending in 2010) and that total per capita drug 
spend stands at €1,149 (Köster et al. 2011). A comparison of diabetes DMP members versus non-
members found significantly higher annual prescription costs in non-members (€1,164 versus 
€1,309/patient; 2006 costs) (Linder et al. 2011). 
Italy 
In Italy, total expenditure on medicines in 2010 amounted to €2.34 billion (31.8% of total direct cost), 
of which €492 million are for glucose lowering drugs (6.2% of total direct cost) and the remainder for 
drugs treating co-morbidities and complications of diabetes. 
Spain 
In Spain, 2002 projections suggest that total expenditure on pharmaceuticals stood at €2.55 billion in 
2010, of which only 22% (€570 million) related to diabetes medicines (10.5% of the total direct cost 
of diabetes), whereas the remaining 78% related to non-diabetes drug costs. This split between 
diabetes and non-diabetes drugs is also confirmed by other studies in the Spanish context (López-
Bastida et al. 2002; Oliva et al. 2004). 
United Kingdom 
In the UK, total drug spend related to diabetes reached €4.54 billion (£3.148 billion), of which €1.52 
billion (£1.056 billion) (7.5% of total direct cost) was related to diabetes per se. Overall, diabetes 
medications are a fraction of total diabetes direct costs (Table 5.2): 6.2% in France, 6.2% in Italy, 
7.5% in the UK, and 10.5% in Spain; in Germany it was not possible to calculate this figure. 
                                                     
xviii
 Based on 2007 data that has been inflated to 2010. 
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Figure 5.2: Total direct diabetes cost burden (A), and proportional comparison of in- and 
outpatient costs, and diabetes medicines (B) (2010 estimates, € million).α 
 
 
Notes:
 α 
All data and sources as per cost outline in Table 5.2. 
No non-diabetes medicine costs are available for Germany. No ‗Other‘ costs available for France, Italy, Spain. 
* Germany diabetes drugs include also non-diabetes drugs (ie drugs for managing diabetes complications and 
other non-diabetes-related conditions) as both diabetes and non-diabetes drugs were included in the same 
accounting. 
^ UK ‗Other‘ includes social care costs, and overall total derived from a bottom-up approach. 
Source: The authors from Table 5.2. 
5.3 Complications related to diabetes and associated costs 
There are several complications arising from diabetes, due to the damaging nature of glucose 
molecules on the micro- and macrovascular system, particularly when combined with obesity 
(especially in Type 2 patients).  The main complications are cardiovascular disease, coronary heart 
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disease, blindness, nephropathy, peripheral neural disease, amputations, depression and erectile 
dysfunction.  Scant data on the costs of screening, monitoring and treatment exists; few studies have 
addressed this in a comprehensive way (Ray et al. 2005). As discussed in the methods section, there 
are significant difficulties with examining cost of complications resulting from diabetes (poor coding 
of complications, inclusion of complications cost data in general diabetes costing and poor 
identification of diabetic patients with complications). None of the study countries collect national 
data on costs of complications resulting from diabetes, thus all cost data come from regional studies.  
Complications can lead to hospitalisation of patients. The hospitalisation rate is highest among 
patients under age 20 (54%) and patients over age 80 (42%). In the UK, the 2010 National Diabetes 
Inpatient Audit (with 93% PCT participation rate with 12,191 visits) found the median length of stay 
was 8 nights versus 5 for non-diabetic patients.  Other significant findings were that older patients (75 
years versus 67) experienced higher rates of emergency admissions (86% vs 58%) and almost half 
were treated with insulin (NHS Diabetes 2010). The Audit also found that 9% of in-patient diabetes 
admissions were due to complications such as ketoacidosis, hyperosmolar hyperglycaemic state, 
active diabetic foot disease, hypoglycaemia or hyperglycaemia with established diabetes (NHS 
National Information Centre 2010). Of this 9%, 44.4% had been admitted for active diabetic foot 
disease and 20.4% for hypoglycaemia (NHS National Information Centre 2010). 
Köster et al. (2011) estimate that the average incremental direct in-patient costs attributed to diabetic 
patients in Germany (in comparison to non-diabetic patients) were €819 per patient in 2007 (Köster et 
al. 2011)
xix
. Complications relating to diabetes substantially inflate per patient treatment costs.  
Findings from the French ENTRED 2007 study indicate that the cost for diabetic patients with 
complications is 1.7 times higher for macrovascular complications, 1.1 times higher for microvascular 
complications, 6.7 times for nephrology complications, 2.51 times for major comorbidities (cancer, 
dementia, Parkinsons, stroke, heart disease) and 1.55 times higher for morbid obesity (BMI>40) 
(Ricci et al. 2009). The German CoDiM study found 41% of Type 2 patients on oral antidiabetic 
agents had macrovascular complications compared to 52% of Type 1 and Type 2 with insulin (Köster 
et al. 2006). Total Spanish annual direct costs per patient with no complications are €883; this figure 
increases significantly with the addition of complications: microvascular €1,403, macrovascular 
€2,021 and multiple complications €2,132 (1998 costs) (Mata et al. 2002). Eighty-six percent of total 
chronic complication costs relate to macrovascular complications, the remaining 14% relates to 
microvascular complications (Oliva et al. 2004). 
Many patients present with more than one complication; the cost of two complications is greater than 
one, while the addition of a third complication further raises this cost substantially.  An exploration of 
a UK patient dataset finds that coronary heart disease plus cardiovascular disease costs €3,339 
                                                     
xix
 Cost figures were standardised to match the age and gender distribution in the overall population in 
Germany. 
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(£2,250) (per patient, while the addition of a diabetic foot raises it to €4,175 (£2,814) (Currie et al. 
2005)
xx
.
 
Finally, the perspective used in cost analysis impacts the estimated cost calculations; for example, the 
total cost of diabetic retinopathy in Germany, from a societal perspective, using 2002 data, was 46 – 
60% higher than the same cost when applying a payer perspective (Happich et al. 2008).  
5.4 Selected complications related to diabetes and associated costs 
This section outlines the relevant costs of individual complications based on available evidence from 
the literature and the survey tool that was administered in each of the 5 study countries. For the latter, 
data has been collected from regional and/or small scale national studies, as well as from cost 
effectiveness analyses of diabetes treatments.  Individual costs are also given from hospital tariff data 
if comprehensive costs could not be found.  
The part of data obtained from the survey tool is summarised in Appendix 7 for diabetic retinopathy 
(Appendix 7A), diabetic foot (Appendix 7B), cardiovascular disease (Appendix 7C) and renal disease 
(Appendix 7D).  
5.4.1 Diabetic retinopathy and blindness 
The literature suggests that diabetic retinopathy affects 10-28.7% of patients (Delcourt et al. 2009; 
Jaffiol 2009), while blindness develops in 0.5- 3.7% of diabetic patients (Fagot-Campagna et al. 2009; 
Linder et al. 2011). The general cost of eye disease is estimated at €3,124 per patient (Agenzia 
sanitaria e sociale regionale 2009), with specific costs for cataract operations estimated at €1,041-
€1,878 (Spain, Italy), laser treatment €60-€3,477 (Italy, Germany) and blindness €382-€10,547 
(France, Germany) (Ray et al. 2005). The LSE survey found that the cost of cataract surgery ranged 
between €397 (France) and €2,830 (UK). Examination of the UKPDS data for diabetic patients found 
the cost of blindness in one eye was €1,589 (£1,100) (1998, inflated to 2010) (Clarke et al. 2003). 
Some issues in the delivery of care exist, particularly with respect to inequitable access to eye services 
as a result of an insufficiency of optometrists and appropriately qualified ophthalmologists in France 
(Delcourt et al. 2009) and long waiting times for diagnosis in Spain. 
 
5.4.2 Foot disease 
Peripheral arterial occlusive disease (PAOD) is the initial stage of foot disease, affecting 1.5-9.9% of 
diabetic patients (annual incidence 0.5-3% (Fosse et al. 2006)), resulting in ulcers and wounds (Fagot-
Campagna et al. 2009; Linder et al. 2011).
  
If blood glucose control remains poor and foot checks are 
not performed daily this may result in gangrene, amputation of toes or all or part of a foot (0.2-0.3% 
of all cases) (Linder et al. 2011). 
                                                     
xx
 1999 data inflated to 2010. 
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Microvascular complications, including diabetic foot, have been shown to increase diabetes costs in 
the French ENTRED study (Ricci et al. 2010). A French study found that total healthcare costs 
without inpatient care were €840/patient monthly and €2,546-€2,772 with inpatient care (2000 costs 
inflated to 2010)
xxi
 and that costs are highest in patients with inpatient care or amputations, 
particularly in the first month and decreasing thereafter (Girod et al. 2003). The 2009/10 hospital 
tariffs in the UK for foot disease are classified via cardiac status and electivity and range from £7,432-
£13,490 (€8,427-€15,305) for amputation, £863-£5,109 (€979-€5,796) for diabetes foot procedures.  
Amputation in the UKPDS study cost €16,763 (£11,298) (Clarke et al. 2003), and diabetic foot annual 
per patient costs were €1,523 (£1,026) (Currie et al. 2005), while per admission costs were €5,780 
(£3,890)(Morgan et al. 2010) (2001 and 2006 costs respectively both inflated to 2010).  Other broader 
per patient estimates include neuropathy €63-€3,855 (France, Germany), lower limb amputations 
€9,515-€32,000 (Italy, France), prosthesis €1,138-€3,241 (France, Germany), gangrene treatment 
€1,783-€5,611 (Germany, Spain) and ulcer treatment €1,783-€1,999 (Germany, France) (Ray et al. 
2005). 
5.4.3 Cardiovascular disease 
Cardiovascular disease, including angina (16%), myocardial infarctions (1-8%), stroke (1.7-7%), 
ischemic heart disease and heart failure (6.3-11%) are the major complications resulting from diabetes 
(Fagot-Campagna et al. 2009; Linder et al. 2011; Williams et al. 2002), in particular when combined 
with being overweight or obese, which is very common in Type 2 diabetes.  The triad of excess body 
adipose, poor blood glucose control and other cardiovascular risk factors (high blood pressure and 
lipid abnormalities)is often accompanied by additional complications such as diabetic foot, increasing 
costs substantially (Currie et al. 2005).  
A significant proportion of diabetes patients are treated with prescription medicines, including ACE 
inhibitors, with angiotensin 2 receptor blockers, statins, calcium-channel blockers, beta-blockers, 
aspirin, and clopidogrel. Therapeutic options are comparable across the study countries and in some 
cases there is a quantification of the relevant cost (e.g. in France (Robert et al. 2009)). The cost of 
treating MI and stroke among diabetic patients is also important as the cost is substantial due to the 
intensity of treatment and length of stay (LOS), as shown in UK (Clarke et al. 2003; Currie et al. 
2005; Morgan et al. 2010) and French settings. Compared to all inpatients for non-diabetes reasons, 
diabetes results in 6-23% greater costs in this particular therapeutic area (Colin et al. 2007). 
Indicatively, treatment costs range from €2,100 (fatal MI, UK) - €9,767 (MI, Germany) for 
myocardial infarctions and €4,314 (UK) - €11,786 (Germany) for stroke (Appendix 7C).   
                                                     
xxi
 This study also provides costs per Grade 1-4. 
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5.4.5 Renal disease 
Poor blood glucose control results in permanent macro-and microvascular damage of the nephron 
tubules in the kidneys.  Renal insufficiency starts with microabuminuria (20-25%), progressing onto 
renal disease, end stage renal disease (ESRD) (0.4-3.0%) requiring haemo- or peritoneal dialysis, and 
finally kidney transplant (Type 1 incidence 7.7-9.2%; Type 2 0.3-2.6%) (Linder et al. 2011; 
Soedamah-Muthu et al. 2008a; Soedamah-Muthu et al. 2008b; Williams et al. 2002).
 
The incidence of 
ESRD associated with diabetics is 46.7 per million inhabitants and 129 per 100,000 diabetics 
(Couchoud et al. 2008). The majority of annual nephrology treatment costs are attributed to Type 2 
patients, although Type 1 patients reflect 25% of all ESRD patients and 85% of all diabetes kidney 
transplants (Gordois et al. 2004). 
French ENTRED patients with dialysis or transplant (n=25) had inpatient costs at €42,625/patient 
while outpatient costs were €22,758/patient (2007 costs), leading to a total cost of €65,383 (Ricci et 
al. 2010). A Monte Carlo stimulation suggested a total cost of €70,364/patient/year for ESRD 
treatment with dialysis
xxii
 (2002 costs inflated to 2010) (Palmer et al. 2006). Primary evidence 
collected for the purposes of this study showed that in 2010 haemodialysis carried an annual cost of 
€81,449 and peritoneal dialysis €49,953 (see Appendix 7D). 
In Spain, it is estimated that diabetic patients are 25 times more likely to suffer from renal 
insufficiency. Survey data suggest that the cost of haemodialysis is Spain €41,052 and peritoneal 
dialysis at €24,515 per annum (Appendix 7D). Similarly, ESRD disease carries an annual cost 
estimated at €53,764 (£36,237) reflecting the higher costs of dialysis, while the cost of renal 
transplants in the UK is estimated to be €33,437 (£22,537) per patient (Appendix 7D).  Early stages of 
microalbuminuria are estimated at €166 annually for monitoring, while overt nephropathy already 
raises costs substantially to €11,993 (£8,083) per patient annually (2001 costs inflated to 2010) 
(Gordois et al. 2004). A more recent 2006 costing exercise found that renal disease cost €1,742 per 
admission (inflated to 2010) (Morgan et al. 2010). 
 
5.4.6 Erectile dysfunction 
Approximately 32% of Type 1 male patients and 46% of Type 2 male patients suffer from erectile 
dysfunction (Phé et al. 2009)
xxiii
.  Treatment options include inter-cavernosal injections, penile 
implants and PDE-5 inhibitors are available to treat erectile dysfunction.  The cost of penile implants 
is not high and has been reported to be between €225.9 (rigid or semi-rigid) and €261.3 (hydraulic 
penile implants) plus anaesthesia costs in France. In the UK, erectile dysfunction treatment in hospital 
treatment costs £232 (National Tariff). Typical problems in this context are (a) the long waiting times 
                                                     
xxii
 No information on peritoneal versus haemodialysis. 
xxiii
 Data based on France. These figures correlate with an overall prevalence estimate for erectile dysfunction in 
male patients of 30% in Spain.   
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for both diagnosis and treatment as well as the regional variations in this regard (France, Spain, UK), 
(b) the relative lack of urology and andrology specialists (reported in France) and (c) the reduced 
reimbursement potential of treatments in this diagnosis. 
5.4.7 Neurological complaints 
In Spain, 25% of diabetic patients have some form of neurological complaint.  Patients can be treated 
pharmaceutically at considerable cost. Treatment options include duloxetine, amitriptyline, tramadol, 
pregabaline and gabapentine. In Spain and the UK, the primary problem is long waiting times for both 
diagnosis and treatment, which vary between regions and can range between 3-4 months. 
5.5 Indirect cost burden of diabetes 
5.5.1 Historical evidence 
Very little information on indirect costs related to diabetes is available.  However, the potential impact 
of diabetes is manifold: the inability to work to full capacity or at all, resulting in reduced productivity 
or early retirement; routine contact with medical services resulting in absenteeism; inability to work 
during hypoglycaemic episodes; parents involved in the care of their Type 1 children and other 
(family) carers looking after elderly patients.  The long-term impact includes, early retirement due to 
complications from diabetes, premature mortality and potential mobility issues with amputations and 
blindness.  Indirect costs from all five countries are explored here (in as much detail as possible), 
using multiple sources. 
A French study has suggested that indirect costs could represent at least one-third of the total costs of 
diabetes (Ricci et al. 2009). Examination of diabetes patients under the aforementioned ALD8 scheme 
finds that 3.6% of diabetes patients receive disability pensions of €7,060 annually, as well as a 
monthly allowance averaging €228/patient (8.5% of diabetics receive this monthly allowances 
averaging €2,661 annually) (2004 data) (Vallier et al. 2006). Utilising the costs calculated in the 
ENTRED study (2009) indirect cost have been estimated at approximately €5bn (Santé log 2010).  
In Germany, annual indirect costs were estimated to be averaging €5,019/patient (range: €0-€35,808 
based on 2001 data), including productivity losses due to the inability to work (€764 per patient) and 
early retirement (€4,255 per patient). When this figure is multiplied by the German prevalence an 
estimated indirect cost of €36.5bn is produced.   
Older indirect costs estimates are available for Italy, including productivity losses, early retirement in 
Type 2 patients, and produce an estimate of 4.5% of total diabetes costs (1998) (Lucioni et al. 2000). 
When this estimate is applied to 2009 total diabetes costs (Table 5.2), indirect costs are estimated at 
approximately €356.5m – much lower than the other countries and potentially a significant 
underestimation given the date of the data. 
As a proxy for indirect costs in Spain, a study that calculated indirect costs for Canary Islands was 
used (López-Bastida et al. 2002). Costs were calculated using the costs of prevalence in 1998 based 
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on a Type 2 patient cohort.  The costs of premature mortality and time off work were estimated as 
€6.4 billion and €8.4 billion respectively, a total of €14.8 billion.  In contrast, a subsequent national 
examination estimated total indirect national costs as €2.8 billion (Oliva et al. 2004). 
There are no government or academic sources of direct versus indirect costs for the UK.  The 
publication, The Economist, published a special edition on the costs of diabetes, which estimated that 
the 2007 productivity loss costs of diabetes were €1,078 (£746)/patient and the average lifetime 
earning loss to be €54,920 (£38,005)/patient.  Total productivity loss in the UK was estimated to be 
€2.41 billion (£1.7 billion) (The Economist Intellegence Unit 2007). 
5.5.2 Estimates of indirect cost in 2010 
For the purposes of this study we have attempted to calculate the indirect cost of diabetes, focusing on 
three components, namely, the cost of absenteeism due to illness, the cost of early retirement, and the 
cost of social benefits. These were variables for which data was available, both in terms of the 
relevant probabilities and costs. 
Cost estimates for each of these parameters come from national sources, while the respective 
probabilities have been pooled from national sources as discussed in the methods section and, in 
particular, as shown in Table 2.1. Based on these estimates, the indirect and measurable cost of 
diabetes in EU5 stands at €98.4 billion and exceeds that of the total direct cost (Table 5.4). The 
indirect cost calculations are €17.3 billion (£15.4 billion) in the UK, €37.9 billion in Germany, €12.9 
billion in France, €12.6 billion in Italy and €17.6 billion in Spain. Indirect costs are shown to be 
comparable in size to direct costs in Germany, France and the UK, exceed direct costs by a factor of 
2-to-1 in Italy and by a factor of 3.5-to-1 in Spain.  
It has not been possible to include estimates on productivity losses (presenteeism), the cost of 
premature mortality and any carer costs associated with caring for a diabetic relative. Consequently, 
the figures on Table 5.4 potentially under-estimate the true indirect cost of diabetes.  
Based on the calculations in this section regarding direct and indirect cost and taking into 
consideration the limitations in the available evidence and the issues concerning exclusion of the costs 
of conditions not necessarily related to diabetes, the direct and indirect cost burden of people with 
diabetes across the 5 study countries amounts to €188 billion in 2010. A comparison of direct and 
indirect costs is shown on Figure 5.3. 
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Figure 5.3: Direct and indirect cost burden of diabetes in EU5 (2010 estimates, € million) 
 
 
Notes: No ‗Other‘ costs available for France, Italy, Spain. The UK figures are susceptible to exchange rate 
fluctuations; the UK direct cost figure stands at £13.8 billion and is based on data from 2005 and 2007, which 
have been converted to Euros using the prevailing exchange rates (2005: £0.674/€; 2007: £0.692/€), and 
extrapolated to 2010 in order to arrive at the €20.2 billion total direct cost figure. For the 2010 indirect cost data 
(£15.4 billion or  €17.3 billion) the prevailing (2010) exchange rate has been used (£0.893/€).  
* Germany diabetes drugs include also non-diabetes-related drugs as this figure could not be disaggregated. 
Source: The authors based on Table 5.2 Table 5.4. 
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Table 5.4: Estimated total cost of absenteeism, early retirement, and social benefit among diabetes patients in EU countries, 2010. 
  Diabetic 
population in 
active 
employment 
(estimate) 
Average 
daily 
earnings 
(2010) 
Average 
annual 
cost: 
absentee-
ism (per 
person, €) 
Total 
annual 
national 
cost: 
absentee-
ism (in € 
million) 
Diabetic 
population: 
early 
retirement 
Average 
annual 
pension 
(per person, 
€) 
Total 
annual 
national 
cost: early 
retirement 
(€ million) 
Diabetic 
population 
receiving 
social 
benefits 
Total 
annual 
cost: 
social 
benefits 
(in € 
million) 
Total cost: 
absenteeism 
early 
retirement & 
social benefit 
(€ million) 
UK 1,728,290 €130.8 
(£117) 
A
 
€5,428 
(£4,847) 
€9,382.7 
(£8,379) 
645,214  €11,988.6 
(£10,705) 
€7,736.6 
(£6,909) 
89,202  €169.5 
(£152) 
€17,288.8 
(£15,440) 
Germany 3,389,597 €127.8 
C
 €5,303.7 €17,977.4 1,265,449 €15,518 €19,637.2 174,947 €324.8 €37,939.4 
France 1,330,940 €114.2 
C
 €4,739.3 €6,307.7 496,884 €13,015 €6,466.9 68,694 €113.9 €12,888.5 
Italy 1,333,671 €96.9 
C
 €4,021.4 €5,363.2 497,904 €14,439 €7,189.2 68,835 €97.1 €12,649.5 
Spain 1,729,934 €78 
C
 €3,237 €8,044.2 645,842 €14,686 €9,484.8 89,287 €101.2 €17,630.2 
Total  NA NA   NA   €806.5 €98,396.4 
Notes: NA: not applicable; for the UK sterling data have been converted to Euros using the Sterling/Euro rate of 0.893, which was the prevailing exchange rate at the time of 
data availability (2010). 
Sources: A: UK ASHE (2010) (Office for National Statistics 2010); B: UK PPI (2010) (Policy and Pensions Institute (PPI)); C: Eurostat (2009) (Eurostat 2009); OECD 
(2011) (Organisation for Economic Cooperation and Development (OECD) 2011).  
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5.6 Summary and discussion  
None of the 5 countries have accurate or detailed government cost data, either nationally or per 
patient.  However, a number of academic studies have delivered figures, which when extrapolated to a 
common point in time – 2010 - provide an indication of what the direct and indirect cost of diabetes is 
likely to be at national level, or per patient, per diabetes type or per complication(s).   
Overall, the direct cost burden of a person with diabetes varies considerably across countries (France 
€5,432; Germany €5,899 (€2,684 if only the incremental costs are considered), Italy €2,756, Spain 
€1,708, UK €4,744 (£3,233) (T1) - €5,470 (£3,717) (T2)). France, Germany and the UK have 
considerably higher per patient diabetes costs than Italy and Spain.   
The total direct national diabetes cost burden varies substantially across countries in 2010 (France 
€12.9 billion, Germany €43.2 billion (or €19.7 billion if only the incremental cost is considered), Italy 
€7.94 billion, Spain €5.45 billion and the UK £13.8 billion or €20.2 billion), and if they are put 
together they amount to €90 billion in 2010. 
Diabetes drug costs (insulin and oral hypoglycaemic agents) are the smallest component of drug, in- 
and out-patient costs combined, ranging from 6.2% (France and Italy) to 10.5% (Spain).  All countries 
have reported increases in diabetes medication spending, although the majority of diabetes medicines 
are generic and lower cost.  Conversely, non-diabetes medications are 3 to 4 times the cost of diabetes 
medications, with cardiovascular medicines consuming the largest portion in terms of both cost and 
prescribing. 
Inpatient costs are consistently higher than outpatient costs in all countries, due to increased medical 
care required with diabetes-related complications.  Outpatient costs on the other hand, as well as 
diabetes medications, can be less than half of inpatient costs due to the relatively low costs of 
maintaining good glycaemic control via medication and regular monitoring. 
Measurement of direct costs is poor in all countries and accounting for indirect costs is either absent 
(UK) or poor which prevents total diabetes costs from being accurately quantified. 
The presence of complications, particularly multiple complications, can multiply diabetes costs 
several times, particularly in conditions such as renal failure. 
Very little information on indirect costs arising due to diabetes is available. However, the potential 
impact of diabetes is manifold and entails significant indirect costs, chiefly relating to the economy 
(but outside the remit of health care services), such as reduced productivity and sickness absence, the 
wider social sector, such as early retirement and drawing social benefits, as well as the impact on 
family, through informal caring and carer costs as well as dealing with the effects of premature 
mortality. Having identified costs due to absenteeism, early retirement and expenditure on social 
benefits, these amounted to a total of €98.4 billion across the study countries in 2010 (€37.9 billion in 
Germany, €17.6 billion in Spain, €17.3 billion (£15.4 billion) in the UK, €12.9 billion in France and 
€12.6 billion in Italy). In the cases of Germany, the UK and France, these indirect costs are on a par 
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with direct costs, whereas in Italy and Spain, they are shown to exceed direct costs by a factor of 2-to-
1 and more than 3-to-1 respectively. This is an under-estimate since the costs of reduced productivity, 
premature mortality or informal carer costs could not be accounted.   
Country variations in the direct cost estimates provided in this study are due to two reasons: the first is 
prevalence, which altogether affects total cost at country level and, as outlined in the methodology, 
prevalence estimates can vary significantly in the absence of a single monitoring tool that provides 
robust estimates both within and across countries. The second reason for cost estimate variations is 
attributed to the type of costs included in them. All data accounts for portions of diabetes costs 
differently and there appears to be little consistency within and across countries. This is a point that 
merits further discussion, however, due to the complexity of diabetes as a disease. Treating diabetes 
per se represents a fraction of the total cost because of complications arising from diabetes. It is 
known that hospital expenditures for diabetic patients are likely to be even higher because 
hospitalisations for conditions such as a cataract or dialysis sometimes will not be considered 
diabetes-related hospitalisations. In addition, hospitalisation costs can be impacted further because 
diabetes increases the length of stay. For example, the average length of stay for diabetes patients 
following cardiovascular events is longer (stroke: +2.5 days; MI: +1.5 days; unstable angina: +1.3 
days; revascularisation: +2.8 days) and, therefore, costlier (non-fatal stroke: +23.9%; non-fatal MI: 
+10.4%; unstable angina: +6.1%; revascularisation: +9.1%) than for non-diabetic patients (Chevreul 
et al. 2011). 
In this context, disentangling costs that - sensu stricto – are attributed to diabetes and those that are 
not (for example due to a pre-existing co-morbidity) is challenging for two reasons: first, because 
diabetes may exacerbate a pre-existing co-morbidity and the cost, as a result, can be higher than 
would otherwise be the case and, second, health accounting is not always particularly helpful in 
attributing costs in a precise manner, for example, those which are diabetes-related and those that are 
not. Consequently, the majority of direct cost figures represent an approximation rather than a true 
reflection of reality. 
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Box 5.1: Cost burden of diabetes - Key takeaways 
 
 Direct per patient diabetes costs vary considerably across countries (France €5,432; Germany 
€5,899 (€2,684 considering only the incremental cost), Italy €2,756, Spain €1,708, UK €4,744 
(£3,233) (T1) - €5,470 (£3,717) (T2)). France, Germany and the UK have considerably higher 
per patient diabetes costs than Italy and Spain.   
 The direct national diabetes cost burden varies substantially across countries (France €12.9 
billion, Germany €43.2 billion [or €19.7 billion if incremental costs are taken into account], Italy 
€7.94 billion, Spain €5.45 billion and the UK £13.8 billion or €20.2 billion), predominantly 
driven by prevalence, but also due to higher per patient costs in France, Germany and the UK. 
As a result, total direct cost burden of people with diabetes in the study countries in 2010 has 
been estimated to amount to €90 billion. 
 Data availability as well as the chosen cost calculation approach may vary through countries, 
and this can contribute to cost differences. With the data currently available for most countries it 
can be difficult to capture the actual costs of diabetes, in particular because it is hard to 
disentangle diabetes-related costs from the costs of co-morbidities which are not directly related 
to diabetes. In some settings hospitalisations for conditions such as cataracts or dialysis are not 
considered diabetes-related, even if they are the result of diabetes. Furthermore, in an unrelated 
condition, diabetes is known to often have a significant impact on hospitalisation costs because it 
will increase the length of stay. 
 Diabetes drug costs are the smallest component of drug, in- and out-patient costs combined, 
ranging from 6.2% (France and Italy) to 10.5% (Spain). Conversely, non-diabetes medications 
are 3 to 4 times the diabetes medications in terms of total costs, with cardiovascular medicines 
consuming the largest portion in cost and prescribing. 
 Inpatient costs are consistently higher than outpatient costs in all countries, due to increased 
medical care required with diabetes-related complications.  Outpatient costs on the other hand, 
as well as diabetes medications, can be less than half of inpatient costs due to the relatively low 
costs of maintaining good glycaemic control via medication and regular monitoring. The 
presence of complications, particularly multiple complications, can multiply diabetes costs 
several times. 
 The indirect cost of diabetes exceeds €98.4 billion in the 5 study countries, although this is more 
than likely to be an under-estimate, as it does not take into consideration the cost of premature 
mortality, productivity losses and carer costs. 
 The total (direct and indirect) cost burden of diabetes has been estimated to amount to €188 
billion in the 5 study countries. 
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6. Outcomes 
6.1 Recommendations for monitoring patients with diabetes 
A number of tests are recommended for monitoring diabetic patients (Table 6.1).  In practice, the 
percentage and frequency of patients tested does not always reflect the guidelines. Routine 
measurement of glycosylated haemoglobin (HbA1C
xxiv
) every 3 to 12 months is recommended, 
depending on country and diabetes type (more frequent in Type 1 and Type 2 with insulin). While 
quarterly HbA1C monitoring is recommended in France, 2007 survey data found only 44% of Type 2 
diabetics had their HbA1C tested three times, although 90% had at least one test (Robert et al. 2009). 
The 2008/09 UK National Diabetes Audit found over 86% of adult and paediatric patients had their 
HbA1C measured during the past year, with 25% of adult patients and 16% of paediatric patients 
meeting the recommended target of HbA1C<6.5%.  Spanish data indicates that, in 2007, 82% of Type 
2 patients had their HbA1C tested.  However, these figures are misleading, as they do not allow a 
measurement of the degree of quarterly or biennial testing, which is actually recommended (NHS 
National Information Centre 2011). No data is publicly available on the frequency of HbA1C testing 
in Germany, as this information is specific to the sickness funds, or Italy (although in Italy, the AMD 
collects information on process measures relating to HbA1C). 
Total cholesterol (TChol), high density lipoprotein (HDL), low density lipoprotein (LDL) and 
triglyceride (TG)) monitoring is recommended as markers for cardiovascular disease, particularly 
when combined with HbA1C, body mass index (BMI) and blood pressure.  Monitoring frequency 
varies between countries, but all recommend minimum annual testing (Table 6.1).  In France, 
ENTRED evidence indicates that only 72% were monitored for LDL-cholesterol and 76% for 
Triglycerides (TG).  In Spain, 85% had their cholesterol levels tested and 77.5% had their total 
cholesterol measured in 2007.  In the UK, at least 75% 90% of adults and 30% of children received 
cholesterol monitoring, with over 73% of both groups achieving recommended total cholesterol levels 
of <5.0mmol/L (NHS National Information Centre 2010). No data is available for Germany. 
Both creatinine and albumin should be tested regularly to monitor for renal damage. In France, annual 
urinary albumin testing is recommended, however, in 2007 only 26% of patients were monitored.  In 
Germany only 20% of diabetics are tested annually, while in Italy, urinary protein measurements are 
rarely undertaken, based on available information.  Survey feedback from Italy indicates that 
creatinine and albumin levels are checked as part of routine exams, however the frequency is not 
clear.  In Spain the recommendation is 1-2 times per year, with 71% tested in 2007. In the UK, 
evidence from 2008/09 found that 65% of adults were monitored for albumin and 91% for creatinine, 
however, these figures dropped significantly to 30% for both proteins in paediatric patients (NHS 
National Information Centre 2010). 
                                                     
xxiv
HbA1C is a measure of the average blood glucose levels over the past 3 months, which is a robust indicator 
as it cannot be manipulated just prior to a monitoring visit.  This indicator reflects the average glycaemic 
management and provides evidence on which physicians can make necessary adjustments in diet or medication. 
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Regular measurement of blood pressure is recommended to test for hypertension.  This occurs as part 
of regular physician visits in France.  In the ENTRED study, Type 2 patients were seen nine times (on 
average) during the year by their doctor, at which time blood pressure is routinely measured (Robert 
et al. 2009). In Spain, Type 1 patients have their blood pressure measured 3-4 times per year, while 
Type 2 patients undergo this testing with more variation, between 1-6 times per year.  In the UK, over 
90% of adult patients had their blood pressure monitored during the 2008/09 period, with 50% 
achieving the targeted blood pressure (NHS National Information Centre 2010). 
Other physical tests are also recommended, including foot exams to look for microvascular and neural 
damage, eye exams for retinopathy, and anthropometry (BMI, hip to weight circumference). In 
France, the Association de langue française pour l‘étude du diabète et des maladies metaboliques 
(ALFEDIAM)
xxv
, recommends a foot examination at each visit, even if asymptomatic.  But an 
ENTRED study in 2002 found that only 20% of patients questioned said that they had received a 
screening with monofilament. In Spain, fewer than 50% had their feet examined in 2007.  The UK 
2008/09 National Diabetes Audit found that in adult patients BMI was measured in 89%, retinal 
screening in 77%, and foot examinations in 83% of patients during the period.  In children, the uptake 
of these examinations was worse at 66%, 27% and 23% respectively (NHS National Information 
Centre 2010). 
Clinically, all the monitoring processes mentioned above should occur at least annually in all patients 
with diabetes, however, there is evidence that this is not occurring. In the UK (2009/10), monitoring 
all nine care processes occurred in 52.9% of adult Type 2 patients, but only 31.9% of adult Type 1 
patients and 4.1% in paediatric patients (decrease from 5% in 2008/09).  This suggests either poor 
monitoring of children or that the measures chosen for adults and indiscriminately applied to children 
are largely inappropriate for the paediatric population.  Lack of monitoring procedures results in 
diagnosing complications and co-morbidities later and, potentially, proving costly to both patients and 
the health system.  
                                                     
xxv
 ALFEDIAM is now known as the Société Francophone du Diabète (SFD), however the website remains the 
same – www.alfediam.org. 
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Table 6.1: Recommended frequency and cost of diabetes biomarker monitoring 
  France Germany Italy Spain UK 
HbA1C Type 1 q3m na q1-3m q3-4m q3m 
Type 2 (insulin) q3m na q6m q0-4m q3m 
Type 2 (oral 
hypoglycaemic) q3m na - q0-4m q6m 
Average cost €50.00  €10.50 €59.00 €18 
HDL Type 1 q12m q12m q6-12m q6-12m q12m 
Type 2 (insulin) q12m q12m q6-12m q4-12m q12m 
Type 2 (oral 
hypoglycaemic) q12m q12m q6-12m q4-12m q12m 
Average cost 
€36HDL, LDL, 
TG
 - - €3.00 €18 
LDL Type 1 q12m q12m q6-12m q6-12m q12m 
Type 2 (insulin) q12m q12m q6-12m q4-12m q12m 
Type 2 (oral 
hypoglycaemic) q12m q12m q6-12m q4-12m q12m 
Average cost 
€36HDL, LDL, 
TG
 - - €2.00  
Triglyceride Type 1 q12m q12m q12m q6-12m q12m 
Type 2 (insulin) q12m q12m q12m q4-12m q12m 
Type 2 (oral 
hypoglycaemic) q12m q12m q12m q4-12m q12m 
Average cost 
€36HDL, LDL, 
TG
 - - €  2.20  
Urinary 
albumin 
Type 1 
q12m 
Rarely: 
20% 
patients/y Rarely q6-12m q6-12m 
Type 2 (insulin) 
q12m 
Rarely: 
20% 
patients/y Rarely q6-12m q12m 
Type 2 (oral 
hypoglycaemic) 
q12m 
Rarely 20% 
patients/y Rarely q6-12m q12m 
Average cost €28.00   €3.00 €2 
Blood 
pressure 
Type 1 per Dr visit   q3-4m q3-4m 
Type 2 (insulin) per Dr visit   q2-12m q3-4m 
Type 2 (oral 
hypoglycaemic) per Dr visit   q2-12m q3-4m 
Serum 
creatinine 
Type 1 q12m   q6-12m q12m 
Type 2 (insulin) q12m   q4-12m q12m 
Type 2 (oral 
hypoglycaemic) q12m   q4-12m q12m 
Average cost €8.00   €2.10 €3 
Note: na: not available. 
Source: The authors based on data from the LSE country survey. 
 
6.2 Available evidence on diabetes outcomes 
There is relatively good information on outcomes compared to costs, particularly in France, Italy and 
the UK (England, Wales and Scotland) (Table 6.2).  The latter is due to recent improvements in data 
collection by the QOF and annually reported Diabetes Audits (England/Wales, Scotland, Paediatrics).  
France is also collecting data periodically (2001, 2007) via their ENTRED study and Italy, via the 
AMD data collection.  All three have longitudinal capacities, which will hopefully improve over time 
with greater participation and precision.  The current capacities are: longitudinal (France ENTRED 
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2001-2010; Italy 2004-2009, UK 2006-2010), regional (France: ENTRED Metropolitan v La 
Reunion, ITALY: nationwide, UK: PCTs), Type 1 versus 2 (France, Italy, UK) and treatment groups 
(Germany: diabetes DMP v non-DMP). 
6.2.1 France 
The 2007 ENTRED study shows that the percentage of patients with HbA1C ≤6.5%, indicating tight 
control, in Metropolitan areas was 32% compared to 24% in La Reunion Island), while HbA1c ≤7% 
(still meeting recommended levels) was 52.1% and 24% respectively.  This means 84% of 
Metropolitan and 48% of La Reunion residents with diabetes are showing poor glycaemic control.   
Only 15% of diabetic patients in Metropolitan areas and 22% in La Reunion had blood pressures 
<130/80 mmHg, while 16.5% and 22.9% respectively had worryingly high pressures of ≥160/95 
mmHg (Ndong et al. 2010). 
6.2.2 Germany 
The implementation of evidence-based guidelines into routine outpatient and inpatient treatment is 
difficult. In order to improve the outcomes of diabetic patients and to delay the development of 
complications the implementation of Disease Management Programmes (DMP) started in Germany in 
2002 (for Type 2) and 2004 (for Type 1). As of December 2010, 136,574 patients were enrolled in 
Type 1 DMPs and 3,413,643 patients in Type 2 DMPs according to the Federal Insurance Bureau 
(Bundesversicherungsamt). These enrolled patients amount to approximately half of all estimated 
diabetic patients in Germany.  
The DMP for diabetes includes different medical services, for example, regular laboratory, foot and 
eye examinations, rules for referrals to specialists and participation in diabetes education courses and 
offer a structured approach of diabetes management in GP surgeries, diabetes specialists in health care 
centres (―Schwerpunktpraxen‖) and hospitals.  
The scientific evaluation of DMP is a matter of controversial discussion. Certain recent studies appear 
to prove the effectiveness of DMPs in improving health outcomes (2008), but significant concerns 
remain about their validity (Linder et al. 2011). Some studies also raise the concern that DMPs cannot 
yet be positively assessed because of the inherent selection bias and unclear data quality. For instance, 
it has been found that future DMP patients had a lower risk for diabetes complications, were treated 
more intensively and were more active and motivated in managing their disease than usual-care 
patients (Schäfer et al. 2010a; Schäfer et al. 2010b). 
However, these results underline the problem that DMPs do not yet reach the higher-risk patients and, 
this impairs the assessment of outcome quality between enrolled and non-enrolled patients. Other 
studies have found that outcomes generally improve, but this is the case in both groups of patients, 
DMP- and non-DMP-enrolled (see also Table 6.3) (Linder et al. 2011; Schäfer et al. 2010a; Schäfer et 
al. 2010b). However, DMP-enrolled patients felt better taken care of and were, therefore, more 
motivated to attend education programmes or foot and eye examinations. The same studies reported 
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that, in contrast, no differences could be found between enrolled and non-enrolled patients concerning 
outcome quality indicators, e.g. self-rated health, haemoglobin (HbA1c) levels and blood pressure. 
The finding that DMP-enrolled patients felt they were better looked after and reported better quality 
of care is confirmed by other studies. For instance, it has been found that DMP-enrolled patients felt 
better informed about diabetes, complied more closely with medical advice and participated more 
often in diabetes education programmes (Schunk et al. 2009). The mean HbA1c decreased and they 
reported increased physical activity. However, the authors found that the DMP-enrolled group had an 
increasing Body Mass Index (BMI). Being overweight or obese are relevant risk factors, among 
others, that could lead to the deterioration of the metabolic systems and the development of 
complications. These findings stress the ambivalent effect of DMP enrolment: while feeling better 
informed, patients stick to an unhealthy life style and diet.  
The participation and enrolment in a DMP is optional for physicians and patients. Although the 
programme is open for everyone, it is expected that patients that benefit most from it take part in the 
programme. In reality these are mainly active, educated, motivated and compliant patients. This so 
called ‗short-term benefit approach‘ including the less severely ill, compliant and active patients 
(―good patients‖) could lead to a misperception of the success of DMP by assessing the outcome of 
enrolled patients in contrast to non-enrolled patients. Concerns are raised that DMPs exclude patients 
who are in significant need of assistance and education. However, due to the multi-morbidity of 
patients, especially older patients, individuals may fit into several DMPs e.g. diabetes and coronary 
heart disease. Therefore, it is difficult to assess the appropriate coverage of DMPs. From the 
physicians‘ perspective it could be adverse to run DMPs and include more severely ill patients as 
physicians could fear negative consequences from health insurance, e.g. offering exclusive contracts 
to surgeries which produce ‗better‘ results.    
Overall, it is very difficult to evaluate the success of DMPs for diabetes in Germany (Birnbaum et al. 
2010). However, the enrolment in DMP is a substantial step in the direction of implementing 
evidence-based guidelines into the daily routine treatment of diabetes patients and a positive 
development. Greater efforts should be made for the integration of ‗difficult‘, high-risk patients – 
those who need to be taken care of the most, e.g. by providing case management programmes for 
selected patient groups.  
6.2.3 Italy 
The AMD annals have been collecting data from 2004 to 2009, excluding 2008 (The AMD Annals 
working group 2009). Measurement of average quarterly glucose control via HgA1C, has been high in 
both Type 1 & 2 patients (>90%).  Blood pressure measurement is also stable, but at much lower 
adherence (or data entry) at roughly 75%, however, measurement of lipids has increased (Type 1 
59.5%-73%, Type 2 63.9-73%, 2004-2009).  Renal sufficiency testing is decreasing (Type 1 56.7%-
51%, Type 2 49.2-41%) along with foot checks (Type 1 23.8-15%, Type 2 15.4-15%) despite the 
addition of 100 new diabetes centres in 2009 to the dataset (Figure 6.1).  
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Monitoring outcomes in Italy shows that 24-44%% of patients are achieving good glycemic control, 
37-42% good lipid management and up to 57% have good blood pressure levels (Figure 6.1).  There 
are a number of patients who have warning signs, almost 20% with poor glycemic control (46% in 
2009) and poor lipid management, and 30% with high blood pressure.  These patients will have 
greater likelihood of developing complications. 
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Table 6.2: Diabetes monitoring: Proportion of patients testing annually and their results (yellow 
shaded figures show recommended biological ranges) where available 
Notes: The numbers in brackets are paediatric patients; α Results based on patients in disease management 
programmes (DMP) at time of follow-up (2003); for HBA1C, a figure of 81.1% has been reported, however, this 
is specific to a particular study; see also Table 6.3; β 2008, combined result for Type 1 and Type 2 patients 
tested;  
μ May be measured but is not part of the QOF reporting. 
Sources: France ENTRED 2007 (Ricci et al. 2009), Germany 2003 (Schäfer et al. 2010a; Schäfer et al. 2010b), 
Italy (Cimino et al. 2010), Spain (Franch Nadal et al. 2010), England (NHS National Information Centre 2010, 
2011), Scotland (Scottish Diabetes Survey Monitoring Group 2010). 
 France Germany
α
 Italy Spain England Scotland 
   
Type 
1 
Type 
2 
 Type 1 Type 2 Type 1 Type 2 
HbA1C      
% tested 90%    81.6% 85.8% (90) 91% 87.7% 91.9% 
<6.5% 
24-
32% 
 24% 44%  25% (16)   
≤7% 
24-
52% 
   59%     
≤7.5%      28.2%(16) 66.5% 21.8% 64% 
>9%   46% 29% 4.6% (30)  38.3% 13.7% 
>10% 8%     17% 6.7%   
Blood pressure      
% tested     - 68.6% (59) 95.4% 93.9% 
<140/80mmHg      69.3% 60.7% 79% 74.5% 
Targeted BP
CVD
 
≤130/80mmHg 
15-
22% 
 36% 15%  63.3% 49.5% 45.4% 31.5% 
≤140mmHg 46%        
≤140/90mmHg   31% 57% 65%     
Albumin     
% tested 26%    71% 54.4% (36) 73.7% 48.6% 53.6% 
Creatinine     
% tested 79.7%    - 54.4% (33) 73.7% 82% 92% 
Cholesterol    
% tested 72%    85% 74.8% (30) 92.4% 89.6% 
Total 
≤5.0mmol/L 
    77.5% 72.5% (75) 78.3% 71.5% 81.4% 
Total 
≤4.0mmol/L 
     30.2% 40.9%   
LDL <100mg/dl 34%  37% 42%  
μ
    
LDL ≥130 
mg/dL 
18%  25% 26%  
μ
    
Triglycerides 
TG - % tested 
76%         
BMI    
% tested     - 83.2% (70) 90.5% 82% 82% 
Overweight: 
BMI 25-29.9 
30-
40% 
    35.3% 34.5% 36.6% 31.9% 
Obese: BMI ≥ 
30  
14-
40% 
   48.5% 17.3% 28% 25.4% 55.1% 
Eye exam    
% tested     57% 68.1% (25) 78.9 80% 86% 
Foot exam     
% tested 20%    48% 67.8% (24) 85.2 59.5% 78.1% 
Foot lesion        7% 4% 
Smoking     
% tested     - 86.8% (na)  99% 
All care 
processes 
tested (%) 
    - 31.9%(4.1) 52.9%   
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Table 6.3: Key outcome indicators results from a German DMP (2003) 
  DMP 
 
Baseline (%) 
Patients not 
enrolled   
Baseline (%) 
DMP 
 
(Follow-up)* 
Patients not 
enrolled 
(Follow-up)* 
Mean HbA1C (%) 6.9 6.9 6.9 6.8 
High HbA1C 
(>7.5) 
((>8,5 for over 
75+ 
72 (21.8%) 52 (18.1%) 46 (18.8%) 35 (17.5%) 
Mean BP 132/79 135/80 133/80 133.9/81 
High BP 
(>140/90) 
137 (38.1%) 186 (46.7%) 129 (44%) 116 (42%) 
Mean BMI  29,7 29,4 29,5 28,3 
Obese (BMI>30) 188 (42.7%) 191 (39.6%) 149 (42.5%) 137 (40.1%) 
Diabetic foot 
lesions 
45 (10%) 49 (10%) 29 (8.3%) 29 (8.5%) 
 
Note: * Follow-up occurred approximately 10.4 months after baseline interviews. 
Source: Based on (Schäfer et al. 2010a; Schäfer et al. 2010b). 
 
 
 
Figure 6.1: Diabetes outcomes: Italy AMD data 2004 – 20091,α, β 
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Notes: HbA1C ≥9%, LDL≥130mg/dL, BP (blood pressure) ≥140/90 mmHg are associated with poor outcomes.  
No data for 2008 available.  In 2009 100+ new diabetes centres were added to the database, which may explain 
some of the variations.  In 2009, new interpretations were added of a lower BP limit (BP≤130/80 mmHg v 
≤135/80 mmHg) and higher HbA1C (HbA1C ≥9% v HbA1C ≥8%).   
Source: The authors based on (The AMD Annals working group 2009). 
 
6.2.4 Spain 
The GEDAPS Network study of Diabetes in Primary Care publishes diabetes process and outcomes 
every 2 to 5 years, with the latest results published for 2007 (Franch Nadal et al. 2010). Results show 
a gradual improvement in both types of indicators since 1996, particularly in a reduction of dangerous 
HbA1C levels, as well as obese diabetes patients (Figure 6.2).  Measurement of lab work is good, yet 
physical measurements for retinal screening and foot checks are less impressive. 
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Figure 6.2: Adherence to patient monitoring (A) and results of monitoring outcomes (B) in 
Spain (1996-2007). 
 
 
Source: (Franch Nadal et al. 2010) 
 
6.2.5 United Kingdom 
Some of the key finding from the UK National Diabetes Audits (NDA) are the differences between 
paediatric (UK) and adult patients (England, Wales), both in the adherence to measuring indicators 
and their outcomes.  The number of children being tested for relevant indicators was significantly less 
than for adult patients, even for albumin (32% versus 64%) and creatinine (31% in children versus 
91% in adults), which are important indicators to screen for early kidney damage especially in Type 1 
patients.  Only 4.1% of children were tested for all monitoring indicators compared to 52.9% of Type 
2 adult patients and 31.9% of Type 1 adult patients (NHS Information Centre 2010; NHS National 
Information Centre 2010). 
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Examining the outcomes of the monitoring indicators finds only 25% of adults and 16% of children 
meet tight blood glucose control (HbA1C ≤6.5%) (2008/09).  More than 60% of Type 2 adults had 
HbA1C ≤7.5 (28.2% of adult Type 1), however, over 30% of children had HbA1C levels ≥9.5% and 
some with HbA1C >15.5% associated with significant permanent damage. Examination of Scottish 
Diabetes Survey (SDS) data found only 22% of Type 1 patients achieved good control (HbA1C ≤7.5) 
(Scottish Diabetes Survey Monitoring Group 2004). Over 61% of English/Welsh adult patients met 
adequate blood pressure control (<140/80 mmHg) and 74% of Scottish patients (≤140 mmHg).  
Approximately 30% of Type 1 English/Welsh adult patient met tight lipid management criteria (total 
cholesterol ≤4.0 mmol/dL), and 41% of Type 2 English/Welsh adult patients, while over 70% of all 
UK adult patient met adequate lipid management (≤5.0 mmol/dL).  Higher cholesterol measures were 
more common in both adult and paediatric patients with certain ethnic origins (Asian, black).   
The 2009 SDS found the degree of overweight (BMI 25-29.9) in Type 1 patients was 37% and in 
Type 2 32%, while the degree of obesity (BMI >30) in Type 1 patients was 25% and Type 2 55% 
(Scottish Diabetes Survey Monitoring Group 2010). The NDA was similar for overweight, but far less 
for obese, particularly Type 1 obese (26%, Type 2 50%). 
There are other measures relating to complications, which are reported in the NDA for both children 
and adults: ketoacidosis (adults 0.48%, children 7.4% with 10% in 12-24 age group, and 10% having 
≥2 episodes), angina, myocardial infarction, cardiac failure, stroke, renal failure, diabetic retinopathy 
treatments, as well as minor and major amputations.   
Both the NDA (2003/04-2009/10) and the SDS (2003-2009) have longitudinal information (Figure 
6.3, Figure 6.4).  Although the degree of overweight appears to be decreasing in Scotland, obesity is 
increasing in both Type 1 & 2 patients in Scotland, England and Wales.  This partially represents 
‗graduation‘ of overweight patients to obese, although it appears that fewer ‗new‘ patients are joining 
overweight patients.  More patients are meeting outcome targets for glucose, lipid and blood pressure 
management, and the degree of dangerous glucose control has slightly decreased.  Measurement of all 
key diabetes processes has increased from 7% to 47% (2004/05-2009/10), but only 4.1% of paediatric 
patients have all key processes measured annually (NHS Information Centre 2010; NHS National 
Information Centre 2010). 
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Figure 6.3:  Diabetes outcomes National Diabetes Audit (2003/04-2009/10). 
 
Figure 6.4: Diabetes outcomes Scottish Diabetes Survey (2003-2010). 
 
Source: (Scottish Diabetes Survey Monitoring Group 2010). 
The Quality and Outcomes Framework (QOF) 
The UK QOF voluntarily collects data from GP practices, including 17 diabetes specific indicators 
(Appendix 8).  Aggregated results are available by PCT and Strategic Health Authority (SHA). 
Practice level QOF data is available, but only to the medical community.  This data is due to be made 
publicly available later this year.  Of note, only a minority of QOF diabetes indicators are outcomes 
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indicators (blood pressure (1), cholesterol (1), and low but not high HbA1C levels (3)), but they do 
provide an indication of information available in the UK.  This data does not establish a link between 
patients with diabetes and related complications, or distinguish between the different types of 
diabetes. When aggregated SHA figures are compared, outcome disparities across different regions 
are less marked (Figure 6.5) outlining 3 of the 17 quality targets), and conversely when data for 
individual practices within a PCT is compared, the variation can be considerable.  Examination of 
DM12 (blood pressure), DM17 (cholesterol), DM23 (HbA1C) outcomes indicators across all SHAs in 
England finds small variations, and the poorest performing variable was only half of patients 
achieving glycaemic control (Figure 6.5).  
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Figure 6.5: QOF indicators (DM12 (blood pressure), DM17 (cholesterol), DM23 (HbA1C)) in 
individual SHAs (2009/10)* 
 
PCT with highest achievement score PCT with lowest achievement score 
 
Notes: * ‗Underlying achievement‘ equals number of QOF points per indicator (numerator) over total QOF 
points available per indicator (denominator) 
DM12: Percentage diabetic patients with the last blood pressure is ≤145/85 mmHg;  
DM17: Percentage of diabetic patients with last total cholesterol in previous 15 months is ≤5mmol/l; 
DM23: Percentage of diabetic patients with last HbA1c is ≤7 (or equivalent test/reference range depending on 
local laboratory) in the previous 15 months.  
Source: The authors. 
 
6.3 Conclusions 
Evidence on outcomes is highly variable between countries, with Italy and the UK having fairly good 
annual data collection procedures in place, while countries have intermittent (France, Spain), or 
limited and private (Germany, insurance).  Some of the indicators point to how frequently a 
monitoring test is performed (process indicator) while others report results of the monitoring test.  
Both are important, as adherence to monitoring guidelines is important to catch early signs of 
complications quickly, and change treatment accordingly (such as change from oral hypoglycaemic to 
insulin).  The difficulty lies with the disagreement in timing between these process indicators and the 
actual guideline.  For example, the guidelines for HbA1C measurement are quarterly to biannually, but 
the collection and reporting are annual (or every 15 months in Scotland).  This makes it much easier 
for the health system to appear to be adhering to monitoring guidelines, when in fact it may not be. 
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Monitoring results of the outcome indicators are usually banded into categories created to find ‗safe‘ 
and ‗danger‘ zones.  For example, HbA1C tight control is ≤6.5% and good control is ≤7.5% in most 
countries.  These are both reported across countries, however, Germany neglect to report the 
dangerous levels of HbA1C ≥9-10% which may be more telling.  It is also impossible to see if patients 
end up in more than one ‗safe‘ or ‗danger‘ zone to identify patients at high risk for developing or 
experiencing complications. 
Finally, the identification of which monitoring indicators to track or report is not always ideal.  Most 
of the emphasis appears to be placed on cardiovascular risk factors, by reporting outcomes for BMI, 
lipids and blood pressure, however, no results are given for urinary albumin, serum creatinine or foot 
checks.  The latter three are significant and prevalent complications, and are very costly (in fact, more 
costly than cardiovascular complications). 
 
Box 6.1: Outcomes - Key takeaways 
 
 Outcomes datasets are available in France (intermittent), Italy (annual), Spain (intermittent) and 
the UK (annual), but not in Germany. 
 More process than outcome indicators are measured, and the number varies between countries: 
France 7, Italy 5, Spain 14 and the UK 17. 
 Due to a scarcity of complete, longitudinal diabetes outcomes datasets, little comparison of 
outcomes is possible across countries or over time, however, this is to some extent possible in 
Italy and the UK particularly in recent years, with greater participation. 
 There are some variations in outcomes targets between countries.  France, Italy and England 
data report proportion of patients with HbA1C ≤6.5% (‗tight‘ control), while Spain and Scotland 
report proportion of patients with HbA1C ≤7.5% (‗good‘ control). 
 Monitoring uptake and reporting is variable across and within countries, none reflecting the 
more frequent testing frequency actually recommended by the guidelines. 
 The cost of testing outcomes varies substantially – for example, the cost of HbA1C test is lowest 
in Italy (€10.50) and highest in Spain (€59.00). 
 In the UK, the uptake of monitoring is worse in children than adults, although whether this is 
due to poor selection of paediatric variables (application of adult variables to paediatric 
population), poor recording or actual poor monitoring is unknown. 
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7. The Challenges of Diabetes – Outlook for the future 
This chapter discusses the various limitations and challenges facing the EU5 countries with regards to 
diabetes prevalence trends, data insufficiency and information problems, inadequate prevention 
strategies and resources (human and financial), variations in access to and quality of care, incomplete 
outcomes data and insufficient national diabetes treatment plans and guidelines. In doing so, it builds 
on the discussion in the previous sections as well as material from the survey that was conducted for 
this study and opinions of experts that contributed to it. 
All 5 study countries face several challenges in terms of the rapidly increasing numbers of patients 
with diabetes, pre-diabetes and obesity in their population; rising morbidity and mortality related to 
diabetes and its associated risk factors and the escalating costs (both direct and indirect) relating to 
diabetes and its complications. For instance, a particular challenge for Germany is in addressing the 
Type 2 diabetes prevalence rate (14.9%) of the Turkish origin population in the country, which is well 
above the national average (Parmakerli-Czemmel et al. 2007); in Italy, poor levels of diabetes 
education and health awareness are also a problem, particularly as these tend to result in low rates of 
medical compliance and unhealthy lifestyle choices among patients and in the broader population; for 
the UK, a further key concern is the population of African/Afro-Caribbean and south Asian origin, 
who are three to six times more likely to develop Type 2 diabetes. 
 
7.1 Current and future trends in prevalence and the impact of aging 
Despite acknowledging diabetes as a leading cause of morbidity associated with serious disability, 
health complications and premature mortality, few countries collect diabetes prevalence data.  This 
means accurate prevalence figures are not available for any of the EU5, however, available data does 
show steady increases during the past two decades, particularly for Type 2 diabetes.  
Primary reasons for increasing diabetes prevalence are (a) an aging population including those who 
were children during the second world war, often experiencing food shortages associated with higher 
diabetes development, (b) increasing rates of obesity and overweight, (c) improvements in data 
collection methods (e.g. the UK) and wider implementation of diabetes screening programs (France, 
Germany) and (d) changes in the ethnic make-up of the EU5 population, with increasing African, 
Afro-Caribbean and Asian populations with higher (genetic) prevalence of diabetes. 
7.2 The challenge of poor data: prevalence, costs and complications 
7.2.1 Scarce prevalence statistics 
None of the study countries have national diabetes registries; in contrast cancer registries exist in most 
of these countries, with the exception of Scotland in the UK.  This omission becomes apparent when 
searching for comprehensive diabetes data.  Accurate national prevalence is not available, as no 
population-size databases exist on which true prevalence estimates can be based.   
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7.2.2 Incomplete direct cost data 
There are few robust datasets relating to diabetes costs and related complications, those that exist are 
mostly academic studies.  These studies often focus on only one aspect of diabetes, thus the resulting 
estimates here are piecemeal and cross-sectional. Diabetes costs gathered from these studies are likely 
to be underestimates, usually neglect indirect costs and potentially under-estimate the cost of 
complications.  For example, ENTRED (2007) is based on reimbursement data, excluding non-
pharmacologically treated patients (i.e. patients treated through diet and exercise). 
Hence, our calculations were based on a small selection of academic studies and government sources, 
none of which were comprehensive. French cost estimates are principally derived from ENTRED, 
using 2007 as a base year. German cost estimates are derived from the CoDiM study. Italian cost 
estimates are derived from two key sources, notably (Marchesini et al. 2011) and (Osservatorio Arno 
Diabete 2011), while further material has been obtained from three earlier studies by the same authors 
(Marchesini et al. 2010 ; Osservatorio Arno Diabete 2007), and (Marchesini et al. 2011). Spanish cost 
estimates are derived from two studies, one national and one regional (Mata et al. 2002; Oliva et al. 
2004) and supplemented with another regional study (López-Bastida et al. 2002). The UK cost 
estimates are primarily sourced from two regional studies (2005, 2007 data) (Currie et al. 2010; 
Morgan et al. 2010), and supplemented by various smaller studies. 
As each data source has differing methodologies (cost dates, sample size, region, which costs are 
included) and the underpinning assumptions (diabetes prevalence, ratio Type 1:2, per patient cost), 
opportunity for accurate comparison across countries is limited. 
7.2.3 Direct diabetes cost burden  
Despite the paucity of data, the direct cost of diabetes was estimated to be €90bn in the study 
countries in 2010. As diabetes prevalence and its related complications increase, direct costs, 
particularly for inpatient care, will continue to rise.  All EU5 countries show increases in diabetes 
spending estimates (regardless of the poor data precision), but highlighted by Germany where total 
diabetes costs increased by 49% (2000-2007) due to the concurrent
increase in prevalence of 37%.
xxvi
 
7.2.4 Cost of diabetes-related complications 
The true costs of diabetes-related complications are unclear, with complication cost estimates difficult 
to disentangle and considerable variation across countries. These costs are likely underestimated 
either as a result of the way the DRGs are coded (primarily by diagnosis at the time of discharge), the 
lack of detail in coding, the omission of diabetes in the coding, and coding via admission versus per 
                                                     
xxvi
 Further evidence these cost increases are not a result of increased in direct per patients costs 
(approximately 8.5% over 2000-2007, lower than the rate of inflation).  Patients with the highest 
incremental costs are those treated with insulin and insulin & OAD, but those treated with diet only 
had the highest rise in incremental costs (+42%). 
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patient.  Patients with diabetes related complications are very complex to treat and to follow from a 
cost perspective as they use a variety of in- and outpatient services from different sources.  
The available evidence suggests complications represent a considerable economic problem. Diabetic 
patients without complications represent a small proportion of the national health expenditure, since 
both insulin and oral glucose lowering drugs are relatively inexpensive nowadays. When 
complications occur, the direct costs of diabetes increase dramatically, primarily due to amplified 
instances of hospitalisation and the cost per patient almost proportionally increases according to the 
number of complications.  If patients have multiple co-morbidities (common in Type 2 patients), 
estimating the cost per complication is a difficult, if not impossible, task using current cost data 
collection methods in the EU5 countries. 
7.2.5 Insufficient outcomes data 
Comprehensive outcomes data is vital in order to understand where deviations from optimal diabetes 
practice and patient care may occur, including regional variations.  Unfortunately for diabetes care, 
outcomes data is limited in most countries, except Italy and the UK. Although regular monitoring and 
evaluation is recommended in all EU5 countries, it is unclear how often monitoring occurs and what 
outcomes are achieved.  Italy and the UK have measured both process and outcome indicators since 
approximately 2004, showing improvements in both measurement and laboratory outcomes, as well 
as increases in complication rates.  Academic sources for outcomes are available in Germany, but are 
not comprehensive.  Both France and Spain intermittently produce both outcomes and process 
indicators. 
National Prevention Plans (France, Spain, UK) appear to have done little to reduce the rate of 
complications.  These plans are usually idealistic yet none encompass targets or pathways to success 
and the lack of monitoring leaves a platform without a path.  This is unfortunate, as it leaves useful 
documents and plans, but powerless to act or implement change. 
7.2.6 Indirect diabetes cost burden  
None of the EU5 countries have comprehensive information on the indirect costs of diabetes or its 
complications.  What is available is limited data on the components of indirect costs (early retirement, 
disability benefits, absenteeism, productivity losses, premature mortality).  Diabetic patients often 
represent a ‗duplicate‘ cost to public systems, in need of health care and placing a burden on the 
social security system, by requiring social benefits and making frequent labour market exits and re-
entries. The time family members spend caring for an ill relative is also largely unaccounted for. 
These costs are an important component of total diabetes cost, as they work to shape our 
understanding of the costs of diabetes from the perspectives of employers, society, and the family.  It 
is increasingly important these are measured accurately and incorporated into cost estimates. 
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Due to the paucity of indirect cost information, calculations in this study are even more of an 
approximation than - and, most certainly an under-estimate of - direct costs. Based on these, the total 
indirect cost of diabetes across the five study countries was found to be €98.4 billion. 
7.3 Lack of effective prevention strategies 
Prevention is the most powerful approach to stop the rise in diabetes prevalence, as excess body 
adipose and diabetes are highly correlated.  It appears there is still much work to be done in 
preventative health.  Most country campaigns appear to be broad, rather than targeting at-risk 
populations, and there is insufficient encouragement of lifelong exercise participation and activities in 
daily living. In many instances there is poor access to professionals who may help with non-
pharmacological aspects of glycemic control.  A Diabetes UK survey (Diabetes UK 2010c) found 
many patients had poor access to dieticians and psychologists who may help with maintaining good 
glycemic control. 
7.4 Inadequate human and financial resources 
Rising diabetes prevalence creates challenges in meeting the increasing demand for diabetes care.  In 
certain countries (France, Germany, Italy) the lack of some types of specialists has been indicated as a 
problem.  In Italy, this occurs particularly in highly populated regions where the number of treatment 
centres is inadequate to address patient needs.  The excess burden on services often results in a 
breakdown in care coordination, creating inefficiencies where uncomplicated patients without 
complications are referred for specialist treatment rather than being cared for by GPs.  Due to 
financial constraints and education policy reforms, the number of trained endocrinologists in Italy is 
limited; as a result there will not be sufficient clinicians to replace those retiring, let alone to meet the 
growing demand for care. 
7.5 Variations in access and quality of care 
There are a number of causes of disparities in patient access and quality of care across EU5 countries: 
 Service provision based on geography has resulted in variations in patient access to 
comprehensive care, specialist care and education services (Italy, Germany, Spain, UK).  In Italy, 
differences between the North-Centre regions and the South, payment structures and care delivery 
result in variations in comprehensive care.  In Spain, insufficient endocrinologists, specialised 
nurses and trained family physicians limit access to appropriate care in some regions.  In the UK, 
educational services are regionally variable, some regions only offering education to Type 1 
patients and others only to Type 2, however, all regions indicated a need for periodic diabetes 
‗refresher‘ courses for their patients. 
 Inconsistencies in the quality of care within all countries are evident.  For example, in the UK the 
QOF results vary between GP practices from 51 to 100 points (maximum 100 points for 17 QOF 
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diabetes indicators) (NHS Information  Centre 2010).  The specific variation in care is unknown 
in all other countries, as none publish regional outcomes.   
 Access to care may be erratic as a result of variations in payment structures within the health 
system.  In France, different tariffs are allocated to different professionals.  The majority of 
endocrinologists (64.74%) practice in ―sector 2‖, meaning that they may charge fees in excess of 
the officially set tariffs, not covered by the ALD8 programme. In contrast, 92% of GPs practice in 
―sector 1‖ and accept the statutory tariffs.  Dietician consultations are not covered and podiatrist 
visits have only recently become covered, but only for grade 2+ lesions.  Patients incur these 
additional treatment costs as out-of-pocket expenses, unless they have complementary insurance, 
acting as a barrier to care access and possibly greater rates of complications due to poorly 
managed care. 
 There may be variability in access to the services dictated by guidelines. In the UK, access to 
endocrinologists and multi-disciplinary care appears to be limited to patients treated with insulin 
(both Type 1 or 2), or patients with poor control.  This is also true of all other countries surveyed - 
specialist care appears to be reserved for patients treated with insulin or with poor control.   
 There may be variability in the quality of treatment guidelines.  Guidelines for diabetes 
management have been produced in all EU5 countries, either by a national health body (HAS and 
AFSSAPS in France, Guiasalud in Spain and NICE in UK) or by professional diabetes 
associations (DDG and Bundesärztekammer in Germany and AMD and SID in Italy), however, 
the focus of the recommendations varies by country. Although some countries (Germany, Italy, 
UK) have begun to include patient-centred care in their treatment guidelines, most countries have 
little focus on individuality of diabetes type, complications (except the UK), and care plans.  None 
have patient-specific pathways (i.e. for care tailored to each patient), significant in a disease with 
high patient involvement and diversity in daily treatment and monitoring. 
7.6 Incomplete outcomes data 
Although robust datasets pertaining to diabetes outcomes are not available in Germany (where such 
information may be the privilege of the sickfunds), good progress has occurred in developing 
outcome measures and improving annual data collection in the UK and Italy. France and Spain have 
periodic collections, which are less useful, but still important.  Only the UK includes separate 
reporting for children and young people.  General outcome indicators are: HbA1C, blood pressure, 
urinary albumin, serum creatinine (rarely), cholesterol and BMI, although target thresholds vary 
(France, Italy, England use HbA1C ≤6.5%; Scotland and Spain use HbA1C≤7.5%). 
Compliance with monitoring and evaluation recommendations for diabetes process and outcome 
indicators is unclear as measurements are rarely recorded and reported in a central national database.  
The UK appears to be the exception, with annual reporting via their National Diabetes Audit and 
Scottish Diabetes Survey, as well as a separate pediatric report, and Italy with their annual AMD 
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reports.  Limited longitudinal data hinders assessment of whether countries are delivering 
improvements in patient care, or the risks that the current population or sub-populations are at for 
complications.  
Patient involvement in daily self-care is very high with medications, HBGM, periphery checks, 
injection site rotations, dietary limitations, carbohydrate counting and frequent physician visits.  If 
patients do not receive sufficient medical and family support in their care, ideal control of the disease 
becomes difficult.  This problem is more relevant where multi-disciplinary case management is less 
developed, for example in the Southern regions in Italy (compared to the North and Centre).   
Due to these data limitations, it is currently not possible to accurately establish causality between 
costs and the prevalence of diabetes complications on patient outcomes.  As a result, it is difficult to 
assess the efficacy of diabetes guidelines and diabetes related spending on patient outcomes. 
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8. Policy options 
Based on the analysis so far, it appears that across the study countries, the main policy priorities need 
to be a focus on diabetes prevention, the implementation of lifestyle strategies to improve population 
health, investing in early detection or screening initiatives for people with diabetes and pre-diabetes 
and enhancing cooperation between healthcare professionals and patients to avert severe 
complications. In France, additional priorities are the establishment of diabetes as a public health 
issue, rather than a socio-economic problem and the training medical staff to educate patients better 
about the disease. In Germany, further precedence needs to be given to targeting women and 
immigrants as vulnerable groups (i.e. not just children) in the existing diabetes guidelines as well as 
the new diabetes plan. In Italy, improving awareness and education about diabetes is also key. For the 
UK, precedence could also be given to increasing the number of specialist diabetes foot teams, in 
order to reduce amputations.  Additionally, enhancing access to (and ensuring receipt of) the 
recommended annual healthy checks for diabetics is important, so as to reduce the risk of 
complications. 
Overall, five main areas emerge where policy development can be targeted to best address diabetes 
and related complications: first, data systems for the trio of prevalence, costs (direct and indirect) and 
outcomes; second, prevention of diabetes development (primary prevention) plus complication 
development (secondary and tertiary prevention); third, creation and use of evidence-based 
guidelines, including patient perspective; fourth, emphasis on patient-centred multi-disciplinary care; 
and, fifth, monitoring, evaluation and learning from each other.  This section discusses various 
options for each of the above policy development areas (see also Box 8 for a summary). 
8.1 Understand the effects of diabetes through data 
Three areas of diabetes data collection need improvement: prevalence (and incidence), costs (direct 
and indirect) and outcomes.  Creation of national diabetes registers, like cancer registers, linked to 
primary care systems would be a good start to enable precise monitoring of existing and new diabetes 
diagnoses, differentiating between Type 1 and 2, the latter including details of control via oral 
medication, insulin injections, or lifestyle intervention.  Furthermore, patients with impaired glucose 
tolerance should also be registered along with their intervention.  The primary diabetes treatment 
provider (GP, endocrinologist, diabetologist, paediatrician) should also be included.  In order to deal 
with the paucity of indirect costs data, this register could also collect age of retirement, employment 
status, procurement of social benefits as well as primary caregiver details.  This would provide a 
starting point for indirect cost calculations. 
The direct diabetes costs should have the following improvements in accounting data collection 
services.  A diabetes diagnosis (Type 1 injections, Type 1 pump, Type 2 lifestyle, Type 2 oral, Type 2 
insulin) should be attached to a patient accounting record once diagnosed and updated when treatment 
classification changes.  This ‗tag‘ should follow the patient in all treatment access points, community 
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and hospital, regardless of whether the treatment access is not at all related to diabetes or 
complications.  The majority of treatment received is directly related to the diabetes diagnosis; where 
necessary, DRG payments ought to risk-adjust for diabetes.  Furthermore, the ‗tag‘ should follow the 
patient longitudinally, to understand how the diabetes diagnosis unfolds and impacts on treatment 
choices over time. 
Indicators of care (process and outcome) should be reported and collated annually.  Participation 
should be mandatory, and linked to primary and specialist funding to facilitate participation.
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Indicators should include minimum annual testing and reporting of HbA1C, blood pressure, total 
cholesterol/LDL/HDL, urinary albumin, serum creatinine, BMI, foot checks, retinal screening and 
smoking status.  Additional paediatric indicators should include weight and height percentiles, insulin 
pump use, ability to carbohydrate count, and number of hyper- and hypo-glycaemic episodes over the 
past year.  Annual complications data should include ketoacidosis, diabetic comas, foot ulceration, 
minor and major amputations, microalbuminuria, ESRD (haemo- or peritoneal dialysis), kidney 
transplantation, MI, angina, pacemaker, cardiac arrest, congestive heart failure, stroke, 
hypoglycaemia, retinopathy, blindness, presence of lung disease, and any type of cancer.  Additional 
data collection considerations are attendance of education services, specialist services (i.e. 
cardiologists, nephrologists), retinal screening attendance and outcome, and allied health professional 
visits (DSN, dietician, chiropodist). All this data is useful in halting the onset of complications and 
best direction of preventative care, but also aids in examination of the direction of best use of limited 
health care resources. 
8.2 Enhance and expand prevention strategies for diabetes 
Of the two key drivers of Type 2 diabetes - ageing and obesity, only obesity can be actively targeted 
by policy and treatment.  In most instances, Type 2 diabetes can be considered a potentially 
preventable, non-communicable disease, thus diabetes prevention could aid in prevalence reduction 
and associated lifetime costs. To do so, a number of macro and micro steps need to be considered. 
Obesity has been found to be socially ‗contagious‘ via social networking, meaning that a person has a 
higher chance of getting obese if obesity is present in their  network. Norms and social acceptability 
of obesity need to be modified, particularly during childhood.  A broad macro approach of socially 
responsible health messages targeted at specific age and social groups could be a start.  Further, 
promoting of activities of daily living and lifelong exercise to all age groups is key to obesity 
prevention and weight management.  In Italy in 2007 the ―Guadagnare Salute‖ project coordinated a 
series of prevention activities addressing poor diet, physical inactivity, smoking and alcohol 
consumption.  In the Emilia Romagna Region cities have tailored town planning to facilitate 
movement of pedestrians and cyclists to promote elevated activities of daily living.  These macro 
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 The UK shows that pediatric reporting is minimal, and pediatric treatment is diverse from endocrinologists 
to pediatricians, the latter perhaps not having a vested interest in diabetes outcome reporting. 
89 
 
multi-sectoral approaches involving different agencies to promote exercise and good health are 
integral to obesity prevention. 
From a micro standpoint, a series of programmes and projects targeted to high risk or high obesity 
prevalence groups are needed.  For example, cooking classes for new immigrants at risk for diabetes 
can help to modify cooking habits as well as deliver targeted messages.  Schools can disseminate 
messages about optimal nutrition to bring home, as well as ensure that all children exercise daily. 
The second area for prevention activities is for diabetes patients of all ages to prevent the 
development of complications.  Education programmes targeted to specific age groups, social groups 
and diabetes types are useful in this regard, particularly when supported by a good multi-disciplinary 
care team that monitors patients regularly (minimum bi-annually).  Use of accredited web-based 
materials to reach diabetes patients, as well as telephone support lines, can also be effective in aiding 
patients in their daily self-care.  Sophia, a (pilot) patient support programme in France, provides free 
information, monitoring and educational support to diabetes patients covered by ALD8 and is 
currently being expanded due to its success. 
The third area for prevention activities is the population at high-risk, individuals with undiagnosed 
diabetes, or impaired glucose tolerance.  Targeted message campaigns to find these patients early on, 
when inexpensive lifestyle modification can be used, is one method, in addition to the implementation 
of GP screening (France, Germany, implementation UK).  Recent German studies have proven that 
the cost-effectiveness of preventive screening (Schaufler et al. 2010), and early identification may 
provide individuals with motivation to lose weight, particularly if there are programmes in place to 
support such action.   
8.3 Evidence-based guidelines 
Diabetes guidelines across countries are not ideal, as many are not tailored to diabetes type or 
complication, and are produced by different organisations.  The best scenario is when guidelines are 
produced by either the diabetes register or by the central medical guideline agency.  All countries 
could develop and consolidate further evidence-based guidelines via consensus, with input from 
clinical experts; these should be specific to diabetes type.  Further guidelines of management under 
complication conditions must also be created, as well as paediatric care and pregnancy care.  All 
guidelines should be based on the most recent clinical evidence, including care pathways, screening 
and monitoring protocols, and separate guidance should be produced for patients themselves (in a 
multitude of languages, to assist and inform the broadest possible spectrum of the relevant patient 
population). These guidelines must be created with full support and input from clinicians in order to 
aid implementation and ownership; current adherence to monitoring measurements suggests there is 
room for improvement.  An education campaign directed at clinicians should accompany their 
implementation. 
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8.4 Multi-disciplinary diabetes care 
Despite diabetes being largely patient-centred, requiring high self-care involvement, only recently 
have patients become part of the care strategy.  As discussed above, ideal guideline content for 
clinical professionals should incorporate as much patient-centred care as they are comfortable with 
and able to facilitate; in addition, literature and guidelines for patients and caregivers should also be 
developed and disseminated. 
In the same regard, patient care should also include multi-disciplinary care, due to its multi-faceted 
nature.  This is for two main reasons: first, each speciality will have its own merits and perspectives, 
and second, dividing particular care responsibilities among providers, provided it is appropriate to the 
professional, can be less costly (e.g. DSN and dietician fees are lower than those for endocrinologists 
and GPs). Additional advantages include variations in disclosure to DSN versus physicians, and 
increased access to care.  Care plans that are developed need to include patients and main treatment 
providers, as well as caregivers (when needed).  Education should also be included in these plans, 
ideally as outlined previously.  Complex patient cases require the participation of several parties - 
patients, caregivers, and multiple treatment providers (GP, endocrinologist, DSN, dietician and other 
specialists) to plan for complication restriction and possible scenarios. 
Multi-disciplinary care requires improved communication between caregivers.  Electronic charting 
should support the communication between primary treatment providers and specialist providers, as 
well as other allied health professionals.  Division of patients between GPs and endocrinologists 
should be supported as long as GP care provides good patient monitoring and prompt response to 
required treatment changes. 
Psychology services need to have a greater role in diabetes treatment.  Primary diabetes care 
physicians must recognise that depression is a common scenario for many patients with diabetes, 
adversely affecting their ability to self-care.  Monitoring of social networks and observing patients‘ 
emotions with respect to their diabetes diagnosis during regular diabetes monitoring visits must be 
included in order to respond promptly to compromised mental health. 
Finally, clearly delineating treatment pathways and the roles of each professional along the way, 
including the mechanisms for referral and interaction, is a key area. This could include early detection 
of diabetes, access to a spectrum of healthcare professionals (not just GPs and diabetes specialists), 
and early intervention with appropriate treatments to prevent complications. This should of course be 
based on an individual patient‘s needs and best practice. 
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8.5 Monitoring, evaluating and learning from each other 
Each country has made progress into diabetes care in one way or another.  What is important is for 
countries to look at each other and investigate whether successes in one country can be applied 
elsewhere.  Here are some examples of country improvements in diabetes care. 
Three countries in particular (France, Italy and the UK) have made some progress in data collection of 
outcomes.  The UK in particular has made some aspects of diabetes reporting mandatory through the 
QOF, which culminates in the production of annual National Diabetes Audit, Scottish Diabetes 
Survey and the Paediatric Diabetes Audit.  Further improvements would include investigation of poor 
Type 1 monitoring in adults and in children, broadening monitoring methods (i.e. report dangerous 
levels, measure LDL/HDL, measure paediatric specific variables) as well as aligning ideal outcome 
measures between Scotland and England/Wales.  France has recently widened their ENTRED data 
collection to include Type 1 patients, further improvements would include national data collection 
with annual reporting.  Italy reports almost annually and the recent expansion of participating centres 
is encouraging.  Germany needs to begin reporting outcomes data collected by various SHI providers, 
while Spain‘s GEDAPS needs to increase their data collection and report more regularly.  Ideally, all 
countries participating in outcome data collection should specify which indicators are notable, what 
levels to report as ‗normal‘ and ‗abnormal‘, which diabetes details should be reported (Type 1, Type 2 
(oral), Type 2 (insulin), multiple complications, among others), inclusion of paediatrics, as well as 
how to collect data for longitudinal examination. 
All countries have poor prevalence estimates due to the lack of national registries.  All countries have 
poor cost data services – at best only regional piecemeal situations.  Germany could provide better 
cost estimates via their SHI systems, however the SHI institutions need to co-operate. Improvements 
to cost accounting services are costly in themselves, however, without implementation health systems 
are powerless to drive forward needed changes. 
Many countries have micro and macro prevention activities targeted to general population, specific 
age groups and social groups.  These programmes need to be shared at conferences, or via a European 
Diabetes Observatory, to give their ingredients of success to others along with their failures.  
Identification of undiagnosed patients is beginning to occur in France, Germany and the UK via 
screening of high-risk patients; however, it appears that uptake is low.  Factors for poor uptake need 
examination, as early identification of diabetes or identification at pre-diabetes stages can avoid costly 
treatments and complications.   
Data on the cost implications of diabetes and improved formal monitoring of the disease should be 
used to shape holistic national policies (such as National Diabetes Programmes) for managing 
diabetes. National Diabetes Programmes should encompass national diabetes registries, screening 
programmes, effective prevention strategies, evidence-based guidelines and ensure a multi-
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disciplinary, patient-centred approach to providing diabetes care. In order for these policies to be 
effective, they must be based on clear objectives measured against hard targets, underpinned by strong 
data collection. This will require a significantly greater top down effort if the current policy 
framework for managing diabetes is to be improved. 
All countries appear to have guidelines in one shape or another – only the UK appears to have made a 
concerted effort and instigated a substantial uptake of these recommendations, with over 40 guidelines 
or discussion papers produced by NICE.  As a minimum, the remaining countries need to have 
guidelines for Type 1 and Type 2, plus, ideally, additional guidelines for paediatrics, pregnancy, and 
complications.  Barriers to uptake by physicians need to be examined in all countries, and the creation 
of guideline documents written for patients should be initiated by examining the patient guidelines 
and pathways produced by the American Diabetes Association.  Linked to these guidelines then is the 
emphasis on multi-disciplinary care, in which all countries could improve their participation. 
The purpose of these internal and external examinations is to prevent new diabetes diagnosis (where 
possible), improve overall health of our populations, improve overall health of our diabetes 
populations and ensure that diabetes-related complications are kept to a minimum.  This effort 
requires participation by many players in society, including political influences, health care structures, 
community organisations, schools, transportation and medical personnel.  This will benefit actual and 
potential diabetes patients, averting costly care from personal, social and health system perspectives. 
The European Union has the potential to play a crucial role in supporting Member States to share their 
best practices in the fields of data collection, screening, prevention strategies, management 
programmes and the establishment of diabetes registries. The Lisbon Treaty gives the European 
Commission the mandate to implement initiatives to promote coordination between Member States in 
the field of health. Such initiatives can lead to the establishment of guidelines and indicators, the 
organisation of exchange of best practice and ensure periodic monitoring and evaluation. There is a 
need to follow-up on the European Council‘s Conclusion of 2006 on promotion of healthy lifestyles 
and prevention of Type 2 diabetes, which clearly sets out a number of initiatives to support 
cooperation between Member States in this area. The establishment of a European Diabetes 
Observatory could provide the vehicle for greater coordination between EU Member States, partly by 
establishing criteria for standardised data that is internationally comparable, and by encouraging the 
establishment of national diabetes registries. This approach has already been successful in the field of 
cancer (European Cancer Observatory). A European Diabetes Observatory could also monitor and 
report on the level of implementation of national policies for managing diabetes in order to identify 
potential gaps and assist in the sharing of best practice across Europe. 
 
93 
 
Box 8: Policy options - Key takeaways 
 
National level policy options 
1. Establish national diabetes registries to drive improvements in data collection methods, 
including improving methods for direct and indirect cost measurements of diabetes and its 
complications. As diabetes can exacerbate the amplitude and extent of potentially unrelated co-
morbidities, it may be necessary to risk-adjust payment formulae, particularly in in-patient care 
(e.g. through DRGs), where this is not done. National registries should also be used to improve 
formal monitoring of diabetes care, including collection of prevalence, outcomes and 
complications data. 
2. Data on the cost implications of diabetes and improved formal monitoring of the disease should 
be used to shape holistic national policies (such as National Diabetes Programmes) for 
managing diabetes. 
3. Enhance and expand prevention strategies by investing in coordinated lifestyle awareness 
initiatives and promotion of healthy diet and lifelong physical activity with specific focus on 
childhood obesity; targeting high risk groups; applying a multi-sector approach involving sectors 
outside of the health arena; patient education programmes that enable patients to manage 
diabetes through diet and exercise. 
4. Support and encourage tailored high risk screening programmes for diabetes to identify 
patients at an earlier stage. 
5. Ensure guidelines are evidence-based with input from clinical experts, including screening 
protocols, best treatment pathways and management of complications. 
6. Improve primary healthcare to enhance disease management and increase adherence whilst 
also improving tertiary prevention targeted to reach at risk groups to reduce complications. 
7. Expand co-ordinated and integrated multidisciplinary care that clearly delineates treatment 
pathways and the roles of each professional along the way to create care pathways in 
conjunction with individual patient‘s needs. 
8. Develop diabetes care and quality targets that are specific, measurable and realistic.  
European Union policy options 
9. Under the mandate of article 168 of the Lisbon Treaty, the European Union should facilitate the 
sharing of best practice between countries; monitor and report on data related to cost, 
prevalence, outcomes, and complications; establish criteria for standardised data that is 
comparable between Member States; monitor and report on national policies to manage diabetes 
in order to facilitate and support best practice sharing amongst Member States. The above could 
be achieved via the establishment of a European Diabetes Observatory. 
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Appendix 1 LSE survey of diabetes and diabetes costs in 5 EU countries: Experts interviewed, 
by country 
United Kingdom 
Ann Dolben Cardiff and Vale UHB 
Iona Lidington NHS Kingston: Public Health 
Olivia Winchester NHS Diabetes, Leicester 
Dr Craig Currie Cardiff University 
Naomi Holman Diabetes Health Intelligence 
Gavin Terry Diabetes UK 
Spain 
Dr Julio Lopez Bastida Spanish Health Care Service, Santa Cruz de Tenerife and 
University of Castilla la Mancha 
Dr Mauro Boronat Section of Endocrinology and Nutrition, Hospital Universitario 
Insular, Las Palmas de Gran Canaria 
Dr Pedro Serrano Aguilar Spanish Health Care Service, Santa Cruz de Tenerife 
Dr Juan Oliva Moreno University of Castilla La Mancha 
Germany 
Professor Dr Andrea Icks University of Duesseldorf and German Diabetes Centre 
Professor Dr Hans Hauner Technical University of Munich 
Professor Dr Ferdinand 
Gerlach 
German College of General Practitioners and Family Physicians 
(DEGAM) and University Hospital Frankfurt am Main 
Dr Christina Scheidt Nave Robert Koch Institute, Berlin 
Dr Lutz Altenhofen and Dr 
Bernd Hagen 
Central Research Institute of Ambulatory Health Care, 
Berlin/Cologne 
France 
Dr Karine Chevreul, Karen 
Berg Brigham and 
colleagues 
URC Eco (AP-HP) (Paris Health Economics and Health Services 
Research Unit), Paris, France 
Clara Bouche Endocrinology Department, Saint-Louis Hospital, Paris 
Italy 
Dr Roberto D‘Elia General Department of Prevention, Ministry of Health, Rome. 
Dr Emanuela Faloia  Endocrinologist at the Endocrinology Unit of the Regional Hospital 
of Ancona ―Ospedali Riuniti‖ 
Dr Paolo Foglini 
 
Director of the diabetic centre of Fermo (Regione Marche) and 
Member of the directive panel of AMD (Italian Association of 
Diabetologists) 
Dr Franco Gregorio Director of the diabetic centre of Fabriano (Regione Marche) 
Prof. Giulio Marchesini Director of the metabolism diseases Unit of the S.Orsola-Malpighi 
University Hospital of Bologna, Regione Emilia Romagna 
Dr Paola Pisanti General Department of Health Planning, Ministry of Health, Rome 
and President of the Italian Commission of diabetes 
Dr Vincenzo Pomo Health Regional Agency, Regione Puglia 
Dr Franco Stazio Health Department of Marche Region, Diseases with Social 
Relevance  Unit (PO Area delle patologie a rilevanza sociale e del 
sistema residenziale) 
Dr Giacomo Vespasiani 
 
Director of the diabetic centre of San Benedetto, Madonna del 
Soccorso Asl 12, San Benedetto del Tronto (Ap) (Regione Marche) 
and Former President of AMD (Italian Association of 
Diabetologists) 
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Appendix 2 Availability of cost and prevalence of diabetes-related complications data 
  France Germany Italy Spain UK 
 Treatment Cost Prev Cost Prev Cost Prev Cost Prev Cost Prev 
General 
Microvascular    ㄨ    ㄨ    
Macrovascular    ㄨ   ㄨ ㄨ    
Emergency visits       ㄨ  ㄨ  
In-patient visits       ㄨ  ㄨ  
Diabetic 
Retinopathy 
Eye disease - total     ㄨ ㄨ     
Retinopathy   ㄨ  ㄨ   ㄨ  ㄨ 
Eye disease - general  ㄨ   ㄨ ㄨ     
Eye screening ㄨ  ㄨ    ㄨ    
Cataract surgery ㄨ  ㄨ  ㄨ  ㄨ  ㄨ ㄨ 
Post cataract surgery ㄨ    ㄨ  ㄨ    
Laser treatment ㄨ ㄨ ㄨ  ㄨ  ㄨ    
Blindness (general) ㄨ  ㄨ    ㄨ    
Blindness - one eye  ㄨ       ㄨ  
Foot disease 
Neutropathy ㄨ          
Amputation - foot         ㄨ ㄨ 
Amputation - lower 
extremity 
ㄨ ㄨ   ㄨ  ㄨ    
Amputation -minor          ㄨ 
Amputation - major          ㄨ 
Diabetic foot         ㄨ  
Prosthesis ㄨ      ㄨ    
Gangrene treatment ㄨ      ㄨ    
Ulcer treatment ㄨ ㄨ         
Cardio-
vascular 
disease 
CVD general         ㄨ  
CHD general         ㄨ  
Statin therapy ㄨ  ㄨ    ㄨ    
Coronary 
revascularisation 
 ㄨ         
Coronary bypass         ㄨ  
Heart failure  ㄨ       ㄨ ㄨ 
Myocardial infarction ㄨ ㄨ ㄨ  ㄨ ㄨ ㄨ   ㄨ 
MI - non-fatal         ㄨ  
MI – fatal         ㄨ  
Angina  ㄨ ㄨ  ㄨ  ㄨ  ㄨ ㄨ 
Congestive heart 
failure 
ㄨ  ㄨ  ㄨ  ㄨ    
Stroke ㄨ ㄨ ㄨ  ㄨ  ㄨ   ㄨ 
Stroke - non-fatal         ㄨ  
Stroke - fatal         ㄨ  
IHD         ㄨ  
Renal disease 
Renal disease - 
general 
    ㄨ ㄨ ㄨ ㄨ ㄨ  
Microalbuminuria 
screen 
ㄨ  ㄨ  ㄨ  ㄨ    
Proteinuria screen ㄨ  ㄨ  ㄨ  ㄨ    
Microalbuminuria         ㄨ  
Glomerular filtration     ㄨ      
Dialysis ㄨ ㄨ   ㄨ ㄨ     
Peritoneal dialysis   ㄨ    ㄨ    
Haemodialysis   ㄨ    ㄨ    
Transplant ㄨ ㄨ ㄨ  ㄨ ㄨ ㄨ  ㄨ  
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2nd renal transplant         ㄨ  
Nephropathy   ㄨ     ㄨ ㄨ  
ESRD         ㄨ ㄨ 
Erectile 
issues 
      ㄨ     
Neuro-
logical 
disease 
Neurological 
complaints 
          
Neuropathy   ㄨ     ㄨ   
Acute events 
Ketoacidosis ㄨ  ㄨ  ㄨ  ㄨ   ㄨ 
Hypoglycaemic 
events 
ㄨ  ㄨ  ㄨ  ㄨ    
Multiple  
CHD+CVD         ㄨ  
CHD+Diabetic Foot         ㄨ  
CHD+Diabetic Foot + 
CVD 
        ㄨ  
CVD+CHD         ㄨ  
CVD+Diabetic Foot         ㄨ  
CVD+Diabetic Foot + 
CHD 
        ㄨ  
Diabetic Foot+CVD         ㄨ  
Diabetic Foot+CHD         ㄨ  
Diabetic Foot+CVD + 
CHD 
        ㄨ  
Notes: Prev: prevalence;ㄨ: data available 
Source: LSE survey in diabetes and diabetes costs in 5 EU countries. 
. 
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Appendix 3: Diabetes databases and information sources in EU5 countries  
France Germany Italy Spain United Kingdom 
 No regional or national diabetes 
registries 
 4 regional registries of Type 1 
(1988-1997). Discontinued for 
financial reasons.   
 ENTRED (Echantillon National 
Témoin Représentatif des 
personnes Diabétiques): Periodic 
survey (2001, 2007, 2010). 
Random sample of 9,781 Type 2 
patients.  In 2007 added paediatric 
Type 1 patients (n=924).  
Longitudinal periodic sampling 
includes specific Type 1 and Type 
2 questions, quality of life, 
adherence, hospitalisations, 
socioeconomic position, sleep 
apnea, sexual problems, 
paediatrics, treatments, outcomes 
and complications: eye disease, 
renal disease, foot ulcers, 
amputations, hypertension, stroke, 
angina and myocardial infarctions  
(Fagot-Campagna et al. 2009).  
 No regional or national diabetes 
registries 
 Care data collected by social health 
insurance, but limited access. 
 CoDiM: Sampling of 18.8% of the 
AOK social health insurance 
regarding costs and outcomes of 
diabetes care.  
 DiaRegis: Prospective, 
observational study on Diabetes 
Treatment Patterns and Goal 
Achievement in Primary Diabetes 
Care, based on a multi-centre 
registry of 313 primary care 
covering 3,810 patients (2009-10).  
Data collected included 
anthropometrics, HbA1C, plasma 
glucose levels, co-morbidities and 
medications.   
 Praxisstudien: GP surgery surveys 
of 40,000 patients, and includes 
diabetes care and complications 
prevalence.   
 Zentralinstitut Kassenärztliche 
Vereininung: Diabetes disease 
management programme data 
collected by the central institute for 
state health insurances.   
 No regional or national diabetes 
registries 
 DAI: Incidence of macrovascular 
complications in the Type 2 
diabetes population, based 
HbA1C levels, HDL cholesterol, 
smoking and microvascular 
complications (2007). 
 Regional registries for Type 1 
diabetes, including the ―Diabetes 
Catalonia Registry‖ – (Abellana 
et al. 2009).  
 A number of studies have been 
conducted to collect patient-level 
data (primarily focused on costs) 
that relate to diabetes - (Mata et 
al. 2002; Oliva et al. 2004) and 
updated by (López-Bastida 2010) 
.  
 
 No national diabetes registries 
 UKPDS (UK Prospective Diabetes 
Study Group):  Followed 5,102 Type 2 
patients for over a decade, examining 
complications, glycemic control, 
anthropometrics and biochemical data.  
Costs data were retrospectively added 
when it became apparent this 
information would be useful (Adler et 
al. 2000; Stratton et al. 2000) .  
 GPRD (General Practice Research 
Database): GP practice database 
recording Type 1 and 2 patients for 
complications, prescribing and 
resource use (Soedamah-Muthu et al. 
2008a; Soedamah-Muthu et al. 2008b).  
 National Diabetes Audit (England and 
Wales): Annual compilation of key 
diabetes data from Primary Care Trusts 
(PCTs) and participating GP practices 
via the Quality and Outcomes 
Framework (suffers from problems in 
participation and reporting particularly 
in paediatric patients).All collect 
limited data on complications 
(primarily prevalence), often not 
addressing treatment or intermediate.   
 Scottish Diabetes Survey: Annual 
survey of Scottish NHS Boards for 
Type 1 and 2, very similar to the 
English National Diabetes Audit 
(similar variables collected), (Scottish 
Diabetes Survey Monitoring Group 
2010) 
 SCI-DC Scotland diabetes information 
technology system 
Source: Authors‘ compilations from our survey and PubMed searches. 
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Appendix 4: Diabetes databases and information on health outcomes 
France Germany Italy Spain United Kingdom 
 ENTRED: HbA1C, blood 
pressure, BMI, HDL 
cholesterol, LDL cholesterol, 
triglycerides and urinary 
proteins; also includes 
information on key 
complications and their 
prevalence within the diabetic 
population (Ricci et al. 2009).  
 
 DMP: HbA1C >7.5%, blood 
pressure (systolic) ≤140mmHg, 
BMI (Birnbaum et al. 2010; 
Schäfer et al. 2010a; Schäfer et 
al. 2010b). 
 Information on complications 
only through sickness fund 
databases. 
 AMD Annals: Annual 
examination of diabetes 
centres.  Include proportion 
of HbA1C <7% and >8%, 
LDL <100mg/dl and >130 
mg/dl, blood pressure 
<130/80 mmHg and 
>140/90 mmHg, BMI 
classes and percentage of 
smoker patients; information 
on complications also 
included (AMD Annals 
2009). 
 A study of the Emilia 
Romagna Region in Italy 
examined specific costs 
associated with eye and 
renal complications and 
myocardial infarction 
(Agenzia sanitaria e sociale 
regionale 2009). 
 No national outcomes data 
is collected. Complication 
data scarce. 
 Longitudinal quality of care 
study (RedGEDAPS) (1996-
2007 data) examining 
HbA1C, total cholesterol, 
HDL, BMI, blood pressure 
(Franch Nadal et al. 2010). 
 National Diabetes Audit and 
Scottish Diabetes Survey: 
complications, HbA1C, albumin, 
creatinine, systolic blood 
pressure, total cholesterol, 
smoking, foot checks and retinal 
screening (Scottish Diabetes 
Survey Monitoring Group 2004). 
 UKPDS and GPRS: 
anthropometrics, additional 
biochemistry, costs and mortality.   
 
Note: Additional information pertaining to outcomes data, databases and monitoring can be found in Section 7 of the report. 
Source: LSE survey in diabetes and diabetes costs in 5 EU countries. 
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Appendix 5 Direct diabetes costs based on International Diabetes Federation estimates (2007, €) 
    France  Germany  Italy Spain  UK 
Diabetes health 
expenditure 
(millions) 
α, β
 
2007 IDF 
(Lower) 
€6,941 €14,607 €5,090 €2,326 €3,033 
2007 IDF 
(Upper) 
€13,032 €26,596 €9,641 €4,410 €6,029 
Diabetes % total 
expenditure 
2007 3.3 - 6.3% 5.8 - 10.5% 3.8 - 7.2% 2.6 - 4.9% 1.7 - 3.5% 
Per patient diabetes 
expenditure
δ
 
2007 €1,921 €1,982 €1,324 €932 €1,776 
2010 €3,125 €2,831 €2,118 €1,718 €2,697 
Notes: 
α
 Lower and upper IDF diabetes expenditure derived from lower (R=2) and upper (R=3) estimates (R = 
all medical care expenditures for diabetes patients / non-diabetes patients age- and sex-matched) (IDF Diabetes 
Atlas, 2006 for 2007 estimates).  
β
 Converted EUR (2007: USD/EUR=0.7296724; 2010: USD/EUR=0.75) 
δ 
Per patient diabetes expenditure derived from (International Diabetes Federation (IDF) 2006). 
Source: (International Diabetes Federation (IDF) 2006). 
 
Appendix 6: Total direct diabetes costs: estimates from regional studies extrapolated nationally 
(France, Germany, Italy, Spain) or from government data (UK) (2001-2010) 
 
  France
d
 Germany
c Italy 
β
 Spain 
α
 UK 
D
ia
b
et
es
  
d
ir
ec
t 
co
st
s 
(m
il
li
o
n
s)
 
2001 €5,700 €30,616Koster06 - - - 
2002 - €33,300 - €2,964 €2,067
Ϫ
 
2003 - €35,500 - €3,003 - 
2004 €8,966 €35,400 - €3,135 - 
2005 - €38,200 - €3,875  
2006 - €40,000 €6,640 €4,033 - 
2007 €12,500 €41,974 - €4,246 €13,488ε 
2008 - - €7,635 €5,023 - 
2009 - - €7,921 €5,120 - 
2010
μ
 €12,932 €43,244 €7,937 €5,447 €20,322n 
Notes: 
d
 (Ricci et al. 2009; Vallier et al. 2006). 
c
 (Köster et al. 2011; Köster et al. 2006). 
α 
Based on (López-Bastida 2010; Mata et al. 2002; Oliva et al. 2004) 
β Based on annual cost estimates of €2,762/patient (Marchesini et al. 2010 ; Marchesini et al. 2011; Osservatorio 
Arno Diabete 2011), extrapolated nationally using 4.8% total diabetes ISTAT prevalence and 2009 OECD 
population estimates.  Accounting for inflation of 3.5% (2008) and 0.8% (2009) (Eurostat).  
ε 
Based on 10% total health expenditure (c.£9bn) (DOH, 2007).  Additional annual social services costs of 
£230m added to 2007, but not 2002 or 2005.  Converted to Euros (2007 GBP/EUR=1.46127).  
Ϫ
 (Wanless 2004).  
n
 Based on (Currie et al. 2010; Morgan et al. 2010). 
μ 
Costs extrapolated to 2010 using annual GDP deflator for each country (International Montary Fund (IMF); 
Trading economics Main website; World Bank).  
Source: The authors based on the scientific literature.  
100 
 
Appendix 7: Diabetes complications and their cost: data collected through the LSE survey 
Appendix 7A: Diabetic retinopathy - Screening, diagnostic and treatment costs  
 France Germany Italy Spain UK 
Patients routinely receiving eye checks: 
Type 1 
Frequency q12m - q12m 80% >90% 
Treated OPTH - OPTH OPTH OPTH 
Type 2 (insulin 
dependent) 
Frequency q12m - ✓ 70% >90% 
Treated OPTH - n/a OPTH OPTH 
Type 2 (oral 
hypoglycaemic) 
Frequency q12m - ✓ 50% >90% 
Treated OPTH - - OPTH OPTH 
Treatment Costs (per patient annually) 
Laser treatment 
(%) 16.6% - - 18% - 
Cost €113.36 - - €177 - 
Panretinal 
photocoagulation 
Cost €125.40 €2,058 - €50.29 €1,096 
Cataract surgery Cost 
€271.70 + €125.40 
for anaesthesia 
- - €1,564 €2,830 
Notes: OPTH: ophthalmologist. 
Germany: Markov modelling in Type 2 patients with macrovascular disease, 2005 costs (inflated to 2010) 
collected from variety of government sources and other German CEA studies. 
UK: UKPDS dataset 1998 costs inflated to 2010 costs and converted to Euros (€1,549/£). Monitoring frequency 
from the 2009/10 National Diabetes Audit (England and Wales). 
Source: LSE survey in diabetes and diabetes costs in 5 EU countries.  
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Appendix 7B: Diabetic foot: Costs of monitoring and treatment 
 France Germany Italy Spain UK 
Patients routinely receiving foot checks 
Type 1 
Frequency q12m - q12m 50% 
82% 
(23%*) 
Treated by Endo/Diab - - Endo/Diab Endo/GP 
Type 2 (insulin 
dependant) 
Frequency q12m - q12m 50% 82%  
Treated by Endo/Diab - - Endo/GP Endo/GP 
Type 2 (oral 
hypoglycaemic) 
Frequency q12m - ✓ 50% 82% 
Treated by Endo/Diab U- - GP GP 
Treatments costs (per patient annually) 
Debridement, 
wound care 
€/patient  - - €1,598-2,510 €979-5,796 
Diabetic foot 
ulcer 
€/patient 
€2,546-
2,772/month 
€988-2,010  -  €979-5,796 
Amputation: toe €/patient € 32,000 - € 9,515 €3,897-3,980 - 
Amputation foot 
€/patient € 32,000 - € 9,515 €4,606-5,489 
€8,427-
15,305 
Amputation 
lower limb 
€/patient € 32,000 
Event 
€15,405 
Follow up 
€3,652 
€ 9,515 €4,606-5,489 
€8,427-
15,305 
Notes: Endo/Diab: Endocrinologist or Diabetologist. 
*refers to paediatric patients. 
France: Retrospective detailed study of 239 patients with diabetic foot (n=192) and amputations (n=40).  2000 
costs inflated to 2010. 
Germany: Markov modelling in Type 2 patients with macrovascular disease, 2005 costs (inflated to 2010) 
collected from variety of government sources and other German CEA studies. 
UK: NHS 2009/10 Hospital tariffs, converted to Euros (€1.1346/£).  Range due to presence of cardiovascular 
disease (increasing costs) and emergency procedure (increasing costs). Monitoring frequency from the 2009/10 
National Diabetes Audit (England and Wales). 
Source: LSE survey in diabetes and diabetes costs in 5 EU countries. 
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Appendix 7C: Cardiovascular disease resulting from diabetes - Costs of testing and 
treatment 
  France Germany Italy Spain UK 
Patients routinely receiving cardiovascular disease checks 
Type 1 
Frequency q12m - q12m 90% 
>90% (30-
50%*) 
Treated by - - - Endo/Diab Endo/Cardio 
Type 2 
(insulin 
dependent) 
Frequency q12m - q12m 90% >90% 
Treated by - - - Endo/GP 
Endo/ 
Cardio/GP 
Type 2 (oral 
hypo-
glycaemic) 
Frequency q12m - q12m 90% >90% 
Treated by - - - GP 
Endo/ 
Cardio/GP 
Treatments used for cardiovascular disease 
ACE 
inhibitors 
Generic: 
€/patient 
- - - 
€42.36  
ACE 
inhibitors 
Branded: 
€/patient 
- - - €110 
(Captopril 
25mg/day) 
 
Myocardial 
infarction 
inpatient  €/patient 
€5,272/patient 
(non-fatal) 
€4,737/patient 
(fatal) 
MI: €9,767 
Follow up: 
€4,032 
- €6,960 
Non-fatal: 
€7,418 
Fatal: €2,100 
Congestive 
heart failure 
inpatient  
€/patient - - - €3,428 - 
Stroke 
inpatient  
€/patient 
€6,368/patient 
(non-fatal) 
€7,537/patient 
(fatal) 
Stroke: 
€11,786 
Follow up: 
€6,831 
- €6,375 
Non-fatal: 
€4,314 
Fatal: €6,166 
Notes: 
France: Tuppin P et al. Characteristics and management of diabetic patients hospitalized for myocardial 
infarction in France. Diabetes Metab (2010)36:129-36. 
Endo: Endocrinologist; Cardio: Cardiologist;  *: paediatrics 
France: DRG/PMSI dataset 2003 costs (inflated to 2010) of inpatient visits for diabetic patients with CVD 
(Colin et al, 2007). 
Germany: Markov modelling in Type 2 patients with macrovascular disease, 2005 costs (inflated to 2010) 
collected from variety of government sources and other German CEA studies. 
UK: UKPDS dataset 1998 costs inflated to 2010 costs and converted to Euros (€1,549/£). Monitoring frequency 
from the 2009/10 National Diabetes Audit (England and Wales). 
Source: LSE survey in diabetes and diabetes costs in 5 EU countries. 
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Appendix 7D: Renal disease resulting from diabetes - Costs of testing and treatment 
  France Germany Italy Spain UK 
Patients routinely receiving renal checks 
Type 1 
Frequency q12m ✓ ✓ q6-12m 
60-90% 
(30%) 
Treated by  
Urinary 
albumin, serum 
creatinine 
- - Endo/Diab Endo/Nephr 
Type 2 
(insulin) 
Frequency q12m ✓ ✓ q6-12m 60-90% 
Treated by  
Urinary 
albumin, serum 
creatinine 
- - GP / Endo Endo/Nephr 
Type 2 
(oral 
hypo-
glycemic) 
Frequency q12m ✓ 
q12m 
q6-12m 60-90% 
Treated by  
Urinary 
albumin, serum 
creatinine 
- 
- 
GP / Endo 
Endo/Nephr/
GP 
Treatments costs in renal disease (per patient annually) 
Dialysis 
% patients 
20.9% 
haemodialysis 
patient are 
diabetic  
- - 
23% 
haemodialysis 
patient are 
diabetic  
- 
€/patient €81,449 
€65,511 - 
€41,052 €53,764 
Peritoneal 
Dialysis €/patient €49,953 
€52,187 - 
€24,515 - 
Kidney 
transplants 
€/patient 
- 
Transplant 
€76,852 
Follow up 
€12,291 
- 
€35,171 €33,437 
Notes: 
Germany: Markov modelling in Type 2 patients with macrovascular disease, 2005 costs (inflated to 2010) 
collected from variety of government sources and other German CEA studies. 
Spain: Oliva et al (2002); Amenabar et al, 2000; costs inflated to 2010. 
UK: Haemodialysis cost comes from ESRD costs from study comparison of US (n=2.5m) and UK (n=0.33m) 
nephrology patients, 2001 costs inflated to 2010 and converted to € (€1.549/£).  No annual UK peritoneal costs 
found, kidney transplant costs come from same source. Monitoring frequency from the 2009/10 National 
Diabetes Audit (England and Wales). 
Sources: LSE survey in diabetes and diabetes costs in 5 EU countries and evidence from the literature. 
. 
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Appendix 8: Quality and Outcomes Framework (QOF) 
 
Diabetes QOF indicators (17) (2009/10).  Outcome indicators are highlighted yellow. 
DM19 The practice can produce a register of all patients aged 17 years and over with diabetes mellitus, 
which specifies whether the patient has type 1 or type 2 diabetes. 
DM02 The percentage of patients with diabetes whose notes record BMI in the previous 15 months 
DM05 The percentage of patients with diabetes who have a record of HbA1c or equivalent in previous 15 
months 
DM09 The percentage of patients with diabetes with a record of the presence or absence of peripheral pulses 
in the previous 15 months 
DM10 The percentage of patients with diabetes with a record of neuropathy testing in the previous 15 months 
DM11 The percentage of patients with diabetes who have a record of the blood pressure in previous 15 
months 
DM12 The percentage of patients with diabetes in whom the last blood pressure is 145/85 or less 
DM13 The percentage of patients with diabetes who have a record of micro-albuminuria testing in the 
previous 15 months (exception reporting for patients with proteinuria) 
DM15 The percentage of patients with diabetes with proteinuria or micro-albuminuria who are treated with 
ACE inhibitors (or A2 antagonists) 
DM16 The percentage of patients with diabetes who have a record of total cholesterol in previous 15 months 
DM17 The percentage of patients with diabetes whose last measured total cholesterol within the previous 15 
months is 5mmol/l or less 
DM18 The percentage of patients with diabetes who have had influenza immunisation in preceding 1 
September to 31 March 
DM21 The percentage of patients with diabetes who have a record of retinal screening in previous 15 months 
DM22 The percentage of patients with diabetes who have a record of estimated glomerular filtration rate 
(eGFR) or serum creatinine testing in the previous 15 months 
DM23 The percentage of patients with diabetes in whom the last HbA1c is 7 or less (or equivalent 
test/reference range depending on local laboratory) in the previous 15 months. 
DM24 The percentage of patients with diabetes in whom the last HbA1c is 8 or less (or equivalent 
test/reference range depending on local laboratory) in the previous 15 months. 
DM25 The percentage of patients with diabetes in whom the last HbA1c is 9 or less (or equivalent 
test/reference range depending on local laboratory) in the previous 15 months. 
Source: UK NHS. 
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